




Risk assessment tool for diabetic neuropathy 
 
Jugal Manoj Dave 
The thesis is submitted in partial fulfilment of the requirements of Faculty 
of Science and Technology, Bournemouth University for the degree of 
Doctor of Philosophy 
 
 






This copy of the thesis has been supplied on condition that anyone who consults it is 
understood to recognise that its copyright rests with its author and due acknowledgement 


























I hereby declare that except where specific reference is made to the work of others, the 
contents of this thesis are original and have not been submitted in whole or in part for 
consideration for any other degree or qualification in this, or any other university. The work 
shown in this thesis is carried out by me the guidance of Prof. Venketesh N. Dubey and under 
Dr. David Coppini. This thesis contains nothing which is the outcome of work done in 
collaboration with others, except as specified in the text and Acknowledgements.  





















I would like to express my thanks to Prof. Venketesh N. Dubey and Dr. David Coppini for their 
support, careful supervision, recommendations and strong guidance through my Doctoral 
research program. I am grateful to my supervisory team for their constructive criticism on this 
project. Also thanks to Naomi Bailey (Research Administrator) for administrating the process 
so efficiently. 
Special thanks to Dr. John Beavis for guiding me in statistical part of the research. His insight 
and suggestions has motivated me in exploring my knowledge in the field of data analysis. 
I would like to thanks Poole hospital NHS Foundation Trust for providing Neurothesiometer 
device which was used in this research to perform comparative study. 
I would like to thanks my family for their love, patience and support during my study. Lastly, I 
would like to thank all my friends in United Kingdom and in India for their support and 

















Peripheral neuropathy is one of the serious complications of diabetes. Symptoms such as 
tingling and loss of touch sensation are commonly associated with the early stages of 
neuropathy causing numbness in the feet. Early detection of this condition is necessary in 
order to prevent the progression of the disease. Out of many detection techniques vibration 
perception is becoming the gold standard for neuropathy assessment. Devices like tuning fork, 
Biothesiometer and Neurothesiometer use this technology but require an operator to record 
and manually interpret the results. The results are user-dependent and are not consistent. To 
overcome these limitations, a platform-based device “VibraScan” was developed that can be 
self-operated and results displayed on a user interface. The development of the device is 
based on studying the effect of the vibration on the human subject by identifying the 
receptors responsible for sensation. The requirement of generating vibration was achieved by 
selecting a specific actuator that creates vibration perpendicular to the contact surface. The 
battery operated VibraScan is wirelessly controlled by software to generate vibration for 
determining the vibration perception threshold (VPT). Care has been taken while developing 
the user interface for human safety with the vibration intensity. The device can be operated 
without any assistance and results are automatically interpreted in terms of severity level 
indicated similar to the traffic-light classification. In order to provide consistent results with 
the existing devices a study was undertaken between Neurothesiometer and VibraScan with 
20 healthy subjects. The results were compared using Bland-Altman plot and a close 
agreement was found between the two measurements.  
VibraScan accurately measures VPT based on the perceived vibration threshold, however, it 
does not predict any risk associated with neuropathy. In order to supplement this device with 
the progression of neuropathy a risk assessment tool was developed for automated prediction 
of neuropathy based on the clinical history of patients. The smart tool is based on the research 
related to the risk factors of diabetic neuropathy which was studied and analysed using 
summarised patient data. Box-Cox regression was used with the response variable (VPT) and a 
set of clinical variables as potential predictors. Significant predictors were: age, height, weight, 
urine albumin to creatinine ratio (ACR), HbA1c, cholesterol and duration of diabetes. Ordinary 
Least Squares Regression was then used with logarithmic (VPT) and the significant predictor 
set (Box-Cox transformed) to obtain additional fit estimates. With the aim to improving the 
precision of VPT prediction, a simulated patient data set (n = 4158) was also generated using 
the mean and the covariance of the original patient variables, but with reduced standard 
errors. For clinical or patient use, providing direct knowledge of VPT was considered less 
helpful than providing a simple risk category corresponding to a range of VPT values. To 
achieve this, the continuous scale VPT was recoded into three categories based on the 
following clinical thresholds in volts (V): low risk (0 to 20.99 V), medium risk (21 to 30.99 V) 
and high risk (≥ 31 V). Ordinal Logistic Regression was then used with this categorical outcome 
variable to confirm the original predictor set. Having established the effectiveness of this 
“classical” baseline, attention turned to Neural Network modelling. This showed that a 
carefully tuned Neural Network based Proportional Odds Model (NNPOM) could achieve a 
classification success >70%, somewhat higher than that obtained with the classical modelling. 
A version of this model was implemented in the VibraScan risk assessment tool. Integrating 
VibraScan and the risk assessment software has created a comprehensive diagnostic tool for 
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Chapter 1 Background literature on diabetic neuropathy 
There are many chronic complications of the Diabetes Mellitus affecting eye, kidney and 
nerves. Microvascular complications with Diabetic retinopathy, nephropathy, and neuropathy 
are the commonest complications amongst them. Diabetic Neuropathy is one of the common 
long term diabetes complications which causes damage to about 50% of patients with diabetes 
(Mukesh et al. 2006). Early detection of neuropathy is necessary to avoid further complications 
that can lead to ulceration and foot amputation.  
Long term poor control of diabetes can cause damage to the nerves that transmit the signal to 
and from spinal cord, skin, muscle and organs. Reduction of touch sensation on the skin 
causing numbness in feet and hands, reduced ability to feel pain and temperature changes, 
tingling or burning sensation, shooting pain or cramps and muscle weakness are the early 
symptoms of the disease (Jayaprakash et al. 2011). This symptom starts at the big toe and as 
the disease progresses it ascend proximally. If the disease is untreated and undiagnosed it may 
lead to long-term complications such as foot ulceration and non-traumatic lower limb 
amputation. 
Despite much medical advancement, devices and methods available for diagnosis of diabetic 
neuropathy are very basic and the incidence of foot ulceration and lower extremity 
amputations are proportionately very high. There are many methods, treatments and medical 
devices available which are used to detect neuropathy, however, there is a need for an 
instrument which can accurately detect and assess the effects of neuropathy at an early stage. 
Thus, from early symptoms of the disease, it is possible to focus and develop residual 
measures which can arrest further progression and save from amputation. 
This project focuses on developing a device for early detection of neuropathy and correlation 
to patient’s clinical history. The device will focus on touch and vibration sensations on skin that 
can accurately provide data related to neuropathy. Based on the data generated from the 
device it would be possible to assess the level of neuropathy and how it progresses over time. 
This research will investigate on devices used to detect the neuropathy based on vibration, 
describing the way for conducting the test and will discuss the results of the test. After 
conducting a thorough literature survey and consulting with the clinicians we have put forward 




1.1 Diabetes mellitus and its prevalence 
Diabetes Mellitus (DM) is the chronic metabolic disorder which usually occurs due to 
hyperglycemia or the body cannot produce more insulin or the body is unable to use the 
produced insulin. Thus, looking at both the financial as well as effects on the patient’s quality 
of life, control of the disease is important. Increasing sugar level or hyperglycemia is a common 
effect of uncontrolled diabetes. There are three major types of diabetes as type 1 diabetes, 
type 2 diabetes, and gestational Diabetes. 
Type 1, Diabetes mellitus (T1DM) and Diabetic Neuropathy  
Diabetes mellitus (T1DM) also called insulin-dependent diabetes as the body is unable to 
produce insulin. The pancreas is responsible for producing the hormone called insulin. When 
there is autoimmune destruction to the B-cells of the pancreas gland, the body is unable to 
produce insulin. Viral infection is one of the reasons to damage the pancreas, however, a 
common cause is body’s own immune system. Worldwide the prevalence of Type1 DM is 
increasing. In 2014, Out of total 3.5 million diabetes patient in the UK, it has been estimated 
that including all adults and children 10% population is having type 1 diabetes and 90% people 
are having type 2 diabetes (DiabetesUK 2016). Type 1 DM causes major complications that 
affect eye, kidney, and nerve. T1DM affecting the nerves in such a way that the function of the 
nerves deteriorates commonly termed as diabetic neuropathy. There are various symptoms of 
diabetic neuropathy, and as the disease progresses there is a risk of foot ulceration.   
 
Type 2, Diabetes Mellitus (T2DM) and Diabetic Neuropathy  
Diabetes mellitus (T2DM) is also called non-insulin dependent diabetes. Previously it was 
known as adult onset diabetes however as a result of obesity in children, more teenagers are 
now suffering from type 2 diabetes. Type 2 DM is not as serious as type 1 diabetes as there is a 
lack of production of insulin in the body or body cells are restricted to it. People who are obese 
are at the high risk of developing type 2 diabetes as the body cells are resistance to it and 
results in increasing sugar level. Insulin resistance primarily starts in liver and muscle cells. 
However, the long-term effect of type 2 diabetes can affect small blood vessels. Diabetes is 
not curable however type 2 diabetes can be controlled by proper dietary therapy, exercise and 
nutrition management (Kumar et al. 1998). As mentioned in type 1 diabetes, type 2 diabetes 
can also cause complications which affect the nerve known as diabetic neuropathy. The 
number of type 2 diabetes patients is more than type 1 diabetes it is important to know the 
number of neuropathy cases under each category as well as the prevalence of severe 
neuropathies based on ulceration. A report published by Clinical Audit and Registries 
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Management Service Health and Social Care Information Centre is shown in Table 1.1 
comparing type 1 and type 2 diabetes (Ince et al. 2008). 
 
Table 1.1: The audit recorded for ulcer severity in 2014 and 2015 for England and Wales. Patient ulcer severity  
Disease Total number of 
diabetes N=5215 
Type 1 diabetes 
N=610 




Percentage Number Percentage Number  Percentage 
Neuropathy 4309 82.6 534 87.5 3344 81.8 
SINBAD score ≥ 3 2411 46.2 313 51.3 1842 45.0 
 
SINBAD score refers to the Site, Ischemia, Neuropathy, Bacteria infection and Depth (SINBAD) 
which is useful in predicting ulcer outcome and comparison among them (Ince et al. 2008). 
Table 1.1 shows that ulcers occurrence due to the type 1 diabetes is higher than the ulcers 
occurrence due to type 2 diabetes; that is 51.3% compared to 45.0%. Looking at the above 
data, it can be concluded that rates of neuropathy due to type 1 is higher than type 2 diabetes.  
Gestational Diabetes: 
Gestational diabetes is the type of diabetes that occurs during pregnancy, as there is insulin 
resistance during pregnancy. This diabetes needs to be controlled once it is diagnosed. Usually, 
the disease is diagnosed at the later stage of the pregnancy. If the diabetes is not controlled 
then the high blood sugar levels in the mother can be circulated through the placenta to the 
baby which can hamper the growth and development of the baby.  After pregnancy, this type 
of diabetes usually resolves itself. There is a 10% chance that the mother is at the risk of type 2 
diabetes at the later stage of life. Type 2 diabetes usually occurs after few weeks or months or 
a year later. Due to gestational diabetes, there is a high risk to the unborn baby than that of 
the mother. Over gained weight before birth, breathing problem to the baby and diabetes at 
the later stage of life are the major risks to the baby. Due to an overly large baby, the mother 
has to go through the cesarean procedure and there could be risks of damaging heart, kidney, 
and eyes as well.  
 
Effects of Diabetes: 
DM has affected a large number of the population worldwide. According to World health 
organization, the number of people having diabetes have raised from 108 million to 422 
million from 1980 to 2014 (WHO November 2016). In 2016, there were approximately 3.6 
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million people in the UK diagnosed of diabetes (Diabetes UK November 2016) and this figure 
predicted to exceed 5 million by 2025.  
This growing rate of disease causes huge cost burden to the patient, NHS and the society as a 
whole. The Health and Social Care Information Centre recently published a report that the cost 
of primary treatment for diabetes is 2005-6 was £513.9 million and it has risen to £803.1 
million in 2013-14 (NHS Digital, 2014). The total cost attributed to treating type 1 and type 2 
diabetes in UK has been estimated to be 23.7 billion in 2010.  
1.2 Complications of diabetes   
 
Macrovascular complications of diabetes: 
Macrovascular complications due to diabetes are the major cause of death which occurs two 
to four times more likely in the individuals with diabetes than without the disease (Kannel and 
McGee 1979; Morrish et al. 2001; Mulnier 2012; Vamos et al. 2012). Coronary artery disease, 
peripheral arterial disease, and stroke usually refer to Macrovascular complications of 
diabetes. 
Microvascular complications of diabetes: 
Because of Diabetes, there is a high risk of damaging eye, kidney, and nerves of the body 
which can lead to various types of Diabetic retinopathy (DR), Diabetic Nephropathy (DNEP) 
and  Diabetic Neuropathy (DN). 
 
1.2.1 Diabetic neuropathy 
Diabetic neuropathy damages nerve which carries signal from brain, spinal cord, blood vessels, 
muscles, skin and organs. Controlling blood glucose level is the best way to prevent this nerve 
damage. There are about 3.6 million people diagnosed with diabetes in UK, out of which 50% 
of patients may get affected by neuropathies. Chronic painful neuropathy is the common type 
of neuropathy i.e. up to 26% of diabetic patients. It impairs quality of life, considerable 
mortality and increase morbidity (Alleman et al. 2015).  
The exact cause varies based on the type of Neuropathy. Mostly it is believed that 
uncontrolled diabetes damages nerve that reduces the ability of transmitting signal causes 
diabetic neuropathy. It also affects the small blood vessels and restricts the supply of oxygen in 
blood.  There are certain factors such as inflammation in the nerve due to autoimmune 
response, genetic factors and smoking. Smoking can also cause nerve damage as it narrows 
and hardens the arteries and reduces blood flow in limbs which will ultimately damages the 
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peripheral nerves. Usually the risk of developing diabetic neuropathy increases due to poor 
glycaemic control, diabetes history, overweight, and kidney disease because diabetes can 
damage the kidneys and due to toxins available in the blood can cause nerve damage. Diabetic 
neuropathy is classified into various types such as distal symmetric polyneuropathy, acute 
Sensory Neuropathy, diabetic amyotrophy, diabetic mononeuropathies and painful diabetic 
neuropathy. Diabetic neuropathy affects sensory, autonomous and motor neurons of nervous 
system. 
(a) Distal symmetric polyneuropathy 
DSPN occurs in both type 1 and type 2 diabetes mellitus. In this type of neuropathy, 
the patient may remain asymptomatic and could be unnoticeable for a longer period 
of time. On clinical examination, it is possible to diagnose neuropathy, usually 
symmetrical sensory loss in feet (Kasznicki 2014). The ankle reflexes are mostly small 
or absent. The abnormal muscles sensory function which causes imbalance also occurs 
in patients with DSPN (Van Deursen et al. 1998). 50% of patients with DSPN may suffer 
from these symptoms and pain. There is around 3% to 25% incidence of painful DSPN 
which mostly remains undiagnosed and untreated (Bril et al. 2011). In another study, it 
was found that painful DSPN occurs in 27% of diabetic patients (Harris et al. 1993). It 
was shown that the occurrence of painful DSPN mostly associated with the severity of 
DSPN rather than risk factors related to diabetes (Mondelli et al. 2012). The pain is 
usually symmetrical, distal and severe at night. The painful DSPN can be diagnosed 
through clinical ways or based on the pain as described by the patients. They mostly 
describe the pain as a deep ache, burning, sharp and prickling (Apfel et al. 2001). 
Diagnosis of DSPN should be performed using vibration perception (128-hertz tuning 
fork), 10 g monofilament test, ankle reflexes and pressure sensation (Boulton et al. 
2005b). 
 
(b) Acute Sensory Neuropathy  
Acute sensory neuropathy (ANS) is the form of DSPN (Apfel et al. 2001). Most of the 
symptoms of ASN are similar to DSPN, however, there are major differences in onset, 
signs, and prognosis of the disease. In males, symptoms like weight loss, depression 
and erectile dysfunction are seen commonly. The pain is usually as deep and burning 
as described by the patients. ASN occurs usually in patients with poor blood glucose 
control. As per the report, achieving stable glycemic control can be helpful in resolving 
the symptoms in several months (Boulton et al. 2004). 
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(c) Diabetic amyotrophy (Radiculoplexus neuropathy) 
Diabetic amyotrophy usually affects the nerves in the hips, thigh, buttocks or legs 
causing difficulty in standing, walking or climbing stairs.   It is also known as proximal 
neuropathy or femoral neuropathy. It is commonly seen in patients with type 2 
diabetes. It is characterised by progressive, acute, weakness and pain in the muscles of 
the proximal lower extremities (Pasnoor et al. 2013).  It causes acute disability with 
varying degree of recovery (Nagsayi et al. 2010). The symptoms are usually at one side 
of the body such as causing severe pain in hip, thigh or buttock, causing weak and 
shrinking thigh muscles, abdominal swelling and weight loss. The diagnosis of diabetic 
amyotrophy is possible through neurological examination and getting a clinical history 
of the patients. There are several other neurological examinations available such as 
nerve conduction studies, nerve biopsy, electromyography, and imaging technique 
may be used to confirm the disease. For diagnosing this complication, nerve biopsy is 
considered only when the screening of diabetic amyotrophy remains unclear using 
other techniques. The pain due to neuropathy may be difficult to control. The severe 
pain may be resolved after several months of onset; however residual pain may last 
for years. It has been noted that doses of corticosteroids may be helpful to a few 
patients with diabetic amyotrophic to reduce severe pain (Pasnoor et al. 2013). 
 
(d) Diabetic mononeuropathies 
Mononeuropathies appears greater in patients with diabetes than in general subjects. 
Mononeuropathy or focal neuropathy damages nerve in the face or middle of the 
body. Neuropathies can be developed at the different areas of the body like an elbow 
(ulnar neuropathy), wrist (median neuropathy) and fibular head (peroneal 
neuropathy). It has been noted that if the neuropathies developed in upper 
extremities refers to mononeuropathies or multiple mononeuropathies rather than 
polyneuropathies (Dyck and Harper 1998). Mononeuropathy also occurred when a 
nerve is compressed.  Carpel tunnel syndrome is the common type of neuropathy in 
the subject with diabetes which caused numbness in hand or fingers.  Symptoms 
depend on the particular nerve which is involved. The patient may have pain in the 
lower back, front of the thigh, foot, abdomen or chest. These symptoms may resolve 





(e) Painful diabetic neuropathy 
Painful diabetic neuropathy is the common phenotype of diabetic neuropathy. It is 
more significant in type 2 than type 1 diabetes (Hartemann et al. 2011). The pain is 
mostly bilateral which involves lower extremities especially foot and sometimes in 
upper extremities including palms and fingertips (Ziegler 2009). Pain is usually worse 
at night, during stress and fatigue (Davies et al. 2006). The pain described by patients 
are like hot, electric, jolts, sharp and pins and needle (Galer et al. 2000). Study shows 
that patients with painful diabetic neuropathy have a poorer quality of life than with 
patients with neuropathy without pain or with non-neuropathic pain (Davies et al. 
2006). Due to the severe pain, it causes a significant increase in anxiety, depression 
and sleep impairment. It causes disability in walking in one-third of the patients and 
requires cane, walker or wheelchair due to neuropathy (Galer et al. 2000). Various 
methods such as nerve conduction studies, 10 g monofilament test, superficial pain 
sensation test, vibration tests, and electromyography are used for its diagnosis. The 
pain related portion of the Michigan Neuropathy screening instrument could be used 
to get the knowledge of painful symptoms.  
 
(f) Sensory Neuropathy: 
Sensory Neuropathy is considered as one of the most devastating nerve dysfunction. 
Sensory deficit and symptoms are appearing first at the distal portion of the 
extremities and progress proximally in the stocking-glove distribution (Bowker and 
Pfeifer 2008). As the loss of this fibre types recur there is an effect of diminishing light 
touch and proprioception later resulting in ataxic gait and unsteadiness along with 
weakness of intrinsic muscles affecting the feet (and hands) (Bowker and Pfeifer 
2008). Ignoring these symptoms may lead to foot ulceration and lower limb 
amputation. As the disease progresses, chronically it will not directly cause ulceration 
and limb loss by itself, however, if the period of diagnosing the sensory neuropathy is 
shortened then it is possible to prevent these complications occurring in future. 
Various screening tools are used to check the loss of vibration perception and pressure 
perception which is the main area of interest for this research. 
 
(g) Autonomic Neuropathy: 
Diabetic autonomic neuropathy (DAN) is the most understood and least organized 
complications of diabetes (ERBAS 2001; Vinik et al. 2003). Autonomic neuropathy can 
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occur when nerves responsible for controlling involuntary functions are damaged. It 
affects the autonomic neurons of either or both the parasympathetic and sympathetic 
nervous system. Skin atrophic and sweating abnormalities of the feet at an early stage 
are the signs of autonomic neuropathy which is often connected to somatic 
polyneuropathy (Mayfield et al. 1998). A sensitive indicator of the skin may be called 
plantar callus (hyperkeratosis) (Murray et al. 1996; Pataky et al. 2002). Cracking of the 
skin, the formation of fissures and loss of sudomotor function are the indicators. One 
of the outcomes of autonomic neuropathy is auto sympathectomy which could lead to 
arteriovenous shunting, increase cutaneous blood flow, increased skin temperature 
and distension of the dorsal veins in the foot (Edmonds et al. 1982; Corbin et al. 1987). 
 
(h) Motor Neuropathy: 
Nerves which are responsible for controlling movements are affected due to motor 
neuropathy. This will lead to muscle weakness and wasting of nerves which receive the 
signals from the nerves being affected by an imbalance of flexor and extensor muscles 
causing foot deformities (clawing of the toes and prominence of the metatarsal 
heads). Abnormal plantar pressure occurs due to reduced subcutaneous tissue 
thickness at the metatarsal heads and anterior displacement of the sub-metatarsal fat 
pads (Pataky 2012). 
 
Diagnosis: 
For the diagnosis of diabetic neuropathy, test should include assessment of sensation of 
pinprick, examination of muscle power, vibration and touch sensation. Mostly for touch 
sensation monofilament test is recommended. Vibration test should be performed by 128 Hz 
tuning fork.  Sensory test should be done on hands and feet bilaterally. Quantitative sensory 
test are not recommended for routine clinical practice (Shy and Frohman 2003). Nerve biopsy 
may be useful to find or explore the other causes of neuropathy. For assessment of 
polyneuropathy confocal corneal microscopy is recommended. The autonomic function tests 
which are available are based on blood pressure, heart rate response is commonly used in 
subjects with diabetes mellitus. As DN can be asymptomatic in nature therefore it has to be 
diagnosed very carefully.  
According to San Antonio consensus statement held in 1988, for diagnosing diabetic 
neuropathy, consensus panel has recommended that at least one measure from each of the 
categories is needed like clinical symptoms, neurophysiology, clinical signs, autonomic function 
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test and quantitative sensory tests (Association and Neurology 1988). This may be needed for 
research protocol. However, in the clinical practice this is difficult to implement so two of five 
criteria have been recommended (Dyck 1988). 
 
Complications of diabetic neuropathy 
 The complications in the individual subject may vary, as it depends on the root cause and 
which nerves been damaged. The early symptoms of diabetic neuropathy cause sensation loss 
result in numbness, burning sensation, tingling and pins and needles. In some cases, it may 
improve with time with proper treatment while in some cases it may cause permanent 
damage or get worse with time. If it is not detected at the early stage or the cause is not 
treated, it may cause serious complications like foot ulcers, further these ulcers may become 
infected and lead to gangrene if remain untreated. In the advanced stage, the affected foot 
may have to undergo amputation. The peripheral neuropathy may affect the autonomic 
functions of heart, due to which there could be a need for increased blood pressure. 
 
(a) Diabetic foot ulcers 
The neuropathic foot remains warm with palpating pulses, without sweating and skin 
remains dry. Due to dryness in skin, it is prone to fissures, fungal and bacterial 
infections. The broken skin takes longer time to heal or may not properly repair itself 
because of nerve damage. The numbness or the sensation loss feelings in the feet can 
get easy cuts by treading on something sharp, tight shoes, blisters and bruises can 
result in diabetes foot ulcers. The common risk factors of diabetic foot ulcers are 
neuropathy, hyperglycemia, poor blood circulation and walking without shoes. 
The blood supply to the feet is restricted due to damage to the blood vessels or 
narrowed arteries. As the blood supply to the skin is less, it takes a longer time to heal 
and causes tissue damage leading to gangrene. 
 
(b) Gangrene 
Gangrene is developed by the poor blood circulation to a certain part of the body 
causing the tissue to die. There are two types of gangrene dry and wet gangrene. Dry 
gangrene is normally caused to the patients by having type 1 or type 2 diabetes. Due 
to hyperglycemia for a longer period of time, it damages blood vessels. The damaged 
blood vessels cannot carry oxygen and nutrition to the tissue and eventually the tissue 
will die causing dry gangrene.  
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The gangrene that is developed due to the infection causes wet gangrene. This type of 
gangrene is usually seen when foot ulcers or wound is badly infected. People with 
diabetes are less able to fight off the bacteria and other types of infections causing a 
risk of developing wet gangrene.  Once the gangrene is developed it can be removed 
by surgical procedure or in severe cases toe or the foot needs to be amputated. 
 Advantages of early detection of diabetic neuropathy 
It has shown that subjects with good glycaemic control can help in slow progressions of 
diabetic neuropathy in type 1 but less benefit in subject with type 2 diabetes.  With the 
increasing number of type 1, type 2 diabetic patients, the incidence of diabetic neuropathy 
causes a huge impact on the quality of life of patients as well as their families. To deal with 
devastating complications such as foot ulceration, limb amputation due to diabetic 
neuropathy, early diagnosis and effective treatment is necessary. This is because once the 
peripheral nerves function deteriorates, it is difficult to regenerate. It may possible to slow 
down the progression through treatment but not reverse the damage. In case of severe 
neuropathy, there is a need for physical therapy to avoid muscle spasms and cramping. There 
can be a significant drop in the amputation rate by early detection and managing risk factors of 
diabetic neuropathy. Therefore, diagnosis is critical to minimise pain and loss. 
For diagnosing neuropathy various tools and methods such as patient’s questionnaires, an 
examination of nerve conduction velocities, tools based on vibration perception thresholds are 
available which will be discussed in the next chapter. By Studying the limitations and 
advantages of the existing technology based on vibration perception detection, the aim is to 
develop a smart and operator in dependent device for early detection of neuropathy which 
automatically defects the severity level based on the measured vibration perception 
thresholds. 
1.3 Research questions 
To start with the research, first the research questions were identified as listed below: 
1. Considering the electromechanical device Neurothesiometer as the gold standard 
(Coppini et al. 2001), is it possible to develop an independent device which can 
generate the same nature of frequency and voltage with intelligent diagnosis 
features? 
2. Is it possible to provide the vibration with the constant stimulus pressure?    




1.4 Aims and objectives of the project 
 In order to detect diabetic neuropathy, develop a smart, operator independent and user-
friendly device, which is capable of generating a vibration stimulus with a required 
frequency and varying amplitude. 
 To be able to robustly detect diabetic neuropathy, develop a vibration generating device 
which can effectively increase the vibration intensity in order to detect the vibration 
perception threshold of the subject. 
 To develop a more reliable device by maintaining a constant pressure while applying 
vibration stimuli to the patient. 
 To develop the risk assessment tool that is capable of utilising the clinical characteristics of 
a patient to predict the risk level of Diabetic neuropathy. 
1.5 Outline 
The research outlined in section 1.3 and 1.4 are given in the following chapters. 
 Chapter 2 discusses about the existing methods and devices available for early 
detection of diabetes and identified their limitations.  
 Chapter 3 discusses about the designing the device. The device development is based 
on the requirements and limitations as discussed in the Chapter 2. This chapter 
involves design description of the device, its electronic circuit development, software 
programming and development of graphic user interface.  It shows the way of 
conducting the test for diabetic neuropathy subjects.   
 Chapter 4 discusses the experimental study performed using VibraScan and 
Neurothesiometer.  
 Chapter 5 discusses the comparative study between VibraScan and Neurothesiometer 
using human subjects. 
 Chapter 6 explain the development of risk assessment tool of VibraScan based on the 
clinical characteristics of the subject. This tool is developed based on the analysis of 
the clinical data. For data analysis various methods such as ordinary least squares, 
ordinal logistic regression, artificial neural network and neural network based 
proportional odds model were implemented. It shows the results obtained from all 
these methods for comparison purpose and uses of best suited model for the tool 
development. 
 Chapter 7 concludes with the findings of this research and discusses the limitations 




Chapter 2 Methods for diagnosing Diabetic neuropathy  
 
This Chapter focuses on the study and understanding of the existing methods available for 
diagnosing diabetic neuropathy. There are various methods available for screening purpose, 
however, the aim is to analyse the limitation of methods and come up with an idea of 
developing an innovative and smart device that can overcome the gaps in the existing devices. 
All the existing methods which are used for diagnosing diabetic neuropathy have been 
discussed along with their limitations. Another focus is also to investigate the feasibility for the 
patients to use the technology independently of performing the screening test. 
 All these methods will be analysed and the best suitable method for developing the prototype 
will be selected based on the criteria that it is non-invasive, easy to use and accurate. Devices 
that use vibration perception are generally considered as the gold standard for neuropathy 
assessment as they can efficiently predict the onset and progression of the complication 
(Coppini et al. 2001). Therefore, devices based on vibration perception were studied along 
with their limitations which will be discussed in this chapter.  
2.1 Methods used for diagnosing diabetic neuropathy 
There are various methods such as different clinical scores and devices available commercially 
to help diagnose DPN which include nerve conduction studies, DPN check, sudorimetry, 
SUDOSCAN, Neuropad, cardiac autonimic Function test, skin biopsy, corneal microscopy and 
Semmes-Weinstein monofilament test.  
(a) Clinical scores 
Clinical scores such as neuropathy disability score (NDS), Neuropathy symptoms score 
and Michigan Neuropathy screening instrument (MNSI) are commonly available for 
diagnosing purpose. 
Neuropathy disability score 
Neuropathy disability score (NDS) is the scoring system for diabetic neuropathy. NDS 
examines muscle weakness, cranial nerves, sensations and reflexes (Dyck et al. 1980b). 
It used to access 35 items on both sides to examine the sign of neuropathy. Some of 
the items in NDS do not check the abnormality of neuropathy. At present, the 
updated/modified version of NDS is used in practice which considers ankle reflex, 
pinprick, vibration, heat and cold sensation at both the side of the big toe with the 
score of 10. During the examination, if the score is 6 or more then it is considered to 
be an abnormal reaction (Moreira et al. 2005).  
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Neuropathy symptoms score 
Neuropathy symptoms score (NSS) consist of examination related to tingling or 
numbness, burning, fatigue, aching and cramping (Chawla et al. 2013).  It consists of 
17 items which are divided into symptoms of muscle weakness (8 items), autonomic 
symptoms (5 items) and sensory disturbances(4 items)  (Dyck et al. 1980a). If the 
answer is negative/absent then score is zero, if the answer is positive then score is 1 
which can maximum reach to 17.  If the score is greater than or equal to 1, it is 
considered to be abnormal. The limitation of NSS is, it is not used to show the 
progression of diabetic neuropathy (Dyck et al. 1997).  
Michigan Neuropathy screening instrument  
Michigan Neuropathy screening instruments are used to find the degree of 
neuropathy. It includes two types of assessments. One with 15 self-administered 
questionnaires and foot examination which includes assessment of vibratory sensation 
and ankle reflexes. This questionnaire includes questions related to positive and 
negative sensory symptoms (such as numbness, tingling and burning), muscles cramps, 
weakness, foot ulcers, and amputation.   The foot examination is mostly used with the 
maximum score of eight where both the foot are independently measured. If the MNSI 
score is greater than or equal to 2, it is considered as positive for diabetic neuropathy 
instrument (Feldman et al. 1994). It helps to classify the various form of diabetic 
neuropathy, to identify the other causes of neuropathy, and it also provides 
information which can be used to monitor the disease.  
There are few limitations of clinical scores as they are not much reliable and 
reproducible. Hence, it can be used to assess pain severity but not the pain scores to 
evaluate the progression of diabetic neuropathy. Again these scores are user 
dependent and the devices or tools used to obtain the measurements.  
 
(b) Nerve Conduction studies (NCS): 
Nerve conduction studies are used for diagnosis of diabetic peripheral neuropathy; 
since the eighteenth century, the response of the peripheral nervous system to 
electrical stimulation had been recognized (Isaacson 2003). The NCS usually means 
stimulating the nerve and recording the responses elsewhere from the nerve.  The 
modern clinical NCS usually stimulate the peripheral nerve and record the response 
from the skeletal muscle innervated by the nerve. Currently, most of the NCS are 
performed with the surface, stimulating and recording electrodes (Jones 2012). The 
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site of stimulation is very important as surface measurements may not precisely 
provide all the anatomical information and uncertainty of the selecting the proper 
sites of stimulation or recording may limit the value of the study. A large amount of 
current is required for stimulating the deeper nerve such as the lower trunk of brachial 
plexus. Due to this stimulation, there is a chance of stimulating nearby muscle which 
can introduce the recording of the response elsewhere on the limb. The degree of 
uncertainty increases when recording proximal muscles because of the surrounding 
muscles and is more challenging; therefore NCS of distal is easier as it is isolated from 
the limb and other muscles which can help the examiner to be more certain as what is 
being stimulated and what is being recorded.  
The bipolar probe consists of anode and cathode and is generally used as a nerve 
stimulator. To stimulate proximal spinal nerve needle electrode is used. The cathode is 
placed in the direction where action recording is intended to place or oriented distally. 
For the impedance matching the targeted site should be properly cleaned. The 
stimulus is provided at a constant current in the range of mill amperes. The selected 
site for applying the stimulus, all the elements of the nerve should be completely 
depolarized and could be achieved by applying the successive stimulus and start 
increasing the current to that extent when current has increased but the size of the 
recorded potential remains the same. This stimulus is known as the supramaximal 
stimulus. The current should be increased gradually by a constant increment of 10 mA 
until the response is detected. The position of stimulating electrode is carefully placed 
in such a way that optimal point of the nerve stimulation is isolated. Supramaximal 
stimulus is achieved by increasing the current. Usually, the duration of current is 0.1 
milliseconds but it could be increased to 1 millisecond if the supramaximal response is 
not achieved till 100mA of the current (Jones 2012).  
Recording electrodes consist of active and reference electrodes which are placed at 
some distance from the active electrode. This distance is important to generate the 
recorded potential obtained due to the difference in charges (Kincaid et al. 1993). For 
recording muscle or nerve activity, metal or self-adhesive electrodes are used. 
Electrodes placed very close to each other will produce a small response and placed 
very far apart will produce unwanted environmental artifacts. These environmental 
electrical artifacts can be minimized by placing the surface ground electrodes between 
stimulus and at the recording sites gel is applied to the skin to minimize the 
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impedance mostly for the small amplitude responses (response is in the range of 
millivolts to microvolts depending on structured electrodes). 
Although there is a wide application and use of NCS, NCS remains limited due to the 
time involved in performing the test, the cost involved, special arrangements and 
laboratories should be available and most importantly patient has to undergo 
difficulties of long wait and inconveniences due to NCS. Technically NCS is more 
helpful in detecting large fiber neuropathy but unhelpful in detecting small fiber 
neuropathy. Conduction block or demyelination that occurs proximally is quite difficult 
to detect (Jabre 1981; Weber 1998).  
 
(c) DPN check 
 
Figure 2.1: DPN check device (Hamasaki and Hamasaki 2017) 
NC-stat DPN check is a point of care device, manufactured by NeuroMetrix Inc. is 
placed on the skin on the sural nerve to measures sural nerve conduction velocity (CV) 
and sensory nerve action potential (SNAP) as shown in Figure 2.1. The measurement is 
displayed in terms of numbers and based on the thresholds level of the measured 
value the abnormality or the severity can be pre-defined, lower the SNAP and CV more 
associated with diabetic neuropathy (Abraham and Abraham 1987). This can help  
patients to detect the presence of diabetic neuropathy. NC- Stat has shown the 
specificity of 82% and sensitivity of 92% compared to nerve conduction studies 
(Perkins et al. 2006).  
The limitation of using DPN check is it is a bit difficult to locate the sural nerve for 
which trained operator is needed. There are small numbers of people in which sural 





Neuropad usually measures the irregularities in the peripheral nerves.  It consists of 
two tests per kit which can be used for each foot. For performing this experiment 
patient have to remove his/her shoes and socks and wait for a few minutes before 
starting the test (Malik 2008). The experiment has to perform under constant ambient 
temperature. The examiner places the Neuropad at the callus free area between the 
first and second metatarsals head to examine the colour change for 10 minutes 
(Ziegler et al. 2005; Papanas et al. 2013). It measures sweat production based on 
colour change. Cobalt 2 compound is used for the detection which changes the colour 
from blue to pink. The colour change occurs because of the chemical reaction between 
anhydrous cobalt 2 chloride present in the indicator and water from the sweat glands. 
If the sweat glands are functioning normally then water molecules are enough to 
change the colour within 10 minutes. It indicates that if the colour changes from blue 
(dry state) to pink (dermal foot perspiration), it indicates the normal function of 
sudomotor and if it remains blue or stays bit patchy at the time threshold or takes a 
longer period of time then considered as the reduced sudomotor function. The 
absolute time taken by the Neuropad to change the colour may suggest that this 
parameter can be used to determine the severity of diabetic neuropathy (Papanas et 
al. 2007). The advantage of using Neuropad is, it does not require subject cooperation 
as the test is based on the chemical reaction and may contribute to the early detection 
of diabetic neuropathy (Papanas et al. 2011). The limitations are that the time period 
is set to determine the severity level i.e. 10 minutes; however it has not achieved high 
applicability. Because of this reason, various different threshold level was set like 15 or 
20 minutes, however, these thresholds have not shown many significant changes 
(Papanas et al. 2011).  
 
(e) Sudorimetry 
Sweat glands dysfunction is also one of the early symptoms of the DPN. Autonomic 
nerve dysfunction is an important aspect which is always undiagnosed or overlooked 
(Papanas and Ziegler 2011). Sweat glands are affected at the early stage of the 
diabetes mellitus which are innervated by small myelinated cholinergic sympathetic 
fibres. Due to sweat glands dysfunction, the skin will remain dry that is more prone to 
a bacterial and fungal infection which can cause foot ulceration. To prevent this 
complication diagnosing sweat glands dysfunction could be a useful screening tool for 
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DPN (Sumner et al. 2003; Yajnik et al. 2012). Stewart et al (1992) found that autonomic 
nerves controlling heart rate are less likely to damage than that of the sympathetic 
sudomotor fibers which proved that sudorimetry is the useful tool for diagnosing DPN 
at the early stage. There are various methods used for the detection of sweat glands 
dysfunction such as qualitative sudomotor action reflex, silastic imprint method, 
electrochemical sweat conduction, and thermoregulatory sweat test. Small-fiber 
polyneuropathy can be detected with a sensitivity of 80% by qualitative sudomotor 
action reflex test (QSART) (Thaisetthawatkul et al. 2013). The sweat production is 
measured by infusing acetylcholine into the skin to stimulate the postganglionic nerve. 
The limitations of this test are, it is time-consuming and requires expensive equipment 
(Illigens and Gibbons 2009). Electrochemical sweat conductance (ESC) test is 
performed by a chemical reaction between electrodes and chloride of the sweat 
glands after applying low-level voltage stimulation. Studies showed that Lower ESC 
refers to increasing vibration perception threshold (VPT) after testing on 265 diabetic 
patients. Thus the study concludes that lower ESC refers to sweat gland dysfunction 
and can be the sign of the early stage of DPN (Yajnik et al. 2012). In a 
thermoregulatory sweat test, the sweat production is evaluated by increasing the 
temperature of the skin and after that, the dye is used to measure the sweat 
production. This test is non-quantitative and can be used either to test local area or for 
whole body sweat production (Illigens and Gibbons 2009). In Silastic imprint method 
the sweat is produced using acetylcholine and silastic material are placed on the skin 
to quantify the test (Stewart et al. 1994). The drawback of the test is, silastic material 
is prone to dirt and hair. 
 
(f) SUDOSCAN 
SUDOSCAN is the device which is non-invasive, easy to use sudomotor test for 
assessment of sweat gland function (Mayaudon et al. 2010). It consists of two sets of 
stainless steel electrodes for both hands and feet which are connected to the 
computer for recording and maintaining data of the subjects under test. These 
electrodes are alternately used as cathode or anode where the DC voltage of less than 
4V is applied to the anode. The examination is based on electrochemical reaction 
occur between the stainless steel plate electrodes and the chloride ions present in the 
sweat glands when hand and feet are placed (EH Schwarz et al. 2011). Low voltage of 
less than 4V is applied to the electrodes to attract the chloride ions from the sweat 
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glands. Due to the reverse iontophoresis process the voltage is developed at the 
cathode and current between anode and cathode is based on the chloride ion 
concentration.  Iontophoresis is the process where electric current is applied through 
electrodes to deliver a chemical substance to the skin based on electromotive forces 
(Zaid et al. 2018). This will measure the conductance of palms and soles from the 
derivative current of the applied voltage (Ayoub et al. 2010). The electrochemical skin 
conduction (ESC) is measured as the ratio between the generated current and DC low 
voltage applied to the electrode is expressed in micro siemens. ESC is helpful in 
determining sudomotor dysfunction in the subjects with diabetes. The severity of ESC 
is divided into four different categories based on the threshold value of ESC i.e. no 
dysfunction if >60 µS, moderate dysfunction if between 60 and 40 µS while severe 
dysfunction when <40 µS (Casellini et al. 2013). 
This tool is used for the measurement of small fibre neuropathy and peripheral 
autonomic dysfunction. Still, more studies are required which can clearly show that 
SUDOSCAN outcomes are predictive for diabetic neuropathy development and foot 
ulceration (Selvarajah et al. 2015). 
 
(g) Cardiac autonomic reflex tests 
Cardiac autonomic neuropathy (CAN) is one of the chronic and serious complications 
of diabetic neuropathy which occur in patients with long term type 2 diabetes mellitus. 
The report shows that it is found in one-quarter of type 1 and in one-third of type 2 
diabetic subjects which might predict the change of development of stroke. CAN 
patients may suffer from complications like tachycardia, exercise intolerance, postural 
hypotension, enhanced and myocardial infarction (Vinik et al. 2013). This type of 
cardiac dysfunction may affect the quality of life of diabetic patients and major risk of 
life-threatening outcomes. 
There are various methods available for diagnosing CAN such as evaluating symptoms 
and signs through clinical practice, cardiac autonomic reflex tests (CARTs) depending 
on heart rate and blood pressure and using blood pressure monitor (Spallone et al. 
2011).  CARTs examine the cardiac autonomic function by time domain HR response to 
breathing, Valsalva maneuver change, and the response of the heart rate and blood 
pressure changes. In autonomic testing, indirect autonomic measures are considered 
as the gold standard. The non-invasive, easy and safe technique of measuring heart 
rate variations during deep breathing, heart rate measured during lying and standing 
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and Valsalva maneuver refers to parasympathetic function (Vinik et al. 2013). 
Orthostatic hypotension, sustained isometric muscular strain and blood pressure 
response to a Valsalva maneuver refers to sympathetic function (Vinik et al. 
2013). CARTs are considered to be sensitive, specific, reproducible, safe and 
standardized. It has been suggested that CAN assessment should be performed with 
more than one heart rate tests.  These tests are relevant for diagnosis of CAN which is 
the complication of diabetic neuropathy. 
 
(h) Skin Biopsy 
Skin biopsy can be performed at the required site of the body using disposable punch 
with the diameter of around 3mm under local anesthesia using lidocaine. This 
techniques has not reported any side effect and can be performed without the need of 
suture. Healing process mainly complete within a week where scar may not last for 
more than 3 months. This is used to examine innervation of epidermis, dermis, and 
sweat glands . To investigate the only innervation of epidermis, an even less invasive 
technique names  “blistter technique” can be used (Lauria and Lombardi 2007) . Skin 
biopsy is usually considered to be safe, cheap and painless technique used for the 
evaluation of the small fiber neuropathy (include the symptoms of burning, deep and 
aching pains in the feet). Using bright field microscopy to measure the density of the 
fibers. It can also be repeated within nerve fiber territory to determine the effect of 
the treatment in which steroids and immunoglobulin also used to determine the 
progression of diabetic neuropathy. According to one of the study, the positive 
predictive value is estimated as 93% in the detection of small fibre neuropathy, with 
the specificity of 97% and sensitivity from 69% to 82% (Lauria et al. 2005). Skin biopsy 
is used to investigate the various function of the small fiber which is helpful in clinical 
practice. This technique is useful in pain neuropathy to detect the abnormality i.e. 
unmyelinated axon that carries pain sensation of the target nerve. Skin biopsy is also 
used for detection of demyelinating neuropathies (Pan et al. 2003). The limitations of 
skin biopsy are, it is an invasive technique,  It has to be performed in a limited number 
of specialised clinics and where the diagnosis of the abnormalities has to be preceded 
in the established laboratory (Lauria and Lombardi 2007). 
 
(i) Corneal confocal microscopy 
It has been reported that the evaluation of corneal nerve structure performed using 
corneal confocal microscopy (CCM) has been considered as a reliable measure of 
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diabetic neuropathy. CCM of human eye is one of the new screening modality which is 
used for early demonstration of nerve fibre damage. In this technique, CMM makes 
use of a light beam to pass through the aperture which is focused by the objective lens 
into the layer of cornea. Elimination of all the light is done by beam splitter and a 
photodetection device. Using this technique,  three methodologies such as tandem 
scanning CCM, split scanning CCM and laser scanning CCM has been developed 
(Papanas and Ziegler 2013). Split scanning CCM and laser scanning CCM are used to 
examine corneal nerve damage in patients with diabetes with or without diabetic 
neuropathy (Papanas and Ziegler 2013).  It is considered to be an effective non-
invasive, repeatable measurement technique for the detection of diabetic neuropathy.  
Considering the fact that corneal nerve fibre damage is more common and severe in 
subjects within DSPN, it is recommended to use CMM for its diagnosis. It was noted 
that in the recently diagnosed diabetic patients also, CMM is sensitive enough to 
determine corneal nerve fiber perturbations (Ziegler et al. 2014b). This technique is 
used for the early diagnosis of high-risk foot and nerve damage with moderate 
sensitivity and specificity (Papanas and Ziegler 2015). Finally, CMM is the non-invasive, 
fast, reproducible, measures small fiber nerves and quantitative technique. However, 
many more critical questions need to be addressed like whether CMM parameter is 
capable enough to predict patients oriented results such as the pain and disability. 
Hence, this technique can be useful in diabetic neuropathy assessment with the 
further implementation of more image processing/analysis techniques for improving 
its performance. 
 
(j) Semmes-Weinstein Monofilament examination – pressure perception examination 
Physicians use many quantitative methods for the detection of diabetic sensory 
peripheral neuropathy. This method is mostly used for the detection of the protective 
loss or for the pressure perception examination. The threshold of 5.07/10 gram 
monofilament was established in 1985 (Birke and Sims 1986). The different size of the 
monofilament 4.17, 5.07 and 6.28 were tested on 72 patient with leprosy and 28 
patients with diabetes mellitus. The test has concluded that 5.07 monofilament is the 
threshold for detecting DPN as no patient with foot ulceration was able to sense the 
5.07 monofilament. Another study was performed where 199 patients were tested 
and it was concluded that 5.07 is best for predicting foot ulceration in diabetes 
mellitus patients (Olmos et al. 1995). The main advantages of using Monofilament 
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examination are it is non-invasive, low cost, rapid, routinely self-assessment and easy 
to use the method. Different sites on the plantar surface of the foot have been chosen 
for the monofilament examination. However, it is not fixed which sites and how many 
times each site needs to be examined. Usually, three or five sites are used for the 
monofilament examination. International Working Group on Diabetic Foot has 
recommended using three sites that are planter surface of the distal hallux, first and 
fifth metatarsals head for the examination (Karl Guttormsen 2017). The cost of 
disposable monofilament is about $0.50 (Feng et al. 2009) and the sensitivity of the 
monofilament test is >87% and specificity is ranging from 68% to 100% (Boulton et al. 
2005a; Dros et al. 2009). Various methods used such as pinprick and a light touch, 
however, one of the most important limitations of these modalities is the application 
of stimulus which is inconsistent while the application of monofilament stimulus 
provides constant pressure (Smieja et al. 1999; Schaper et al. 2016). This test is widely 
used as a screening tool for DPN (Mayfield and Sugarman 2000) but not for the 
definite diagnosis of sensory neuropathy. The Procedure for using Monofilament test 
is as described below:       
 
                                                    
Figure 2.2: Vibration sites for application of monofilament test (Schaper et al. 2016) 
 The patient should feel relax and ready for the 10g Semmes-Weinstein Monofilament 
examination. The test should be performed in a quiet environment. 
 Apply the 10g Monofilament on the hands so that the patient is aware of the type of 
applied pressure. 
 Apply the monofilament on any of the test sites as shown in Figure 2.2. 
 Monofilament should be applied perpendicular to the sites for 1 second until it bends. 
 The total duration of applying the monofilament and removal should be around 2 
seconds. 
 Apply the pressure in all the three sites of both the foot and the patient is asked to 
respond whether they feel the pressure or not and where they feel the pressure. 




 Pressure perception/protective sensation is present if the patient’s two out of three 
answers are correct and there is a loss of protective sensation if two out of three 
answers are incorrect for that particular site (Schaper et al. 2016). 
 
(k) Ankle jerk 
The Ankle jerk is also known as an ankle/Achilles reflex test. This test is performed 
using a standard reflex /neurological hammer.  The shape of the hammer is a triangle 
and flat part of the hammer is used to find the reaction of the reflex on the Achilles 
tendon.  The clinician/practitioner holds the standard hammer using the handle with 
their thumb and forefinger where the flat part is towards the subject’s Achilles tendon 
area. Other than standard hammer there is an availability of advanced reflex hammer 
similar to pendulum hammer. 
 
Figure 2.3: Ankle jerk test (Tanenberg and D. Donofrio 2008) 
This test is simple and a part of lower limb examination. It can be used for diagnosing 
complications like peripheral neuropathy, hypothyroidism or Charcot Marie tooth disease by 
measuring the grade of Achilles tendon. In this test, the patient should be laying on the 
examination table with their Achilles tendon is exposed from superior calf to plantar aspect of 
the foot (Ziff and Stark 2017) shown in Figure 2.3. When the examiner strikes the Achilles 
tendon directly with the standard reflex hammer, it is considered as positive if the calf muscle 
contracts and foot plantar flexes. The degree of the positive results is graded based on the 
scale from 0 to 4+, where 0 is the no response, 1+ is considered to diminish, 2+ is considered 
average, 3+ is above average and 4+ is considered as hyperactive with clonus (Ziff and Stark 
2017).  
This test is used only for finding the Achilles reflex with rare complications of performing this 




2.2 Devices based on vibration perception thresholds 
Vibration perception threshold (VPT) is also one of the widely used concepts for the diagnosis 
of sensory neuropathy. It is defined as the lowest voltage at which vibration is detected up to 
50% of the time tested (Michelle Branigan 2014). VPT is considered as quick and low risk for 
the detection of long-term complications of neuropathy based on the type of the instruments 
used as per the expert opinion (Garrow and Boulton 2006). Clinical tools such as 128-hertz 
tuning fork, a semi-quantitative electromechanical instrument as Biothesiometer and 
Neurothesiometer are commonly used for measuring VPT. 
(a) Tuning Fork 
There are mainly three types of tuning fork used for the assessment of VPT such as 
non-graduated tuning fork, graduated tuning fork and an electronic tuning fork. A 
simple non-graduated 128 Hertz tuning fork is just used to measure the absence and 
presence of vibration perception in the patient, because of this limitation it is 
psychophysical in nature and due to lack of standardization it cannot be used for 
clinical findings. There was a need for a more advanced instrument that can predict 
the amplitude at which vibration is perceptible led to the development of graduated 
tuning fork. The graduated tuning fork uses the vibration extinction threshold with the 
scale from 0 to 8. When the score is  (less than 4/8) then it is the alarm for high-risk 
complications of neuropathy (Garrow and Boulton 2006). There are several 
advantages of using a tuning fork it is easy to use, quick and portable where the 
patient does have to undergo for the long and complex procedure. The procedure for 
the test is fairly simple as shown in Figure 2.4.  
 
Figure 2.4: Procedure to conduct a tuning fork test (Schaper et al. 2016) 
The sensory exam should be carried out in a quiet and relaxed setting. First, vibrate 
the tuning fork and apply the tuning fork on the patient’s wrists (or elbow or clavicle) 
so that he or she knows what to expect. 
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• Tuning fork is applied on a bony part of the first toe on the dorsal side of the distal 
phalanx. The patient must not be able to see whether or where the examiner applies 
the tuning fork 
• Apply the tuning fork perpendicularly with constant pressure. 
• Repeat the procedure for two times and at least one ‘mock’ where tuning fork is not 
vibrating. 
• If the patients is giving correct answers i.e. vibration is provided and subject could be 
able to sense at least two out of three applications then considered as normal and if 
two out of three answers are incorrect then the patient is under the risk of ulceration. 
• If the patient is unable to sense the vibrations on the big toe, the test is repeated more 
proximally (malleolus, tibial tuberositas). 
• Encourage the patient during testing by giving positive feedback (Schaper et al. 2016). 
 
(b) Electronic tuning fork  
As discussed, 128 Hz tuning fork have used for the detection and progression of 
diabetic neuropathy. Although tuning fork is the sensitive tool, however there is a lack 
standardisation and qualification of neuropathy findings (O'Brien and Karem 2014b). 
For improving the standardisation of the testing there is an introduction of a novel  
128 Hz electronic tuning fork (ETF) (O'Brien and Karem 2014b). The ETF produces the 
vibration and the decay rate is the same as the standard tuning fork. In order to 
perform the timed vibration test more accurately the integrated timer is introduced 
electronically that facilitate reproducible timed vibration test (O'Brien and Karem 
2014a).  The time vibration test have shown improved method for detecting diabetic 
neuropathy (Botez et al. 2009).  
The method of using ETF is simple and straight forward. When the device is activated, 
it starts the vibration and integrated timer. When it is applied on the hallux, subject 
will be asked to verbally indicate ‘yes’ or ‘no’ after they perceive the vibration. If they 
indicate ‘no’ it needs to indicate as 0 sec elapsed time. If they say ‘yes’ then they need 
to ask when vibration has subsided after their perception of vibration by saying ‘now’ 
and at that moment vibration needs to be stop  to record the elapsed time. 
The limitation of ETF is there is no variation in applied vibration stimulation in terms of 
vibration amplitude with constant frequency. So if the vibration amplitude can vary 




(c) Biothesiometer and Neurothesiometer 
Biothesiometer and Neurothesiometer are quick, portable and inexpensive 
instruments (Garrow and Boulton 2006). They are semiquantitative electromagnetic in 
nature. It is easy to categories the high risk and low risk of ulceration based on VPT 
scores. If VPT is more than 25 score, the patient is at high risk of ulceration and 
patients having less than 15 scores, the patient is at low risk of ulceration (Van 
Deursen et al. 2001). 
Biothesiometer is the electromechanical device which is used to produce vibration 
through vibration probe.  It is basically used to determine vibration perception 
threshold. Biothesiometer (BioMedical, Newbury, Ohio, USA) is widely used by 
clinicians (Figure 2.5), however, as Biothesiometer is operated on main electric supply 
has raised the concern for safety in United Kingdom that led to the development of 
battery-operated  Neurothesiometer (Arnold Hoi-well, London, UK)(Watts et al. 1986) 
as shown in Figure 2.6.  
 
          
 
Figure 2.5: Biothesiometer (BioMedical, 
Newbury, Ohio, USA) 
 
                
 
Figure 2.6: Neurothesiometer (Neurothesiometer 
2016) 
 
With the advancement of technology, the Analog Biothesiometer is replaced by Digital 
Biothesiometer. The Biothesiometer is the electronic tuning fork where the amplitude 
is completely adjustable in a particular range and based on this amplitude it is possible 





(d) Procedure to use Biothesiometer / Neurothesiometer 
 
 
Figure 2.7: Testing using Biothesiometer (Singh et al. 2012)  
Biothesiometer is very simple, convenient and easy to use. Normally pulp of the big 
toe,1st,3rd and 5th metatarsals are chosen as the vibration sites as shown in Figure 2.7 
(Singh et al. 2012). Vibration probe is placed perpendicular on the selected sites and 
allowed to vibrate at different intensities. The manual potentiometer is used to adjust 
the vibration intensity. The range of the dial is from 0 to 50 Volts in order to provide 
the vibration at different intensities. The operator has to hold the vibration probe on 
the site to be examined. The Vibration intensity is increased until the patient feels the 
vibration. The patient is asked to respond ‘Yes’ whenever vibration is felt. It records 
the exact voltage at which the patient feels the vibration. The degree of loss of 
sensation depends on the recorded voltage. Higher the recorded voltage, the patient 
has more susceptibility to the loss of sensation and greater risk of foot ulceration. 
According to this study (Singh et al. 2012), if the VPT score less than 15V then subject 
is having a low risk of DPN, between16 to 24V the risk is moderate and greater than 
24V is the high risk for DPN. 
To diagnose the sensation loss, the Biothesiometer uses the vibration to stimulate the 
human receptors so, frequency and amplitude of the vibration have to be taken into 
consideration. When measuring this, there are mainly four type receptors Meissner 
receptor, Pacinian corpuscles, Merkel disks and Ruffini endings situated at the dermis 
and epidermis layer of the skin Figure 2.8. In order to diagnose the sensation of the 







Figure 2.8 : Epidermis of the skin (Rochester 2007) 
 
Meissner receptor 
This receptor is responsible for high sensing pressure and primarily related to touch and faster 
movements. In order to activate the Meissner receptor, the activation frequency should be 
(Rochester 2007) in the range of the 40 to 100 cycles per seconds (Goldberg and Lindblom 
1979). 
Pacinian corpuscles 
Pacinian corpuscle is concentrated at fingertips, palms, soles, toes, muscle, around the blood 
vessels, joint ligaments, nerve trunks and bony periosteum (Bolanowski and Zwislocki 1984; 
Temlett 2009). Displacement of subcutaneous tissue and periosteum which contains Pacinian 
corpuscle gets activated by the vibration from the energized tuning fork. If horizontal 
displacement or the stretch is applied then it may be less effective to activate Pacinian 
corpuscle (Mountcastle et al. 1967). It can be activated at frequencies as low as 0.4 Hz. 
 
Merkel disks are sensitive to pressure and slower movements: Although not targeted, these 
are insensitive to changes in frequency and consequently, yields a curve that is essentially flat 
(Verrillo and Bolanowski 2003). 
Ruffini ending are sensitive to pressure and slower movements and can be accessed by using 
an extremely small contractor surface driven at high intensities. 
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The utility of Biothesiometer and Neurothesiometer based on above perception signifies that 
receptors are responding to the frequency of vibrations. Biothesiometer utilizes 100 hertz 
which is the frequency between Pacinian corpuscles (around 250) and Meissner corpuscles 
(around 40) (Duke et al. 2007). However, other studies have found that vibration threshold at 
lower frequencies (for Biothesiometer at 50 or 60 Hz) there is an effect of temperature 
difference within the normal skin temperature (Halonen 1986). Looking at the Biothesiometer 
and Neurothesiometer vibration frequency, different manufacturer have utilized different 
frequencies that are either 50 - 60 Hertz or 100 hertz which ultimately comes under the 
frequency range to target Meissner and Pacinian corpuscles. Young et al (1993) have done the 
comparative study between Biothesiometer and Neurothesiometer. They concluded that 
Neurothesiometer instrument is developed to replace the Biothesiometer to measure the 
vibration perception threshold for the screening of diabetic neuropathy. In this study 85 
diabetic patients having an average duration of diabetes for 12 years and mean age of 61 are 
selected for measuring VPT using both Biothesiometer and Neurothesiometer. There was a 
close correlation between two devices (r = 0.93 p < 0.0001) when both VPTs are compared. 
Biothesiometer VPT was 29.9 ± 15.2V and Neurothesiometer VPT was 26.2 ± 13.4 V. 
Biothesiometer operated from the mains power vibrates at 50 Hz of frequency and 
Neurothesiometer which is battery operated vibrates at 56 Hz.  The patient coefficient of 
variance for Biothesiometer and Neurothesiometer was 8.6% and 8.1% respectively. Although 
Neurothesiometer is more expensive than Biothesiometer but it is self-contained, battery 
operated and well suited for screening for DPN. 
 
Limitations of Biothesiometer/Neurothesiometer: 
1. The VPT normally increases with age so that above the age of 70- a normal VPT score 
is already close to the maximum output of the Biothesiometer (Bloom et al. 1984). 
2. Many subjects with neuropathy appear to have scored at the limit of the 
Biothesiometer amplitude scale – close to or at 50 V indicative of a ceiling effect (Van 
Deursen et al. 2001). 
3. It is noted that the Biothesiometer probe does not vibrate in a single plane. There was 
a  large difference between two Biothesiometer in relation to the applied voltage and 
the actual stimulator movement (Goldberg and Lindblom 1979). 
4. Biothesiometer has not been taken into routine practice perhaps because of the 
confounding effect of limb temperature, psychological factors, the amount of pressure 
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applied by the vibratory probe and choice of the limb as well as tactile surface of the 
skin (Pourhamidi et al. 2014) 
5. Biothesiometer is not sensitive enough to detect the small fiber neuropathy but might 
be useful for the early detection of the neuropathy when used in the combination with 
the measure of small nerve fibres function such as skin biopsies (Pourhamidi et al. 
2014). 
6. Biothesiometer has the disadvantage of being larger and requiring attachment to an 
electrical point to drive an accelerometer to activate the probe although may apply 
vertical pressure more accurately and objectively. However, this limitation has been 
overcome by developing battery operated Neurothesiometer (Ohnishi et al. 1994). 
7. As the vibration probe is handled by the operator, the pressure of the applied stimuli 
may vary while testing vibration perception threshold. 
8. Neurothesiometer and Biothesiometer utilize fixed frequency to vibrate the probe, it 
cannot be changed once it is manufactured (Table 2.1). 
Table 2.1: List of companies’ manufacturer of Biomethiosmeter/Neurothesiometer with frequency specifications 
Serial Number  Company Device Fixed 
Frequency(Hertz) 






2 Beijing beauty equipment 
company 
(Biothesiometer 2017a).  
Biothesiometer 50 








Going through the above limitations of the devices used for the detection of DPN using 
vibration perception method there are several parameters which are really important to 
consider for developing a smart device. The limitations are vibration frequency dependent, 
vibration sites, the pressure of the probe on the skin and temperature are the other factors to 
consider. If all these parameters are considered properly then it will be easy to accurately 
detect neuropathy at an early stage based on receptor activation Figure 2.9 shows factors 









Activating the Receptor – 
Pacinian corpuscles




Figure 2.9: Activation of receptors to determine peripheral neuropathy 
 
As per the gathered information from the literature search, all the necessary parameters such 
as pressure, vibration sites, vibration amplitude, and temperature were considered as shown 
in Table 2.2. 
 
Table 2.2: Key design parameters identified through Literature survey 
Author Description 
Pressure 
Lowenthal et al 
(1987) 
By increasing the weight from 200 g to 400 g, that is increasing the 
pressure of the applied stimulus is increased, there is a considered 
reduction in the vibration sensory threshold (VST) however, this was not 
seen when weight is > 400. 
In peripheral neuropathy, VST decreases as the pressure of applied 
stimulus increases (Lowenthal et al. 1987). 
 
Vibration sites 
Williams et al 
(1988) 
Vibration perception threshold was measured at both big toes and both 
medial malleoli for screening of diabetic neuropathy using Biothesiometer 
(Williams et al. 1988). 
 
Van Deursen et al 
(2001) 
The Plantar surface of the feet was chosen because this area is routinely 
used in screening to characterize the risk of ulceration in diabetic 
neuropathy (Van Deursen et al. 2001). 
 
Loseth et al 
(2007) 
Great toe was chosen to be examined using 256 Hz and128 Hz tuning fork 
(Løseth et al. 2007). 
 
Singh et al (2012) Various points on the foot like the pulp of the big toe, first, third and fifth 
metatarsal head were used for examination using Biothesiometer (Singh 






                                                                     Vibration amplitude                                                  
Van Deursen et al 
(2001) 
The vibration of 1000 micrometer applied to the foot is quite severe and 
can travel through the limb so that it will be perceived at the ankle, the 
knee or even more proximally, despite the fact that they took measures to 
avoid this as much as possible (Van Deursen et al. 2001). 
 
                                                                      Temperature 
Verrillo et al 
(2003) 
The Pacinian channel at suprathreshold levels of vibratory stimulation is 
affected by the temperature at the surface of the skin as is the Ruffini 
channel. As temperature increases, the perceived intensity of vibration 
increases in an orderly manner. Temperature has an effect on the Pacinian 
channel above 100 Hz. 
 
The subjective magnitude of vibration is not appreciably influenced by skin 
temperature at frequencies that optimally activate the Meissner and 
Merkel channel (Verrillo and Bolanowski 2003) 
O’ Brien et al 
(2014) 
 
 An ambient temperature of 70F to 72 F(21 to 22-degree Celsius) was set 
constant during the VPT test using 128-hertz electronic tuning fork in the 
treatment room (O'Brien and Karem 2014a). 
 
If the examiner detected vibration for less than 20 sec in total hallux score 
(10 sec per hallux), the patient was considered to have normal sensation. 
A score greater than 40 Sec (20 sec per hallux) indicated neuropathy 
(O'Brien and Karem 2014a). 
 
In conclusion, most of the methods and test available for diagnosing diabetic neuropathy were 
studied in details. Devices such as tuning fork, Biothesiometer/Neurothesiometer are available 
to measure vibration perception threshold, however, these techniques are operator 
dependent and pressure measurement is not taken into consideration. To overcome 
limitations the aim of developing a standalone, portable, operator-independent device where 
the result can be automatically interpreted is taken into account for developing a device. The 
technique of diagnosing DN through vibration perception is considered for the development of 









Chapter 3  Development of Device 
 
This chapter focuses on the development of the neuropathy assessment device. As discussed 
in Chapter 2, various methods available for detection of diabetic neuropathy were carefully 
studied, the techniques based on the vibration perception threshold were considered for the 
development of the device. Device development involves various steps like requirement 
gathering phase (focuses on parameters like pressure, vibration sites, vibration characteristics, 
and vibration direction), design drawing, hardware designing, electronic circuit and software 
development which will be discussed in detail.  As the device is based on the vibration 
sensation, various available vibrator motors/actuators such as Eccentric Rotating Mass 
Vibration (ERM), linear resonance actuators and C2 HDLF tactor were experimented to identify 
their vibration characteristics (like amplitude, frequency and vibration direction). The analysis 
on selecting these motors were performed and to come out with specific.  C2 HDLF tactor 
which is capable of generating required nature of vibration. Pulse width modulation 
technique was used for controlling the motors in terms of amplitude and frequency. For real-
time monitoring of the pressure, Force sensitive resistors were used and its placement was 
critically analysed. The initial design was developed for one foot for the evaluation phase.  The 
evaluation phase involved hardware design, electronic circuit and software development for 
the initial version of device.  
Based on the evaluation results the design was upgraded for both feet. In the latest version of 
design, to avoid the vibration leakage, the vibration isolation technique was implemented 
using springs with its technical analysis. The step by step development of the device is 
explained in the chapter. Graphic user interface was made user-friendly, easy to understand 
with real time pressure monitoring option. The technique of conducting the test is also 
updated which reduces the overall time of conducting the test. The whole setup is wirelessly 
controlled using Bluetooth module which will be described in the electronic circuit section. 
Later on, the plan to perform comparative study with Neurothesiometer device for 







3.1 Requirements for Device development 









Figure 3.1 : Requirements for activating human touch receptors 
(1) Pressure is considered while applying vibration to the human subject. 
Neurothesiometer is used for detection of neuropathy where the vibration stimulus is 
provided by holding the vibration probe against the body contact surface. During the 
contact, there is a possibility of applying vibration with varying pressure. Applying 
vibration with inconsistent pressure may affect the activation of the receptors. 
According to a study when the weight is increased from 200 grams to 400 grams the 
vibration perception threshold increases and that when the Neurothesiometer 
vibration probe at rest position it exerts the pressure of 320 grams (Lowenthal et al. 
1987).  In order to apply uniform and consistent pressure, innovative design has to be 
developed. In this project a weighing scale like platform is proposed where vibration 
motor can be fixed on the plate and subject is allowed to comfortably place their feet 
on the plate to receive vibration. The plate for placing the feet is kept inclined and 
Force sensitive resistors are used to monitor the pressure. They are used for the 
continuous monitoring of the pressure applied on the plantar surface of the foot. 
Pressure will be monitored during entire test so that it provides consistent result.  
 
(2) It is important to identify the correct vibration sites to apply the vibration, as this is 
the key point for the early detection of diabetic neuropathy. There is a loss of touch 
and vibration sensation at the early stage of the disease. Therefore those sites can be 
selected which are primarily affected and are more likely to experience the early 
consequences of the complication. Usually, for monofilament test as discussed in 















conducting the monofilament test, Big toe, third and fifth metatarsals are selected as 
vibration sites (Foot 2015). Vibration perception threshold examination using 
Biothesiometer were carried out on the big toe, first, third and fifth metatarsal as the 
vibration sites (Singh et al. 2012). An advice for conducting the tuning fork test by 
International Working Group on the Diabetic Foot (2015),  big toe is selected as the 
vibration site (Foot 2015). Based on these studies, Big toe is considered to be the 
most appropriate site for applying the vibration in the proposed study. 
 
(3)  Vibration characteristic is defined by two parameters, Frequency and Amplitude. The 
vibration amplitude is the peak point referred to as the maximum excursion of the 
wave from the zero or equilibrium point. And peak to peak amplitude refers to the 
distance from positive peak to negative peak in the vibration wave. Vibration 
amplitude is measured in three different units such as displacement (mm/microns), 
velocity (mm/s), and acceleration (mm/s2). The displacement is also related to 
voltage. Vibration amplitude is important to precisely identify the vibration 
perception threshold of the skin since the subject will feel the effect of the vibration. 
As the amplitude increases, the effect of sensing the vibration will become more 
prominent. To correlate this information with sensation, the specification of 
biothesiometer and neurothesiometer are studied. In biothesiometer (Beijing Beauty 
Equipment Company) the peak amplitude range of vibration probe is between 0μm -
25μm, maximum peak amplitude range of vibration probe is 25μm, the error range of 
± 10mm (Biothesiometer 2017a). For Neurothesiometer (by Algeos), the range may 
be switched to Normal = 0 to 50 volts/0-250 microns and Expanded = 0 to 25 volts/0-
62.5 microns (Neurothesiometer 2017). This shows that the maximum displacement 
of the vibration goes up to 250 microns which means the vibration amplitude by our 
proposed method should be equal to or more than the required range. This point is to 
be considered and range of the vibration for the proposed design is to be from 0 to 
350 microns (maximum peak amplitude) at 100 Hz. 
 
(4)  Vibration frequency plays a vital role in activating the receptors. As discussed in 
Chapter 2, there are four types of receptors and have different ranges of the 
frequency. Meissner receptors respond at around 40 hertz and Pacinian receptors 
respond at around 250 hertz. To activate these groups of receptors biothesiometer 
and neurothesiometer vibrates at a specific frequency. According to the specifications 
of these existing devices, as discussed in Chapter 2, both 50 Hz and 120 Hz vibration 
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frequencies are provided to the vibration probe and the frequency is generally fixed, 
the user cannot change it. In the proposed design a wide range of frequencies is 
possible to vibrate and can be fixed as well. So the range of the frequencies available 
in the proposed design is from 50 Hertz to 120 hertz. 
 
(5)  Other than vibration frequency and amplitude, activation of the receptor also 
depends on the vibration or displacement direction. Vibration could be on the 
horizontal or in the perpendicular direction of the skin. If horizontal displacement or 
stretch is applied then it may be less effective to activate Pacinian corpuscle 
(Mountcastle et al. 1967). So vibrator motor in the proposed design is selected that 
vibrates in perpendicular to the skin to activate the receptors. 
Considering all these parameters, development of platform based device was considered; here 
the method of conducting the test will be different from the Neurothesiometer/ 
biothesiometer. The detailed design of the device is discussed below. 
3.2 Designing the device 
For providing the vibration stimulus at the big toe, a platform based device was considered. So 
the question here is whether a subject should stand on the plate and start the test or should 
sit on chair while placing the feet on inclined plate. While standing on the platform, there 
could not be the possibility of changing the pressure and depending on the weight of the 
person the pressure may vary while conducting the vibration perception test. However, this is 
not a comfortable position, the idea of conducting the test by placing the feet on the platform 
after sitting on the chair seems more comfortable. In this way, the pressure exerting on the 
vibration motors can be monitored using sensors while vibration is applied. 
The design of the device is first modelled using computer aided software called Solidworks. At 
first it was designed for one foot (left). The intension was to create a portable and easy to use 
device. Keeping that in mind the design consists of three main parts. One is the base plate, test 
plate and the holder plate. It is designed such that there is a possibility of changing the 




Figure 3.2 : Solid works design model of the device 
The design is shown in the Figure 3.2, the inclination angle can be adjusted according to the 
ankle joint of the subject. 
Design Description: 
 
               Figure 3.3 : Schematic diagram of the model 
The design with three plates is shown in Figure 3.3. The base plate is 60 cm long and used to 
support the whole assembly. The base plate consists of 16 V-girders to provide the inclination 
and also gives the support to other two plates.  The holder plate is 25.6 cm long, 21 cm wide 
and 0.5 cm thick used to change the inclination whose one part is on the V-girders to fix the 
inclination angle and another part is connected to the test plate with a hinge joint. The test 
plate is also 25.6 cm long, 21 cm wide and 0.5 cm thick which is connected to the second plate 
and connected to the base via a hinge joint. This test plate will be used by the subject to 
comfortably place their foot on it.  
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To make it light and portable, the whole design is made up of the high-quality acrylic plastic 
sheet due to its durability, easy to use, transparency and chemical resistance. It comes in 
different colors, thickness, and grades. For the current purpose, the clear acrylic sheet has 
been used with thickness of 0.5 cm. The overall weight of the device is not more than 3 
kilograms. The hardware device has two holes to mount the vibrations motor shown in Figure 
3.4. 
 
    Figure 3.4 : Placement of the vibration motors 
Four hinge joints are used, two between the holder and test plate and another two between 
the test and base plate. These joints are used for changing the inclination angle of the test 
plate for testing in a comfortable position. 
3.2.1 Vibration stimulation techniques 
In order to generate the vibration stimulation, there is a need for an external source to 
generate the vibration. One of the technologies which are widely accepted for detection of 
neuropathy is vibration through the electromagnetic coil. It has been implemented on devices 
like Neurothesiometer and Biothesiometer which are operated by alternating signal to 
generate the vibration. When current flows through the coil, the magnetic force is exerted by 
the coil which varies with applied voltage. For varying the voltage, potentiometer is used. For 
this project, different types of vibration motors were studied and experimented to understand 
the effect of vibration on the surface of the skin. Using tuning fork and neurothesiometer 
vibration probe, it was noticed that the vibration should be provided in the perpendicular 
direction to the skin surface to provide the effective stimulation. The technology used in 
Biothesiometer/ Neurothesiometer have several limitations: 
1. The vibration frequency in these devices is fixed. 
2. Electronic circuits were used. 
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3. The vibration parameter such as amplitude is manually controlled using 
potentiometer. 
Criteria for vibration motor selection: 
1. The vibration should be provided in the perpendicular direction to the skin to provide 
the required stimulation. 
2. The physical characteristic of the vibration such as frequency, vibration amplitude 
range should be adjustable i.e. the system should be capable enough to generate the 
vibration in the required range. 
- Frequency range – should cover at least 100 hertz as that of the 
Neurothesiometer. 
- Vibration amplitude should at least cover the Neurothesiometer range that is from 
0 to 250µm (Neurothesiometer 2017). 
3. The surface area of the motor contactor should be large enough to provide the 
required vibration. 
With the available information on vibration generation the challenge was to find a suitable 
vibration motor that could fit these requirements. The aim was to find a vibration motor 
which is capable enough to generate the vibration with required parameters (frequency 
and amplitude). Based on these criteria, various vibration motors such as eccentric mass 
vibration motor, linear resonance actuator and tactor (linear actuator) were examined. 
3.2.2 Eccentric mass vibration motor 
 
Figure 3.5 : Eccentric rotating mass vibration motor 
There are wide applications of this type of motors. Eccentric rotating mass (ERM) vibrator 
motors were mostly used in pagers and mobile phones or by cell phone industries, however, it 
is still being widely used in smartphones. Model 312-101 is a coin ERM DC motor and it is also 
known as shaft less or pancake motor. The benefits of using coin ERM motor, are it is easy to 
use and cheap. According to the specifications of the motor, it is having 12 millimeters of body 
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diameter, vibration speed is 12500 rpm that is 208 Hz of frequency and vibration direction is in 
X and Z directions but not in Y – direction which is required for this application as shown in 
Figure 3.5. 
 
Figure 3.6 : Performance characteristic of the ERM motor (ERM 2017) 
The performance graph of this motor is shown in Figure 3.6. When a voltage is increased from 
the 0 to 3.6 volts the frequency is increased from 60 to 260 Hz. With fixed frequency, the 
motor is unable to vary the amplitude. For example, it is possible to generate 120 Hz of 
frequency by applying a fixed 1.4 Volts. As per the requirement of the device, the frequency 
should remain constant with varying voltage (see Appendix D). 
Limitations of this motor:  
1. Frequency increases with increasing the voltage. 
2. The vibration is in both directions that is X and Z direction as shown in Figure 3.5, so 
when experimented with this motor by mounting on the inclined plate, the whole 
plate was vibrating  making it unsuitable to stimulate the required area of big toe. 
3.2.3 Linear Resonant Actuator  
This is also a coin type of the motor but it is different from ERM motors in terms of its working 
principle, and longevity. Although it has the long lasting life, driving the motor is bit complex. 
LRA motor drive is similar to the loudspeaker which means it requires an analog signal of the 
particular frequency to drive it. From the name itself, it is clear that resonance frequency is 
required to turn it ON. As per the available specifications, it has 10 millimeters of body 




Figure 3.7 : Linear resonant Actuator with its vibrating direction 
 
Figure 3.8 : Input signal to drive Linear Resonant Actuator 
For the above model, 175 Hz of the alternating signal is required as shown in Figure 3.8 to 
vibrate it. In LRA motor is it possible to fix the frequency and change the amplitude from 0 to 2 
Volts maximum (datasheet available in Appendix D). 
Although it is satisfying the requirements of vibrating perpendicularly at fixed frequency and 
able to vary the voltage and unidirectional vibration, however, the range of frequency in which 
LRA motors are available is limited. LRA motor with a frequency less than 175 Hz is not 
available. The requirement of vibrating the motor at 100 Hz is not possible. 
3.2.4 High displacement and low frequency tactor 
High displacement and low frequency (HDLF) tactor (C2) is magnet linear actuator that has a 
frequency range of 60 – 160 Hz of mechanical resonance which provides high force and high 
displacement. It is designed in such a way that any of the frequency between 60 – 160 Hz is 
possible to set. Driving this motor is similar to that of LRA motor. When an electric signal is 





Figure 3.9 : C2 HDLF vibration motor 
 
 
Figure 3.10 : Displacement Vs Frequency graph of vibration motor (C2HDLF 2017) 
The displacement versus frequency graph is shown in Figure 3.10. If the frequency of vibration 
is fixed at 100 Hz, it is possible to obtain the maximum peak to peak displacement of 0.7 mm. 
Varying frequency will vary the displacement (see Appendix D). 
C2HDLF benefits: 
1. By varying the electric drive parameters, it is possible to change the vibration. 
2. The frequency range provided by this tactor is from 60 – 160 Hz which is exactly 
matching the requirements and is possible to match with the neurothesiometer 
device. 
3. Unlike neurothesiometer which always vibrates at fixed frequency, using this motor it 
is possible to adjust any frequency between 60 to 160 Hz. 
4. The direction of vibration is perpendicular to accurately activate the required 
receptors. 
5. The body weight of the motor is only 30 grams with a body diameter of 1.2” and 
height of 0.50”, easy to mount on the required plate. 
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6. The main advantage of using this motor is that the applied vibration will be just 
focused on selected vibration site without affecting the mouting plate and the entire 
system. 
Thus, from this discussion and comparing all these motors it is clear that C2 – HDLF tactor is 
the vibrator motor which is most suitable for providing required vibration stimulus to the body 
and therefore selected for the proposed device. However, the motor does not run on its own, 
a special circuit needs to be designed to operate at the required frequency and amplitude. 
Using this tactor, it is possible to overcome the design constraints as shown in Table 3.1. 
Table 3.1 : Required parameters satisfied using C2 HDLF tactor 
Parameters Requirements Satisfy or don’t Satisfy 
Vibration Direction Perpendicular or in one 
direction 
Satisfy  
Vibration Frequency Should be 100 hertz Satisfy – Is even possible to 
set any frequency between 
60 – 160 Hz. 
Vibration amplitude( 
displacement) 
≥250µ Satisfy – at 100 Hz possible 
to achieve up to 350µ. 
Compatible to use on 
proposed  plate 
Should be easily placed on 
the plate to provide vibration 
Satisfy – Based on the body 
diameter, tactor is possible 
to fit on the plate. 
 
3.2.5 Pressure monitoring using Force Sensitive Resistors (FSR) 
For measuring the pressure, there are various technologies available which can be used for the 
device. The main objective of using pressure sensor is to monitor the pressure during the test. 
In Neurothesiometer, the vibration probe is applied on the skin surface without monitoring 
the pressure during the test. Because of this there is a possibility of human error. To overcome 
this limitation a pressure sensor (Force sensitive resistors) could be used on top of the 
vibrating motors. 
Force sensitive resistors: 
 
Figure 3.11 : Force sensitive resistors for pressure monitoring 
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The purpose of using the FSR in the device is to determine foot placement on the plate and to 
monitor the pressure during the test. FSRs are the special type of resistor consists of 
conductive polymer whose resistance changes by varying pressure on it. The active area of the 
sensor is ø14.68 mm and the thickness of the sensor is 0.46 mm shown in Figure 3.11. If the 
high pressure is applied, the resistance of the FSR decreases and when no pressure is applied 
the resistance remains the same. When these FSRs are connected to a microcontroller and 
pressure is applied, it shows FSR analog reading. The analog inputs of the microcontroller 
Arduino Uno are 10-bit which shows the analog readings between 0 to 1023 values. For 
example, if 100 grams of weight is applied on FSR then the FSR analog value is around 340. 
These values vary with varying pressure which has been calibrated using known weights set of 




), where b is the base length of the plate which is 33.3 cm at the initial 
position and increases by 0.1 cm per inclination from position 1 to 16 shown in Figure 3.13, c is 
the inclination plate length to place the foot which is 29.5 cm and a is the supporting plate 
length to which is 25 cm. 
           
Figure 3.12 : Calculation of inclination angle 
 
Figure 3.13 : Inclination changes from 1 to 16  
When the constant weight of 100 grams is placed on the inclined plate then the weight on 
sensor can be calculated at each inclination as shown below: 
 
Figure 3.14 : Weight placed on an inclined plate 
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Where W is the constant weight of 100 grams, α is the inclination angle. Based on this the 
weight applied on the sensor is Wcosα and the graph of weight versus inclination angle is 
plotted as shown in the Figure 3.14.  
 
Figure 3.15 : Pressure change Vs inclinations 
The relationship between the weight and inclination angle in degree shows that when the 
inclination decreases the weight increases. The same will be applied when the foot is placed 
on the plate, this weight is measured by FSR. 






Figure 3.16 : (a) Myoware muscle sensor (Sensor 2017), (b) Myoware sensor on Extensor Hallucis Brevis muscle 
For the proposed design, the setup also includes a feature of measuring the muscle activity 
during vibration stimulation using electromyogram (EMG) sensor. This may help in monitoring 
muscle activity when vibration is applied. For measuring the muscle activity it is important to 
select the appropriate muscle. Here in Figure 3.16 (a) shows the EMG sensor Figure 3.16 (b) 


































































The main purpose to use this sensor is to capture the muscle activity when vibration is applied 
to the big toe. This is the extra feature which could be added to the device circuit to monitor 
the muscle activity to ensure that the subject is affected by vibration. 
3.3 Integration of various components 
Various components were used to make the electronic circuit of the device as shown in Figure 
3.17. The components such as Arduino Uno, C2- HDLF tactor, FSR, Potentiometer, H- Bridge, 
Lipo Battery were used to design the device. 
 
Figure 3.17 : Electronics components 
 




Figure 3.19 : Pin configuration of the Arduino Uno 
Arduino Uno (Figure 3.19) is a microcontroller based on the ATmega328 operated on 5 voltage 
(Cheppali 2014). It has 14 digital input/output pins of which 6 are PWM output pins and 6 are 
analog inputs, a USB connection, 16 MHz crystal oscillator, an ICSP header, a power jack and a 
reset button are available. It can be connected to the computer using USB cable or wirelessly. 
Force sensitive resistors are connected is such a way that one end is connected to 5 volts and 
another to the pull-down resistor of 10 KΩ value. The point between the fixed pull-down 
resistor and FSR is connected to the analog input (A1) of the Arduino Uno board. When force is 
applied the resistance decreases from 100 kΩ to 10 kΩ and current increases. As the force 
increase from 0 to 100 N, the voltage across the resistor changes from 0 to 5 volts. All six 
analog input of Arduino Uno is 10 bits. So according to the formula of 2𝑛 where n is the slot 
that is 210is equal to 1024. The values changes from 0 to 1023 when pressure is applied. The 
values can be calibrated in terms of grams. 
 
Figure 3.20 : Pin diagram of driver circuit – H Bridge 
The Driver circuit is used as shown  in Figure 3.20 to drive the motors on the circuit, there is 
two standard H-bridge on the chip (TB6612FNG 2017). It is capable of driving two motors at 
the same time. In the circuit one motor (tactor) is connected. The driver circuit is connected to 
the Arduino board. The signal supplied to the vibrator tactor is controlled from the 
microcontroller. As the microcontroller is not capable of providing enough current, an external 
battery of 4.1 Volts and 350mAh current is used. PWMA pin is connected to pin 3 PWM of 
Arduino. AIN1 and AIN2 of the driver circuit are connected to Pins 8 and 9 respectively. STBY is 
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connected to Pin 6 of the Arduino board. A01 and A02 pins of the driver circuit are connected 
to the motor. The Potentiometer is connected between the external battery and VM pin of the 
driver circuit to provide power to the motor. 
 
Figure 3.21 : HC-05 Bluetooth module 
The Bluetooth Module: (HC-05) is designed for transparent wireless serial connection setup 
(Figure 3.21). It uses CSR Bluecore 04-External single chip Bluetooth system with CMOS 
technology and with AFH (Adaptive Frequency Hopping Feature). It has the footprint as small 
as 12.7mmx27mm. The range is approximately 10 meters. To make the system wireless, this 
Bluetooth is connected to the microcontroller board. Four pins of the Bluetooth module as TX 
is connected to RX and RX of Bluetooth module is connected to TX of the microcontroller. Rest 
of the 2 pins are connected to 3.3 volts and ground of microcontroller board as shown in Table 
3.2. 
Table 3.2 : Arduino pins connection with all the modules 
Arduino Uno 
Pins 
Pins of modules Module connected 
A1 FSR 1  Force sensitive resistors 
A2 FSR 2 
A3 EMG Myoware sensor (EMG) 
TXD RXD HC 05 – Bluetooth module 
RXD TXD 
3.3 volts VCC  
Pin 3 PWMA TB6612FNG 
Pin 6 STBY 
Pin 8 AIN1 
Pin 9 AIN2 
5 Volts VCC TB6612FNG,FSRs,Potentiometer,EMG 





3.3.1 Circuit diagram and working principle of the controller 
1. The Arduino board requires 5V to switch ON, which is provided by the external 
power source. It is providing power to the integrated circuits containing H-Bridge 
(TB6612FNG), Force sensitive resistors and the Bluetooth module.  
2. The microcontroller will read the sensor data at the baud rate of 9600 as per the 
installed program. 
3. The programming of the microcontroller is done in C/C++ functions of Arduino 
Uno. 
4. The Analog inputs of the microcontroller is 10 bit, it provides data in terms of 0 to 
1023, once the data from the sensor is read, the analog signal has to be converted 
into a digital signal using A/D converter. 
5. It could be possible to read multiple data from the FSR sensors. 
6. As soon as the data is obtained in the Arduino, it is then read by MATLAB to plot 
the real time graph based on the force sensed from at sensor wirelessly using 
Bluetooth module. If no pressure is applied the graph in MATLAB is at reference 0 
level when the pressure is varied, the graph shows pressure variations. 
7. As the motor driver circuit is connected to the Arduino, the PWM signal which is 
generated by the microcontroller will be provided to the driver circuit i.e. 
generating PWM signal of 100 Hz using a microcontroller and applying to the 
PWMA pin of the driver circuit. 
8. In this way, the same PWM signal is applied to the motor with signal strength of 
4.1 voltages and 350mAh of current using an external battery. As per 
specifications of the motor, it requires 250mAh RMS to be driven. 
9. Due to this a constant 4.1 volts is provided with the fixed frequency of 100 hertz 
and in order to vary the voltage from 0 to 4.1 manual potentiometer is used.  
10. The whole set up is controlled wirelessly using Bluetooth through Graphic User 
Interface (GUI) which is developed using MATLAB framework. 
3.3.2 Drawback of the circuit 
The major drawback of the above circuit is the use of a potentiometer to vary the voltage of 
the motor. The amplitude was changing as per the requirement but the system was incapable 
of getting the value of the potentiometer in order to measure the varying voltage between 0 
to 4.1 Volts. Because of this, it was not possible to capture the vibration perception threshold 
of the subject to interpret the results of the test. 
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To overcome this limitation the circuit was modified where the amplitude and frequency are 
handled through programming using PWM signals as shown in the circuit diagram in Figure 
3.22. 
 
Figure 3.22 : Electronic circuit diagram – for version 2 of the device 
The working of the modified circuit is mostly similar to the first one where the potentiometer 
is replaced and voltage is controlled by programming and the other advancement is the 
introduction of push button to make the system user friendly. The connection of the button is 
simple where one out of three pins is connected to ground, the second pin is connected to 5 
volts and the third pin is connected to A5 the analog pin of the microcontroller board. When 
the push button is pressed the value 1 is captured in the microcontroller else it remains 0. 
Potentiometer replaced by Pulse width modulation (PWM): 
The Pulse width modulation is the technique to generate the analog signal through digital 
control. It consists of two components one is duty cycle and another is frequency. The duty 
cycle described as the amount of time the cycle is on high (ON), state the percentage of the 
total time taken to complete the one full cycle. The frequency is described as the time taken by 
the PWM to complete one cycle which can be measured in cycles per second. The constant 
voltage can be obtained by cycling a digital signal on and off at a fast rate and with a certain 
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duty cycle. The aim is to drive the vibration motor at 100 Hz i.e. 100 cycles per second with the 
varying voltage. In the zero duty cycle the pulse width is almost zero (see Figure 3.23). 
 
 
Figure 3.23 : PWM input signal to the h bridge with 0% duty cycle 
 
Figure 3.24 : PWM input signal to the h bridge driver with 10% duty cycle 
As per the specification of the C2HDLF tactor ( vibration motor), it is recommended to provide 
maximum up to 10% of the average duty cycle. If the digital signal is cycled fast,  then the 
voltage seen at the output will appear as average voltage. The average voltage can be 
calculated by multiplying the digital high voltage with the duty cycle. That means 10% of the 
duty cycle can be calculated as 4.1×0.1 = 0.41 V. Similarly duty cycle of 5% will be 0.205 V. In 
order to varify the voltage change at every duty cycle the test has been performed where the 
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duty cycle is increased from 0 to 10% and the voltages are measured using multimeter shown 
in Figure 3.24.  
 
Figure 3.25 : Voltage versus Duty cycle 
 For creating the frequency of 100 cycles per seconds, the time period should be 10 
milliseconds (1/10ms = 100 Hertz). PWM of 0% duty cycle with 100 cycles per  seconds is 
created which is shown in Figure 3.23 and PWM with 10% duty cycle with 100 cycles per 
seconds created (Figure 3.24) in which 1 ms is the ON cycle and 9 ms is the OFF cycle creating 
the 10% of duty cycle gives the fixed frequency of 100 cycles per second ( 1/(1+9)). During the 
test, the vibration is provided from 0 V and is gradually increased up to 0.41V with the time 
interval of 500 milliseconds. 
3.4 Graphic User Interface (GUI) development 
 
 
Figure 3.26 : Front page for patient details 
The graphic user interface(GUI) is developed for running the device using MATLAB software. 
The first page of GUI, asks for patient details (Figure 3.26). Once the details are provided the 




Figure 3.27 : Main page of the GUI 
This is the main page for detecting VPT. Here three real-time graph for displaying the values of 
FSRs at the Big toe, 1st metatarsals and EMG signal are shown (Figure 3.27). Once the subject 
places foot on the plate a real time graph is displayed on all three windows (Figure 3.28). The 
button named <Tactor> available on the GUI is used to start the vibration motor. The 
proposed system is designed to run the test for three times and an average of all test rounds is 
calculated to display the result, once the <result tab> is pressed. The switch button is pressed 
and  the vibration is applied to the foot, during each test round the subject is allowed to press 
the push button when they sense the vibration. Based on the current round the number will 
be displayed on <Round tab> and as per the level of vibration, the level will be displayed on 
the <level tab>. The duration of the whole test is displaced on the <time tab> in terms of 
seconds. When the switch is pressed by the subject, vibration will be stopped and the level is 
captured to display from the Round 1 tab, similarly, the levels will also be captured for Round 
2 and Round 3 to complete the test, Pressing the <Stop> button finishes the test. Press the 




Figure 3.28 : User friendly graphic user interface (GUI)  
The above figure shows the actual interface available to the user. The Force Sensitive Resistors 
are used to measure the real time pressure during the test. In the experiment two FSRs are 
used and placed on two points of the platform in such a way that when the subject places 
his/her foot on the plate, the force distributed at the planter surface of the foot at big toe and 
1st metatarsals will be recorded and displayed at the same time. 
3.4.1 Procedure to conduct the test  
First, the subject is asked to sit on a chair comfortably and once he/she is ready, the subject is 
asked to remove the shoes and socks for conducting the test. The subjects are asked to place 
their right foot on the platform with attached Electromyogram sensor as shown in Figure 3.28. 
The rest of the procedure is described as below: 
1. The command to start the test is provided through the GUI. 
2. Once the test is started, pressure distributed at the big toe and 1st metatarsals will be 
captured and displayed real-time on GUI in order to make sure that the pressure 
remains constant. 
3. Once the pressure is constant the vibration will be provided by pressing the tactor 
button on the GUI. 
4. The vibration will be provided where the vibration frequency will be constant and 
amplitude will increase from 0 to 0.41 Volts automatically and will be displayed as 
Level on GUI. 
5. The time interval between every vibration stimulus is kept fixed as 1000 milliseconds 
(this can be adjusted as per the requirement). 
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6.  The subject will be holding the switch and the subject will be asked to press the switch 
when the vibration is felt. 
7. Once the switch is pressed by the subject, the level of the vibration will be stored in 
round 1 and vibration will be stopped, to start the next round, tactor button should be 
pressed again.  
8. This procedure should be repeated three times and the average of the three rounds 
will be taken to determine the vibration perception threshold. In the above example, 
if the Level displayed on the rounds i.e. Round 1, Round 2, and Round 3 are 2, 3 and 3 
respectively so the average is 2.6. 
9. Once the test is finished, Download button displayed on the page will be enabled and 
the user is able to download the data of FSRs, EMG with respect to time in a spread 
sheet for further analysis 
10. Based on the average value of the captured level, presence of diabetic neuropathy 
could be determined. 
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Figure 3.29 : Test procedure and data capture 
The complete procedure in the software is shown in the flowchart (Figure 3.29). It shows the 
way the programming is done to operate the electronic circuit. Here based on the average 
value of the voltages level of diabetic neuropathy could be determined i.e. out of total 0.41 
Volts (V), if the threshold value is ≤ 0.25 V then subject is non diabetic neuropathy and if 
greater than 0.25 V then subject is neuropathic in the simplest form. 
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3.5 Device evaluation  
After developing the software as well as the hardware, it is very important to perform the 
evaluation of the device. For this purpose the current version of device is analysed on the 
following basis: 
1. Hardware evaluation: The hardware developed for the device, has several limitations: 
- It can be used only for left leg. 
- There is no need of changing the plate inclination for every test.  
- During the test, it was found that while applying vibration stimulation, significant 
amount of vibration was transmitted through the test plate due to which the 
whole assembly vibrated unevenly. 
- This leakage was examined using accelerometer (Metawear CPRO) by placing it on 
the top of the vibration motor. It was found that if the applied vibration amplitude 
is 50µm then plate vibrates with the amplitude of 18µm i.e. around 36% of 
leakage.   
 
2. Electronic circuit evaluation: There are several drawbacks which need to be upgraded: 
- The electronic circuit used for the device is capable of driving only one vibration 
motor. For driving two motors the circuit needs to be upgraded. 
- For EMG module, it was found that there is no evidence of muscle activity during 
the test; however this is an additional feature of the device which can be used for 
auto diagnosis from muscle activation.  
 
3. Software evaluation: There are several drawbacks in the software: 
- The software developed was capable of operating only one vibration motor at a 
time.  
- The time taken to perform the test was high because subject needed to wait until 
they sense the vibration stimulus which increases gradually from 0 to 0.41 V. 
- For every incremented vibration it takes 5 seconds and to cover the whole range, 
it requires 250 seconds. This needs to be repeated for 3 times to obtain the mean 
value of the VPT so it could take as much as 750 seconds which is almost 12 
minutes. 
- The output of the device varies from 0 to 0.41 Volts and due to this it is not 
possible to compare with any existing devices. This needs to be addressed by 
mapping to standard outcome ( either by calibrating the output in terms of 0 to 50 
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Volts same as the Neurothesiometer), so that it can be easily interpreted by  
clinicians. 
As in the device, FSRs were used for big toe and first Metatarsals, however in order to justify 
their significance, experiments were performed by placing these FSRs at various positions as 
shown below: 
Case 1:  
 
  
Figure 3.30 : FSR placed below the vibration motor 
 The FSR is placed below the motor on the plate as shown in the Figure 3.30, so when 
the foot is placed on the plate, the pressure exerted by the first Metatarsal is 
recorded. 
Using this position of FSR, their pressure remains constant as first Metatarsals will be at the 
same place throughout the test. It is not possible to identify the placement of big toe and 
monitor the pressure. 
Case 2: 
In this case, the placement of the FSRs is shown in the Figure 3.31 and the vibration stimulus is 




Figure 3.31 : FSRs placement at 1st Metatarsals and heel during the test 
 As shown in the above Figure 3.31, out of two FSRs, first FSR was placed just below the 





placed on the plate, the pressure exerted by the first Metatarsal and heel of the foot 
can be recorded. 
 The pressure exerted by the heel was greater than that of the first Metatarsals. 
Similarly, as the size of the foot vary among the subjects, it could be difficult to maintain the 
distance of the FSRs. In this scenario too, when the vibration stimulus is applied to the big toe, 







Figure 3.32 : FSRs placement on great toe and 1st metatarsals of foot during the test 
 Two FSRs were used to perform the experiments, in which the first FSR was placed on 
the top of the vibration motor and another was placed just below the motor as shown 
in the Figure 3.32. 
 The pressure exerted by the first Metatarsal is greater than the big toe. 
With this setting it is possible to track the position of the big toe and can monitor the pressure 
during the vibration application. However, there is no change in the pressure on the first 
Metatarsal which seems that use of the second FSR at first Metatarsal is not significant and 









 With this setting it was possible to track the position of the big toe and can monitor 
the pressure during the vibration stimulus and hence this placement of FSR was 
considered as the best location for conducting the test. 
In order to address all these limitations in the device, there was a need for developing 
advanced version of device. This evaluation can help in developing a user-friendly, accessible 
to both feet, for a smart device. 
3.5.1 Redesigning of the device 
For addressing all the limitations of the previous version of the device, redesigning the device 
was considered for achieving the aim of developing the screening tool for diabetic neuropathy. 
 




(b) Left view 
 
(c) Top view 
 
(d) Isometric view 
Figure 3.34 : Design of the latest device 
The redesigning of the device is started by using software tool Solidworks through which 
device model was developed as shown in Figure 3.34.  The length of the device is kept to 35.6 
cm and width as 42 cm.  The inclination angle of the test plate is kept constant at 36 degrees. 
The test plates consist of two holes to place the vibration motors. The diameter of both the 
holes was Ø3.6 cm as the diameter of the vibration motor is Ø3.17 cm. If the vibration motors 
are connected directly to the test plate then the whole plate will vibrate similar to the previous 
version of the device. To overcome this limitation the vibration motor needs to be isolated 
from the test plate. For that, an additional design feature is added to the test plate. 







Figure 3.35 : Back view of the device 
The bottom view of the test plate consists of vibration motor holder for each motor. It consists 
of a holder, compression spring and a base with three screws. The weight of the brass holder is 
kept nearly 10 times higher than that of the vibration motor. The compression spring is used 
between the holder and the base and the aluminium base plate has three screw holes so that 




Figure 3.36 : Top and isometric view of the device 
The whole device box is made up of wooden plate and it is completely covered from all sides. 
The vibration motor holder is made similar to the design shown above. It consists of brass 
holder as the vibration motors are electromagnetic in nature; so that the holder does interfere 
with the motor. The compression spring is used with the stiffness of 4.837 N/mm which is 
made up of steel. The base plate is made up of aluminium plate. The whole assembly of the 
vibration motor holder is fixed with the test plate using three screws such that both the 
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vibration motors are placed inside (Figure 3.36).  Two FSRs are placed on the top of the motors 
to avoid direct contact with skin surface to the FSRs, it is covered by a thin natural latex sheet 
of 0.20mm. The test plate is fully covered by solid neoprene black colour rubber sheet of 1 mm 
thickness having fire - resistant benefits with good insulating property. It acts as an anti-slip for 
the feet placed on the plate. The LED (light emitting diode) strip is attached on the top of the 
plate which is covered by the white plastic cover for giving traffic light type of indication of 
neuropathy. On the back side of the box, there is a room for placing all the electronic circuits 
along with the battery which will be connected to the vibration motors, LED strip and FSRs. 
3.5.2 Vibration isolation design 
Vibration isolation is the technique of isolating the part of the equipment from the source of 
the vibration. Vibration propagate in the form of mechanical waves and due to some 
mechanical linkages, there is a possibility of vibration conduction. Passive isolation is 
commonly used where a certain type of materials are used to absorb or damp these extra 
mechanical waves. Sensors and actuators produce the interference to cancel the incoming 
vibration known as active vibration isolation.  Mainly mechanical spring or rubber pads are 
used for passive vibration isolation. 
 
Figure 3.37 : Holder for isolating the vibration 
In this case, the vibration motors can be taken as the source of the vibration. If the vibration 
motors are directly attached to the plate then vibration can propagates easily. To avoid this,  a 
proper isolation technique should be implemented i.e. either passive or active. Passive 
vibration isolation technique was implemented, so using the mechanical spring.  
The transmitted force from the vibration unit to the rest of the plate is given by: 








          (1)  
Where, 𝐹𝑇  is the transmitted force, 
𝐹𝑎  is the applied force, 
ω is the frequency of the applied force. 
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𝜔𝑛 is the natural frequency of the spring which can be given as √
𝑘
𝑀
 ,k is the stiffness and M is 
the mass placed over spring. 
After several iterations, a spring with the stiffness of 4.837 N/mm was found suitable which 
can nullify the transmitted force to the device body. 






, showing the transmitted force 
significantly reduced compared to the applied force. 
 
Figure 3.38 : Applied force versus transmitted force 
Figure 3.38 shows the comparison between applied forces of the vibration to the transmitted 
force by using the holder design shown in Figure 3.37.  Using this design, the vibration stimulus 
can be applied directly to the skin surface with negligible vibration leakage to the contact 
surface. 
3.5.3 Electronic circuit design  
 
Figure 3.39 : Schematic diagram of the electronic circuit 
All the electronic components mentioned in the previous version of the device were used 

















addition of LED strip and battery of 5 Volts is used instead of Lipo battery. The connection of 
all the components is shown in the schematic diagram (Figure 3.39).  
1. The circuit consists of 5 volts of battery with two output terminals. 
2. It consists of two circuits, one is the voltage regulator circuit and another is the motor 
and sensor circuit. 
3. Voltage regulator circuit consist of variable voltage regulator IC to vary the voltage 
from 0 to 5 Volts.  
4. One output terminal of the battery is provided to the circuit as an input signal, the 
output of the signal will provide a constant output voltage to drive the vibration 
motors via H bridge. The potentiometer is used to vary the voltage which is provided 
to the motor driver circuit. However, the voltage provided to the driver circuit should 
remain constant and is set to 4.1 Volts. 
5. The second output terminal of the battery which provides 5 Volts is connected directly 
to the Arduino. 
6. The motor and sensor circuit is operated by Arduino programming via graphic user 
interface developed in the MATLAB framework that enables H bridge, Bluetooth, force 
sensitive resistors sensors and LED strip as explained in section 3.4. 






Figure 3.40 : Upgraded GUI for the latest version of device 
FSR reading for the left foot FSR reading for the right foot Equivalent Neurothesiometer voltages 
Buttons to select the 
motor to vibrate 
Exact VPT values 
Selected 
VPT range 
Button to continue 
vibration stimulus 




The upgraded version of the GUI is shown in Figure 3.40. The main purpose of upgrading the 
GUI is to make it user friendly, easy and quicker to conduct the screening on both feet for 
determining diabetic neuropathy. 
1. It consists of two graphs to show the real-time pressure value of the FSRs placed on 
the top of the vibrator motors. 
2. The readings of the FSR placed on the left motor will be displayed on the left side 
graph and readings of the FSR on the right motor will be displaced on the right side 
graph. 
3. In the motor section, there are three switches to select the vibration motor. Once the 
<LEFT FOOT> button is pressed the left side motor should be enabled. Similarly, when 
<RIGHT FOOT> button is pressed right side motor should be enabled. And while 
selecting <BOTH FEET> button both the motors should be enabled. 
4. After selecting the motor, five buttons are available (10V to 50V) to select the 
vibration amplitude. 
5. The range will have the value of the selected VPT range. 
6. Press <Continue> button to start the motor from the selected vibration amplitude 
range as mentioned in step 5. 
7. The exact VPT based on the rounds and levels of the vibration amplitude is captured in 
the window shown in Figure 3.40. 
By enhancing this Graphic user interface, as there is a possibility of selecting the vibration 
amplitude of the motors, has become quicker in terms of the previous version of Graphic user 
interface. Once the range is selected, vibration should increase gradually for next 10 levels. 
Each level will take 5 seconds to move to the next level and whole process should be repeated 
for two times. The total time calculated will be just 20 seconds for one foot. So for both the 
feet it should take only 40 seconds to conduct the test.  
Discussion 
The development of the device is almost completed and it can be used for the both feet for 
measuring the VPTs of the subjects. There are important advancements in the latest version 
from the initial version of the device. The initial version of the device was capable of 
measuring VPT for only one foot and was also vibrating the whole platform resulting into 
noise. There was an option for selecting the inclination of the test platform which was 
removed in the later version because once the inclination of the test platform is fixed; there 
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was no need to change it. Initially, the force sensitive resistors were placed on the top of 
actuator and one on the first metatarsal but later realised that FSR on the first Metatarsal is 
not required. The major drawback about this initial version of device is it was taking longer to 
conduct the test approximately (12 minutes). Again the graphic user interface could only be 
able to determine whether a subject is neuropathic or non-neuropathic. Looking at all these 
drawbacks this version of device was updated where it was capable for measuring VPT of both 
feet. The placement of FSRs was also fixed which is placed on the top of the left and right 
actuators. The problem of vibration leakage was also solved by using passive vibration 
isolation technique. The updated GUI was capable of capturing real time pressure from both 
the feet along with the options of selecting the foot for VPT measurement. Here the idea of 
providing the vibration from 0V to 50V (as same as the Neurothesiometer voltage range) with 
5 divisions is interesting as it can save time, but at the same time the threshold levels of each 
voltage (i.e. 10V to 50V) should be precisely set. This limitation can be overcome by precisely 
measuring the displacement at each voltage of device and comparing with the 
Neurothesiometer displacement for the whole vibration amplitude range to set the exact 
















Chapter 4 Experimental evaluation of the developed device 
 
In this chapter the first thing to understand is the vibration characteristic of Neurothesiometer 
device. Measurement of vibration characteristics includes measurement of frequency and 
amplitude. This is important to know in order to fix the same thresholds for the latest version 
of device. For this purpose, inductive sensor was used to measure the frequency of 
Neurothesiometer vibration probe by gradually increasing its vibration amplitude using 
manual rotating knob. For measuring the displacement of the vibration, a calibrated digital 
microscope was used. The measurement of vibration displacement was performed for whole 
range of vibration amplitude (i.e. 0V to 50V) which is discussed in the chapter.  
Once the frequency of the Neurothesiometer is known, the same frequency should be set for 
the vibration actuator of the device using PWM signal. Similarly the displacement of the 
vibration actuator was measured using the same digital microscope till it reaches the 
maximum vibration amplitude of Neurothesiometer vibration probe (i.e. at 50V) which is 
investigated in the chapter. In order to obtain the device voltage range, equivalent to 
Neurothesiometer voltage range, a curve fitting method is implemented. This will help in 
calibrating the device voltage in terms of equivalent Neurothesiometer voltage for comparison 
purpose. 
4.1 Comparison of the device with Neurothesiometer 
 
 
Figure 4.1 : Neurothesiometer 
The latest version of the device which is developed could be used as a screening tool for 
diabetic neuropathy once it is compared and evaluated with the established techniques. This 
can be achieved only when the vibration amplitude and the frequency of the device has the 
same vibration characteristic of the existing devices.  For comparison purpose, it is necessary 





Vibration Frequency of Neurothesiometer: 
 
Figure 4.2 : Experiment setup for Neurothesiometer 
An inductive proximity sensor is used for the experiment as shown in Figure 4.2. They are used 
for non-contact detection of metallic objects. Their operating principle is based on a coil and 
oscillator that creates an electromagnetic field in the close proximity of the sensing surface. 
The vibration probe is placed very near to the tip of the sensor (less than 1mm distance). 
There are three outputs of the sensor where one of the output is connected to the power 
supply to provide the voltage of 6V and another is connected to ground and the third one is 
connected to the digital oscilloscope to obtain the readings for frequency on the computer. 
The manually controlled potentiometer is used to gradually increase the vibration. Based on 
the vibration intensity, the sensor will sense the intensity in terms of voltage. The vibration 
frequency at 0V, 10V, 20V, 30V, 40V and 50V are measured using the inductive proximity. 
After conducting this experiment, it was clear that the vibration frequency of the 
Neurothesiometer remains constant at 102 hertz at every voltage from 0 to 50V. 
Vibration amplitude measurement of Neurothesiometer: 
The vibration amplitude of the Neurothesiometer probe was measured using a digital 
microscope, however before using a digital microscope, it was important to calibrate it for 
measuring the accuracy of the results. Digital microscopes allow for the rapid acquisition of a 
high-quality image which can be precisely quantified or calibrated (Davis and Freeman 1998). 
The captured image can be analyzed for accuracy and stored for later use.  
Calibration of Digital Microscope: 
To ensure the accurate measurement and quantification of data using image analysis precise 
calibration is important.  Typically images are captured by using a specific zoom or objective 
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lens to determine the overall magnification. The magnification of the microscope is from 50X 
to 500X. The calibration is set at 50X. First, the image of a physical scale is captured as shown 
in Figure 4.3.   
 
Figure 4.3 : Image captured using a digital microscope 
It has been verified on the physical scale as seen in Figure 4.3. As the distance between each 
thread of the scale is 0.1 cm i.e. 1mm, the pixels for the selected distance is measured as 185 
pixels as shown in Figure 4.4. This means that 1mm distance is equal to 185 pixels for 50X 
magnification. Similarly, for all the zooming range for the digital microscope (50X to 500X), the 
distance can be calibrated using the same method. This calibration (1mm= 185 pixel) can be 
added to the software such that it can be used to precisely measure the displacement.  
  
Figure 4.4 : Distance measured in terms of millimetre and pixel 
The experiment has been performed to measure the vibration amplitude of the 
Neurothesimeter vibration probe. The vibration amplitude is increased manually from 0 to 50 
voltages using the potentiometer.         
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  Figure 4.5 : Experimental setup for measuring Neurothesiometer vibration amplitude 
As shown in Figure 4.5, the digital microscope was connected to the laptop in order to get the 
magnified image. The vibration probe of the Neurothesiometer was adjusted using the holder 
in such a way that it is presented on the front of the digital microscope. The distance of the 
digital microscope and the vibration probe was maintained throughout the experiment. Once 
the setup is ready, Neurothesiometer was switched ON and the voltage was kept at 0 Volts. 
Gradually the voltages of the Neurothesiometer probe was increased using the potentiometer 
(vibration knob) and the images were captured for almost every voltage. The Measured 
displacement was in mm as shown in Table 4.1 and graph Figure 4.6. 
Table 4.1 : Experimental results of amplitude measurement of Neurothesiometer 
Serial number  Voltage (V) Measured amplitude  (mm) 
1 0 0 
2 6 0.01 
3 9 0.015 
4 11 0.02 
5 13 0.025 
6 15 0.03 
7 17                            0.035 
8 19 0.04 
9 20 0.045 
10 22 0.054 
11 24                           0.068 
12 26 0.073 
13 28 0.084 
14 30 0.092 
15 32 0.1 
           16           34 0.108 
           17           36 0.119 
18 38 0.133 
19 40 0.143 
20 42 0.165 
21 44 0.175 
22 46 0.187 
23 48 0.208 








Figure 4.6 : Voltage and displacement relationship of Neurothesiometer 
Figure 4.6, shows the relationship between Neurothesiometer voltages and vibration 
displacement. The equation for the above graph can be given as F (𝐷1) = 𝑉1. 
𝑉1 = 3.9𝑒 + 3𝐷1
3 −  2𝑒 + 3𝐷21 + 4.6𝑒 + 2𝐷1 + 2    (2) 
Here, V1 is the Neurothesiometer voltages and D1 is the measured displacement of the 
vibration probe. 
Vibration amplitude measurement for device:  
 
       
                    
Figure 4.7 : Measuring displacement of the vibration motor 
Magnified vibration contactor 
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For measuring the vibration amplitude of the motor, the vibration motor needs to be enabled 
using GUI as discussed in section 3.6.4. The digital microscope was adjusted in such a way that 
the contactor of the motor should be in focus to get its magnified image as shown in Figure 
4.7. Similarly, the distance between the microscope and vibration motor is maintained 
constant throughout the experiment. The motor will vibrate from 0 volts i.e. 0 mm until it 
reaches the amplitude of 225 mm similar to that of the Neurothesiometer maximum voltage. 
As discussed before vibration frequency of the motor was kept constant at 100 hertz 
throughout the experiment. All the readings of the vibration displacement were measured in 
mm. The readings are displayed in Table 4.2.  
Table 4.2 : Vibration amplitude measure for vibration motor of the device 
Serial number Voltage Displacement(mm) 
1 0 0 
2 0.04 0.015 
3 0.08 0.025 
4 0.12 0.043 
5 0.16 0.053 
6 0.2 0.07 
7 0.24 0.08 
8 0.28 0.086 
9 0.32 0.107 
10 0.36 0.113 
11 0.4 0.129 
12 0.44 0.145 
13 0.48 0.151 
14 0.52 0.162 
15 0.56 0.172 
16 0.6 0.183 
17 0.64 0.194 
18 0.68 0.205 
19 0.72 0.218 
20 0.76 0.232 
21 0.8 0.237 










Figure 4.8 : Voltage versus displacement relationship of vibration motor of device 
Figure 4.8, shows the relationship between Vibration motor voltages and the vibration 
displacement. The equation for the above graph is given below, where F (𝑉2) = 𝐷2. 
The Quadratic equation has been derived from the above graph such as: 
D2 = −0.05V2
2 + 0.34V2 + 0.0014                                                             (3) 
Where, V2 is the device voltage, D2 is the measured displacement. 
As the vibration amplitude range is the same in both the devices i.e. D1 = D2, it is possible to 
replace the value of D1 in equation 2 by value of D2 of equation 3 to get the relationship 
between Neurothesiometer voltage V1 and out device voltage V2  such as V1 = F (V2). The 




Figure 4.9 : Device voltage V2 versus Neurothesiometer V1 
Thus, the relationship between the voltages of Neurothesiometer and the proposed device has 
been developed.  The vibration stimulus is applied to the subject based on the selected 
voltage. For example, the voltage applied to the subject using Neurothesiometer and the 
subject sense the vibration at 15 Volts of the Neurothesiometer then the VPT of the subject is 
determined as 15 Volts. The advantage of establishing the relationship between 
Neurothesiometer and device is, when vibration stimulus is applied by the device; the 
determined VPT can be expressed in terms of equivalent Neurothesiometer voltage.  
The derived equation is implemented in GUI to get results of VPT in terms of 
Neurothesiometer voltage range from 0 to 50 Volts. 
 





In Figure 4.10, the average level i.e. 3 shows the average VPT measured by selecting the range. 
The average level is used to determine the actual voltage of device which is calculated as 0.015 
V in the above case. The selected range is shown as 0 to 10 Volts which means that the subject 
has sensed the vibration stimulus within this range. The equation derived in the above section 
is used to obtain the Equivalent Neurothesiometer voltage showing 4.90 volts. The obtained 
VPT is used to determine the severity level of VPT and expressed the results as ‘Normal’ in the 
above case. 
4.2 Design summary  
In the latest model, the progression is finished in terms of device design as it is conceivable to 
test the vibration sensation on both feet. When the vibration stimulus is given to one foot the 
second foot can lay easily on the same platform and this provides for adjustment during the 
test. Due to vibration isolation technique, the vibration will be relatively isolated from rest of 
the device body and is possible to provide vibration stimulus to the skin surface only. 
With the upgradation in electronic circuit, it is now possible to operate any of the vibration 
motors or both the motors at the same time if required. It is capable of operating LED strip, 
switch, FSRs along with the wireless control using Bluetooth module. 
By upgrading the software programming, it can now control the vibration motors. It gives the 
provision of selecting the vibration motors as per the user’s need.  The Graphic user interface 
is much more fexible for users to perform the test. In a way it allows the user to independently 
operate the device where results could be autonomously interpreted.  With all these advanced 
features of device based on the vibration perception threshold, the device has been named as 
‘VibraScan’ (Dave et al. 2018) 
74 
 
4.2.1 Procedure for conducting test with VibraScan  
 
Figure 4.11 : Procedural screening tool of VibraScan 
The detailed procedure of using VibraScan is shown in Figure 4.11. It consists of VibraScan 
device, method of operating VibraScan and the entire flow of the information which will be 
displayed in the form of the results.  
1. For conducting the test, VibraScan should be first placed on the floor in front of the 
user chair.  
2. All the time, test should be performed in the same ambient temperature that could be 
25 degree centigrade. 
3. VibraScan needs to switch ON to establish the serial communication with the Arduino 
microcontroller.  
4. Once the connection is established, user needs to provide the credentials in the GUI 







5. The Pressure sensor data should be captured on the Left and right graph once 
everything is activated. 
6. Now the subject needs to sit on the chair comfortably and put his/her feet on the 
plate as shown in Figure 4.11. 
7. The great toe should be placed exactly on the top of the motor. 
8. The subject needs to hold the switch during the test as shown in Figure 4.11. 
9. After this setup, once the subject is ready for the test, the vibration motors should be 
selected from the GUI to provide the vibration stimulus. 
10. Select <Left foot> button from GUI to enable left side motor (similarly, selection of 
<right foot> button or <both foot> button from GUI will enable right side motor or 
both the motors respectively). 
11. For selecting the correct range of the vibration stimulus, press <10V> button to 
provide vibration amplitude equivalent to 10 Volts to the subject.  
12. If the subject does not sense the vibration, provide vibration stimulus of 20 Volts, 
likewise increase the voltage until subject sense the vibration. 
13. Subject is asked to press the switch at the point of vibration sensation. Once the 
switch is pressed, the vibration will stop automatically and range will be selected. 
14. For example, if the subject presses the switch at 20 Volts, then 10V to 20V range 
should be selected. 
15. After that  <continue> button should be pressed to proceed for providing the vibration 
sensation that starts from 10 Volts and gradually increases until it reached 20 Volts. 
16. The subject is asked again to press the switch to measure the exact VPT. 
17. The procedure should be repeated twice by following the step 15 and step 16 to 
calculate the mean VPT. 
18. Based on the mean VPT, the actual voltage of the VibraScan is captured to calculate 
the equivalent Neurothesiometer voltage shown in the result part in the Figure 4.11. 
19. At the time of showing the outcome, the severity of the condition will be displayed as 
Normal, Mild, Moderate and Severe depending on the level of VPT, at the same time 
colour of the LED also changes from Green, Amber, Dark orange to Red respectively.  
The procedure of conducting the test using VibraScan is straightforward and quick where 
results are interpreted automatically. VibraScan can be used as a screening tool for diabetic 





The vibration characteristics of the Neurothesiometer probe are successfully measured. By 
using inductive sensor and the frequency was estimated as 102 hertz for the whole range of 
vibration amplitude. Using calibrated digital microscope the displacement of the vibration 
probe is estimated as (0V to 50V ≈ 0.2 mm) where 25V is equivalent to 0.07 mm. Similarly in 
VibraScan device the similar range of displacement was set from 0 mm to around 0.2 mm for 
comparison purpose. Using the curve fitting technique, equation is developed which gives the 
relation between VibraScan and Neurothesiometer voltages.  
This shows how VibraScan has been evolved from concept to smart device. It is important to 
perform trial using VibraScan on human subjects to analyse its performance with respect to 
Neurothesiometer. For this purpose, both the tools (VibraScan and Neurothesiometer) should 
be applied on the human subjects to determine VPTs and perform the comparative study, this 
















Chapter 5 Experimental study on Human subjects 
 
This chapter will demonstrate the experiments performed on human subjects using both the 
Neurothesiometer and VibraScan devices. The purpose of the comparative study is to examine 
how well VibraScan is working when applied on subjects. The study will also ensure whether 
the outcome of VibraScan is acceptable by comparing it with Neurothesiometer.  
To fulfil these requirements 20 healthy volunteers were invited to undergo the test using both 
the device after their prior consent. The procedure of conducting the test will be explained in 
the following sections. After conducting the test, a statistical analysis was performed. To 
assess the strength of the relationships of the measured VPTs  
(both right and left foot), correlation coefficient method was implemented. However, to 
check the level of agreement between both the devices Blend’s and Altman test method was 
used which will be discussed in this chapter. 
Ethical approval was given by Bournemouth University’s Research Ethics committee (as shown 
in Appendix A) for conducting this test.  
5.1 Criteria for selecting the subjects 
1. The subject should be non- diabetic. 
2. Should be more than 18 years old. 
3. Should not have any injury or ulcers on the sole of the foot. 
4. Should not have any problem with foot movement. 
5.2 Experimental methodology  
1. All 20 participants were tested using VibraScan and Neurothesiometer alternately. 
2. Calculate the mean VPT using VibraScan for each subject and maintain the pressure 
throughout the test. 
3. Calculate the mean VPT using Neurothesiometer for the same subjects. 
4. Measure VPT for both feet of each subject for comparison. 
5. Calculate the correlation coefficient between two measurements of left foot. 
6. Calculate the correlation coefficient between two measurements of right foot. 
7. Use the difference plots (i.e. Blends and Altman plot) for two measurement of each 





Procedure followed to conduct test using VibraScan 
 For conducting the test using VibraScan the following steps were used: 
  
Figure 5.1 : Screening test using VibraScan 
1. Subject needs to remove shoes and socks to perform the test. 
2. Subject was asked to sit on the chair and place their feet on the VibraScan test plate. 
3. Needs to hold the switch as shown in Figure 5.1. 
4. When subject places the feet on the platform, FSR readings for both feet were 
continuously captured and displayed on the screen (Figure 5.1). 
5. Any foot can be selected and vibration stimulus applied. 
6. The vibration amplitude was measured from minimum to maximum, where subject 
was asked to press the switch for selecting the range. 
7. Once the range of vibration was selected, vibration stimulus was provided again based 
on the selected range. 
8. In the above example, if the selected range was from 0 to 10 volts, then the vibration 
stimulus was started from 0 and gradually increased to 10 volts. 
9. The subject was asked again to press the switch when the vibration sensation was felt 
and was repeated to get the mean VPT. 
 
 
Figure 5.2 : Result displayed on VibraScan colour board 
 
Green colour indicating normal level 
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10. For the above example, the result was shown as ‘Normal’ and green LED light was 
displayed as shown in Figure 5.2. 
11. Similarly, vibration stimulus was provided to another foot and all the above steps were 
repeated after selecting the correct foot to obtain VPT. 
Procedure used to conduct test using Neurothesiometer: 
After conducting the test with VibraScan, the same subject was tested using 
Neurothesiometer to determine VPT. 
 
Figure 5.3 : Conducting test using Neurothesiometer 
1. Subject was tested on both the feet one by one. 
2. The subject was asked to keep their leg comfortably as shown in Figure 5.3.  
3. Vibration stimulus was applied to the subject by holding the vibration probe. 
4. The operator was allowed to control the amplitude of the vibration using vibration 
knob. 
5. The subject was asked to say ‘Yes’ when vibration was felt. 
6. The vibration amplitude ranges from 0 to 50 Volts, and the vibration started from 
0 Volts and progressively incremented until subject felt the sensation. 
7.  The time at which the vibration sensation was felt was noted and the voltage 
showed on the Neurothesiometer determines the VPT of the subject. These were 
repeated thrice and mean VPT was calculated. 
8. Similarly, VPT was obtained for another foot by following all the above steps. 
Results were obtained for all the twenty subjects following the above method. The mean VPT 
obtained using both methods were compared with each other. 
After conducting the test for all the twenty subjects, mean VPT for both feet were calculated 
using VibraScan and Neurothesiometer. For comparing both the methods correlation 
ceoefficient was calculated for each reading. 
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5.3 Correlation Analysis 
Correlation analysis is carried out to measure the strength of the relationship between the pair 
of variables. The correlation coefficient is a statistical method used to compute the strength 
between the relative points of the two variables. The correlation coefficient r varies between -
1 and +1.  For interpreting the value of r there are various ranges set as follow: 
r = 0 shows the absence of linear relationship. 
r = +1 shows as a perfect positive linear relationship in which there is a positive increase in one 
variable when there is an increase in another variable. 
 r = -1 shows there is a perfect negative linear relationship in which there is a positive increase 
in the one variable when there is a decrease in another variable.  
0 > r > 0.3 shows a weak positive (or negative) linear relationship. 
0.3 > r > 0.7 shows a moderate positive (or negative) linear relationship.  
0.7 > r > 1 shows a strong positive (or negative) linear relationship (Ratner 2009). 
If the value of r is between 0 and 1 then it reflects partial correlation which may be significant 
or may not be significant. For example, if the value of r is 0.70 that means 1 variable related to 
variable 2 is 70%. The only correlation that is significant at p < 0.05 or 0.01 needs to be 
considered. In order to have always positive value in some cases, squared value of r is 
calculated which is given as  𝑟2 is also called coefficient of determination and denoted by R2. R2 
indicates the percentage variation in one variable explained by another variable. Linear 
regression is like linear correlation where one variable depend on another independent 
variable. Linear equation 𝑌 = 𝐴𝑋 + 𝐵 is used to show the linear regression equation which is 
produced by using least difference between line point and the actual data point.  Here the 
Slope A is measured from the ratio of 𝑌1 − 𝑌0/ 𝑋1 − 𝑋0 of the line. The correlation coefficient 
is scaled to fit between 0 and 1.  
Calculated Correlation coefficient: 
If A and B are the two variables then correlation coefficient can be calculated after getting 
standardised values as cA and cB  of A and B respectively i.e. mean of cA and cB will be 0 and 
standard deviation ( SD) will be 1. This can be expressed as: 
𝑐𝐴𝑖 = 𝐴𝑖 − 𝑚𝑒𝑎𝑛(𝐴) 𝑆𝐷(𝐴)⁄                     (4) 
𝑐𝐵𝑖 = 𝐵𝑖 − 𝑚𝑒𝑎𝑛(𝐵) 𝑆𝐷(𝐵)⁄                                   (5) 
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The correlation coefficient can be given as the mean product of cAi and cBi shown as below: 
𝑟𝐴,𝐵 =  𝑠𝑢𝑚 𝑜𝑓 [𝑐𝐴𝑖  × 𝑐𝐵𝑖  ] (𝑛 − 1⁄ )       (6) 
Where n is the number of samples. 
Left foot VPT measurement analysis: 
Here the VPT of Left foot was measured using both the devices and shown in Table 5.1. 
Twenty subjects were tested. The central value of the data is expressed as the mean and the 
variation is expressed as the 95% confidence interval (CI). The CI shows the data distribution 
would differ significantly from each other based on the estimates. The lower bound of 95% CI 
is calculated by the equation 7: 
𝐿𝑜𝑤𝑒𝑟 𝑏𝑜𝑢𝑛𝑑 =  𝑚𝑒𝑎𝑛 −  1.96(𝑆𝐷 √𝑛)⁄                                             (7) 
The upper bound of 95% CI can be calculated as  𝑚𝑒𝑎𝑛 + 1.96 ((𝑆𝐷|√𝑛) where n is the 
number of measurements and the CIs provides reliability of the data i.e. any measurements 
outside this limit consider the data from other distribution. The mean with 95% CI was 
calculated for VibraScan (Left foot) as 4.76 ± 0.60 V and similarly, the mean VPT of 
Neurothesiometer (Left foot) was calculated as 4.53 ± 0.65 V. 
Table 5.1 : VibraScan and Neurothesiometer readings for Left foot 
Series Number VibraScan Left foot mean VPT 
(V) 
Neurothesiometer  Left foot 
mean VPT (V) 
1 4.9 5 
2 3.4 4.5 
3 3.4 3 
4 5.26 4 
5 4.9 6.16 
6 4.53 4.6 
7 4.9 4.8 
8 6.7 8.16 
9 3.4 3.16 
10 3.4 4 
11 5.63 5.16 
12 4.16 5.3 
13 3.4 5 
14 7.74 5.5 
15 4.53 5 
16 3.02 4.16 
17 5.63 6 
18 7.05 7.6 
19 5.99 4.8 




Here for the above measurements of the left foot, VibraScan score of VPT is compared with 
the Neurothesiometer VPT scores for all the twenty subjects as shown in Table 5.1. In order to 
get the relationship between the measurements, the correlation coefficient was calculated. 
Based on the value of the correlation coefficient strength of the linear relationship was 
obtained. 
 
Figure 5.4 : Correlation between Neurothesiometer and VibraScan (Left foot), r = 0.816 
Here correlation coefficient for both the individual measurements was calculated as r = 0.816 
significant at p < 0.001 showing the large positive relationship as per Figure 5.4. As the points 
fall close to the line it has a close correlation between the measurements and as one variable 
increases, another variables also increases showing a positive relationship. The equation of the 
line is given by: 
𝑌1 = 0.8922𝑋1 + 0.2779        (8) 
Where, 𝑌1 is the Neurothesiometer voltage, 
𝑋1  is the VibraScan Voltage  
0.8922 is the slope of the line. 
Right foot VPT measurements 
Table 5.2 : VibraScan and Neurothesiometer readings for Right foot 
Series 
Number 
VibraScan Right  foot mean VPT 
(V) 
Neurothesiometer  Right foot 
mean VPT (V) 
1 4.9 5 
2 3.4 4.5 
3 3.4 3 
4 3.4 4 





















Correlation between VibraScan left foot 





VibraScan Right  foot mean VPT 
(V) 
Neurothesiometer  Right foot 
mean VPT (V) 
6 4.9 4.6 
7 4.9 4.8 
8 8.9 8.16 
9 3.4 3.16 
10 4.16 4 
11 5.63 5.16 
12 4.53 5.3 
13 5.26 5 
14 5.99 5.5 
15 4.9 5 
16 5.63 4.16 
17 5.63 6 
18 8 7.6 
19 6.7 4.8 
20 3.78 3.5 
 
Here for the above measurements of VPT, the right foot VibraScan score of VPT is compared 
with the Neurothesiometer VPT scores for all twenty subjects as displayed in Table 5.2. In 
order to get the linear relationship between the measurements, the correlation coefficient 
was calculated. 
 
Figure 5.5 : Correlation between Neurothesiometer and VibraScan (Right foot), r = 0.893 
Here, the correlation coefficient for both the individual measurements was calculated as r = 
0.893 significant at p < 0.001 showing the large positive relationship as shown in Figure 5.5. In 
in this case also points fall close to the line so has a close correlation between the 
measurements and as one variable increases, another variable also increases showing a 
positive relationship. The equation of the line is given as: 






















Correlation between VibraScan right foot 
VPT and Neurothesiometer right foot VPT 
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Where, 𝑋2 is the Neurothesiometer voltage, 
𝑌2 is the VibraScan voltage, 
0.7543 is the slope of the line. 
5.4 Bland and Altman plot 
There is a close linear relationship between the test scores of both feet. Although the 
correlation which is calculated is considered a way of paring the two instruments, the 
measured VPTs may correlate but not agree. Strong correlation may lack the agreement 
between measured scores. In order to find it out whether both the instruments are agreeing 
with each other, Bland and Altman method was applied to verify this (Bland and Altman 1986). 
Bland and Altman's method was used to obtain the limit of agreement between the VPT 
scores. It is also known as the difference plot which is a graphical method to compare two 
measurement techniques. In this method the difference between the test scores (𝑋 − 𝑌) are 
plotted against their average value([𝑋 + 𝑌] 2)⁄ . Through this plot, it is easy to evaluate the 
scatter of the values, level of different and measurement error. It also shows how much data is 
different from the mean value. Secondly, it shows the relationship between size of mean value 
and random error. Thus, this method might be used to figure out the level of random error if 
VibraScan VPT measurement is still acceptable to be used as an alternative to the 
Neurothesiometer measurement.  
Results: 
 


















Mean of both the readings 
Neurothesiometer Vs VibraScan Mean difference - 2SD = -1.492
Mean difference + 2SD= 1.96 Mean difference = 0.236
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Bland and Altman's method was used to plot the difference of VibraScan and 
Neurothesiometer VPT measurement of left foot against the mean of two measurements 
shown in Figure 5.6. The plot also has the benefit of showing the variations in the results. The 
limits of agreement are indicated by the black broken lines that are the interval of two 
standard deviations of the estimation differences on either side of the mean difference 
(0.236). This shows that the 95% of subjects will have a difference in VPTs between the limits 
of agreement on the Bland – Altman plot for the left foot. It is important to see whether the 
range of the limit of agreement is large or small with respect to the range of values. As limits of 
agreement are small, the two measurements methods could be interchangeable. 
 
Figure 5.7 : Bland and Altman plot (right foot VPT measurements) 
Bland and Altman's method was used to plot the difference of VibraScan and 
Neurothesiometer VPT measurement of right foot against the mean of two measurements 
shown in Figure 5.7. The limits of agreement are indicated by the dark broken lines that are 
the interval of two standard deviations of the estimation differences on either side of the 
mean difference (0.344). This shows that the 95% of subjects will have a difference in VPTs 
between the limits of agreement on the Bland – Altman plot for the right foot as well (Dave 
2018) 
Discussion 
After testing the subjects using VibraScan and Neurothesiometer, the measured level of 
agreement proves that both these methods are consistently measuring similar VPTs when 
vibration stimulus is alternately applied on both feet.  This shows that even the method of 

















Mean of both the readings 
Right foot Mean difference -2SD= -0.964
Mean difference +2SD= 1.65 Mean difference = 0.344
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in terms of measuring VPT.  The technique of independently measuring VPT, automatically 
interpreting the severity level of complication, programmable and an additional feature of 
monitoring pressure during the test makes VibraScan, an advanced tool for measuring diabetic 
neuropathy. The limitation of this study is at present, the outcome is based on twenty healthy 
subjects covering the normal range of VPT, however this study can be further extended to 
apply on many diabetic neuropathy patients and cover the whole range of VPT from 0 to 50 






















Chapter 6 Risk assessment Tool of VibraScan 
 
In this chapter, the development of the tool that allows automated assessment of neuropathy 
based on the clinical history of subjects has been discussed. The flow chart below provides the 
overview of this chapter. This chapter will start with an introduction that explains the reason 
for developing VibraScan risk assessment tool.  The risk factors associated with diabetic 
neuropathy were identified in this research study. The summarised patient data collection, it’s 
pre-processing are explained in the data collection and data preparation sections. This chapter 
also covers the need and implementation of Box-Cox transformation and ordinary least square 
method to get an idea of potential risk factors in the summarised patient data.  
The focus is mainly to find the best fitting methods and algorithms for solving the data analysis 
problem. Firstly, a standard artificial neural network (ANN) classifier was selected for the data 
analysis. The ANN classifier section starts with introduction, architecture and its 
implementation using complete set of attributes (attributes are the risk factors available in the 
data) and using only set of potential attributes for comparison purpose. Various classifiers 
such as ordinal logistic regression, discriminant functional classifier are implemented by using 
only potential attributes of the summarised patient data. The need for generating simulated 
patient data along with the implementation of the classifiers such as standard neural network 
classifier, discriminant functional analysis, ordinal logistic regression and neural network based 
proportional odds model (NNPOM) are also discussed. At last, the reason for selecting NNPOM 
method is explained for developing the risk assessment tool of the VibraScan by showing some 
examples. 
Structural overview of the chapter 




OLS using Box Cox 
transformed variables
OLR using patient data 
with 7 best predictors
Neural network classifier 
Patient data With  13 
attributes




Simulated patient data 
with 7 attributes
Ordinal logistic regression NNPOM model
Neural network classifier 
Neural network classifier 
Discriminant functional 
analysis







Diabetic neuropathy (DN) is the serious neurological manifestation in diabetes. If neuropathy 
is not treated at the early stage it may increase the risk of foot ulceration and amputation 
(Adler et al. 1997).  A novel VibraScan device was developed to assess DN based on vibration 
perception as discussed in the previous chapters. This entails that disease will be assessed only 
by vibration perception however, if one can consider the clinical characteristics of the subject, 
then DN can also be diagnosed based on clinical aspects of patients.  This has given us the 
motivation for developing an automated tool for predicting VPT which can help in determining 
DN. This tool will help in getting better understanding of the disease progression by analysing 
the clinical data. There are many research studies available which have identified the risk 
factors associated with diabetic neuropathy. It has been observed that age was directly related 
to painful symptoms of diabetic neuropathy in large UK diabetes populations (Abbott et al. 
2011b). There are several studies that shows there is a direct relationship between the 
duration of diabetes, increased age, obesity and diabetic neuropathy (Abbott et al. 2011b; 
Jambart et al. 2011) ; (Boulton 2008). Many studies have shown that there is no significant 
relation of gender in the diabetic neuropathy whereas in some studies it was shown that 
painful symptoms of diabetic neuropathy are more prevalent in females than in males (Abbott 
et al. 2011b). The study shows that age, insulin use, sex and duration of diabetes 
independently increased the risk factors of DN (Franklin et al. 1994). Likewise, not only 
demographic data but anthropometric and metabolic data could also play an important role in 
the prevalence of diabetic neuropathy. Existing devices like Biothesiometer/Neurothesiometer 
can perform screening test based sensation loss; however, risk factors of diabetic neuropathy 
were not taken into account. None of these existing tools considered both these possibilities 
(early symptoms and associated risk factors) to assess diabetic neuropathy. Taking this 
opportunity, the VibraScan risk assessment tool can be used as the independent tool for 
diagnosing DN from a set of risk factors for assessing diabetic neuropathy. 
6.2 Risk factors for diabetic neuropathy 
It will be interesting to know the common risk factors of diabetic neuropathy. Many research 
articles based on the onset diabetic neuropathy were studied. There are several independent 
risk factors that were significantly associated with diabetic neuropathy. The major risk factors 
of DN such as duration of diabetes, age, height, HbA1c, cholesterol, sex, weight and BMI are 
discussed in this section. 
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Duration of diabetes: Duration of diabetes is one of the major factors of diabetes (Young et al. 
1994). Based on the population selection and applying different methodology the exact 
prevalence of diabetic neuropathy differs, however the duration of diabetes association with 
DN was considered significant (Ziegler et al. 2014a). 
Age: Age is considered to be one of the risk factors of DN. Several groups have demonstrated 
an independent effect of age, leading to a significant increase in diabetic neuropathy 
prevalence (Young et al. 1994; Abbott et al. 2011a).  
Height: Height gives the measure of nerve fiber length, there are studies performed for both 
the types of diabetes where it was shown the association of height with diabetic neuropathy 
(Tesfaye et al. 1996b). According to one study (Papanas and Ziegler 2015), it was shown that 
there was 36% increase in the prevalence for every  5 cm increment in height in the population 
study in Mauritius. 
HbA1c: Glycosylated haemoglobin (HbA1c) level is the important factor which needs to be 
considered to get the assessment of glycemic control, however in addition to HbA1c, glycaemic 
variability could be considered as the independent risk factors of diabetes 
complication.  HbA1c variability had a significant association with diabetic neuropathy in type 2 
diabetes (Lin et al. 2013). 
Cholesterol: According to the study in 1996, it was found that there is a significant correlation 
between increasing level of cholesterol and diabetic neuropathy (Tesfaye et al. 1996a). 
Sex: In one of the research study  it was reported that the prevalence of diabetic neuropathy 
was more in males (30%) compared to females (18%) (Jaiswal et al. 2017), however, Abbot et 
al. have reported opposite that there was a higher prevalence in females (38%) compared to 
males (31%) (Abbott et al. 2011a). 
Weight: As per the study carried out with 452 participants to obtain the risk factors of diabetic 
neuropathy, by linear regression models, weight was considered as one of the factors 
associated with DN (odds ratio [OR] 1.20 [95% Confidence Interval of  1.10;1.31]) per 5 kg 
(Andersen et al. 2018).  
Body mass index (BMI): BMI is considered as an independent risk factor for diabetic 
neuropathy. According to the study (Xu et al. 2014), it was reported that BMI was the 
independent risk for the complication using multivariate regression analysis. This analysis is 
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mostly used to predict the value of one or more responses from the set of predictors where 
predictors can be continuous or categorical or a mixture of both. 
Therefore, in most of the studies, the above-mentioned risk factors are commonly identified 
which were strongly associated with diabetic neuropathy. In these studies, different numbers 
of patient data were collected for which diabetic neuropathy assessment either using 
Michigan Neuropathy Screening Instrument (discussed in Chapter 2), using Neurothesiometer/ 
Biothesiometer by measuring VPT, or by Nerve conduction studies to determine the diabetic 
neuropathy patients and to identify the risk factors associated with it.  
In order to determine the risk factors associated with diabetic neuropathy, there is a need to 
collect medical data where DN is assessed by vibration perception threshold. 
6.3 Medical data collection 
To perform this study, a summarised patient data was collected from the clinical database. In 
the summarised data, foot examination was assessed by Neurothesiometer, where vibration 
was provided at the great toe, the amplitude of the vibration was increased gradually and, 
subjects were asked to say ‘yes’ whenever they felt the vibration. Thus, the voltage at which 
the vibration was felt determines the vibration perception threshold (VPT). As per the VPT 
score, severity levels of diabetic neuropathy can be determined. The summarised patient data 
has patient’s average measurements for the last 28 years which contains around 5158 
subjects. In various studies almost same types measurements were followed to analyse 
independent risk factors for DN. These measurements can be used as the risk factors and need 
to analyse its effect for the prevalence of diabetic neuropathy. The main aim of using this data 
is to get a point estimate of VPT by giving the set of point measurements of some potential 
predictors.  To achieve this aim, first data needs to be processed and used by the classical 
statistical technique for identifying the potential predictors. 
6.3.1 Data preparation and statistical analysis 
These variables in the data were measured once a year or are average of a small number of 
measurements within a year which was continued for 28 years, this longitudinal data was 
measured as an outcome repeatedly over time for the same subjects. There could be a 
possibility of unintended missing data or loss to follow-up which commonly occurs in 
longitudinal trials.  The data can be analysed using multilevel modelling, however the output of 
these models may be less helpful so there is a need of baseline analysis, the output of which 
could be helpful for neural network modelling. For performing any statistical analysis of the 
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collected data, data needs to be further processed. First, the collected data were averaged 
over 28 years. The VPT measurements should be taken for both feet of each individual 
whereas in the collected data all the subjects did not have both the measurements for which 
statistical averaging technique was performed. These manipulations created a summary which 
conveniently eliminates missing measurements over time and over both feet as symmetrical 
neuropathy is the commonest among diabetic neuropathy (Bansal et al. 2006), thus 
maximising the number of patients with non-missing values for further analysis. Averaging is 
commonly used statistical technique which helps in identifying the trends and relationship 
within and between the datasets. After averaging the data, a summary of data count in each of 
the clinical measurements was calculated. 
Table 6.1 : Summary of patient data  






17.815      
 
11.129        
 
1.500            
 
50 
HbA1c 5143 08.728     1.295 4.766      14.4 
High density lipoproteins (HDL) 4864 01.352      0.859 0.420    27.886 
Low density lipoproteins (LDL) 4815 02.636      0.880    0.450        10.8 
Urine albumin to creatinine ratio (ACR) 3886 7.152 18.355 0 293.830 
Random Blood Glucose (RBG) 5078 11.573 3.779         1 38.3 
Age 5158 57.733      18.450 7 98.0 
Weight 5156 83.422     19.676 32.766 192.2 
Height 5111 168.672      10.058 81 207.0 
BMI 5107 29.286       6.426        14.583 104.77 
Triglyceride 4928 02.072      1.292            0.3 22.6 
Cholesterol 4852 03.998      1.193       1.43 18.7 
Sex 5117 01.561      0.496             1 2 
Duration of diabetes 5158 10.632 6.750             1 28 
    
As shown in Table 6.1, it has been identified that out of 5158 data, 3691 subjects were having 
all the clinical measurements as required and rest of the missing data rows can be neglected 
for the analysis. Although a summary of patient data is achieved by averaging the data, 
however, to deal with longitudinal trends and skewness in the data there is still a need for 
statistical transformation to obtain information like relationship between the variables and to 
identify significant predictors. There are traditional types of transformation available such as 
logarithmic transformation, square root, inverting and reflecting that belong to power 
transformation, but for choosing the right type of power transformation which transforms the 
data in a way that its distribution better fits some target distribution, is a challenge. Therefore, 
an option of using transformation from Box-Cox family was taken into consideration, instead 
of just using a logarithmic transformation that makes the result normal and linearly related to 
covariates. Box-Cox transformation belongs to the power transformation family which can be 
used to identify the optimal normalising transformation for each variable (Box and Cox 1964).   
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6.3.2 Box-Cox transformation 
Box Cox transformation was performed on all the individual variable and purpose was to find 
the behaviour when set of variables were used collectively by Box Cox regression model. This 
was found using Stata statistical software. For transforming the data set, the same 
mathematical operation or a transformation parameter should be applied to each data point 
of the set. Box-Cox transformation is defined by yλ where y represents the data and λ is the 
power to which data is raised.  The original form of the transformation is given as: 
                                                                     𝑦(𝜆) =  
𝑦𝜆−1
𝜆
 , λ ≠ 0,                                             
                                                                                    (10)                 
𝑦(𝜆) = log (𝑦) , λ = 0. 
The value of λ is from -5 to 5, and to obtain the value of λ that best fit the data, transformation 
examines the values of it. Here, in the current data set the transformation was applied on both 
sides of the equation i.e. logarithmic transformation on the left-hand side and Box-Cox 
transformation on the right-hand side of the equation.  
Box-Cox Right-hand side model (RHS only) 
In the right-hand side model, all the independent variables were transformed using the 
parameter 𝜆, which can be given in the form of equation 11 as below: 




+ ⋯ + 𝛽𝑘𝑥𝑘𝑗
(𝜆) + 𝑦1𝑧𝑖𝑗 + 𝑦2𝑧2𝑗 + ⋯ + 𝑦𝑙𝑧𝑙𝑗+∈𝑗                        (11) 
Where 𝑦 is the dependent variable,  𝑥1, 𝑥2, 𝑥3… 𝑥𝑘 are the independent Box Cox transform 
variables  with parameter λ and 𝑧1, 𝑧2,𝑧3… 𝑧𝑘  are the independent variables without any 
transformation. 
Hence the equation of the patient data can be expressed as natural logarithmic transform of 
dependent variable VPT as the function of independent transformed variables as age, height, 
weight, body max index (BMI), glycaemic control (HbA1c), High-density lipoprotein (HDL), Low-
density lipoprotein (LDL), Urine albumin to creatinine ratio (ACR), Random Blood Glucose 
(RBG), Triglyceride, Cholesterol and duration of diabetes except variable sex. 







Table 6.2 : BoxCox right-hand side only model 
 
                Log Transformed VPT |                  Coefficient       Standard Error z P>|z|      [95% Conf. Interval] 
 
    
                                       /λ |                     1.106              .0667            16.54   <0.001     .975       1.237 
 Coefficient R test 
statistics 






    
Sex .003 .019 0.89 1 





Duration of diabetes .002 7.092 0.008 1 
Age .019 2908.180 <0.001 1 
Height .006 26.445 <0.001 1 
Weight .004 12.576 <0.001 1 
BMI -.004 1.874 0.171 1 
HbA1c .032 34.914 <0.001 1 
 HDL .007 1.086 0.297 1 
LDL .017 2.483 0.115 1 
ACR .002 35.889 <0.001 1 
RBG .002 1.088 0.297 1 
Triglyceride -.002 0.096 0.754 1 
Cholesterol .023 7.693 0.006 1 






The estimated value of λ is 1.106372 and is seen that the maximum likelihood estimate of the 
transformation parameter is positive and significant at 1%. Out of all the transformed 
variables, duration of diabetes, age, height, weight, glycaemic control (HbA1c), ACR and 
cholesterol are significant predictors.  
6.3.3 Ordinary least squares using Box Cox transformed variables 
The maximum likelihood method is useful as the convenient route to the transform. Running 
the more familiar linear regression using the transformed variables provides additional 
information about model fits, linear relationship and about important predictors in more 
familiar terms. To get the additional fit estimates ordinary least squares regression is 
implemented.  Basically ordinary least squares (OLS) regression method was used to detect the 
linear relationship between the natural logarithmic transformed dependent and Box-Cox 
transformed independent variables by using the formula as : 
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                                         𝐵𝑜𝑥𝐶𝑜𝑥𝑉𝑎𝑟𝑖𝑎𝑏𝑙𝑒 = (𝑉𝑎𝑟𝑖𝑎𝑏𝑙𝑒)λ/𝜆                                                 (12) 
Where λ = 1.106372 
The calculated coefficient of determination (𝑅2) value of the whole test is 0.656 and the 
adjusted R square is 0.655 shows that all the independent variables shows 65% of the 
variability of the dependent variable as presented in  Table 6.3. As per the analysis results out 
of all the 13 variables, duration of diabetes, Age, Height, Weight, glycaemic control (HbA1c), 
ACR and cholesterol are statistically significant predictors as the p- value is less than 0.05. 
However, sex, BMI, LDL, RGB, Triglyceride variables are not statistically significant as the p- 
value is greater than 0.05.  
Table 6.3 : Ordinary least squares performed on all BoxCox transformed variables 
 Coefficients t- statistics 95% confidence limits 
Box Cox transformed 
variables except sex 
  Upper bound Lower bound 
     
Sex            0.002 (0.14)            -0.036 0.041 
Duration of diabetes 0.002** (2.72) 0.001 0.004 
Age   0.020*** (73.21) 0.019 0.021 
Height   0.006*** (5.57) 0.004 0.009 
Weight   0.004*** (3.55) 0.002 0.006 
BMI          -0.004 (-1.38) -0.011 0.002 
HbA1c 0.032*** (6.01) 0.022 0.043 
 HDL           0.006 (1.04) -0.006 0.019 
LDL           0.016 (1.58) -0.004 0.037 
ACR 0.002*** (6.17) 0.001 0.002 
RBG           0.002 (1.04) -0.002 0.005 
Triglyceride          -0.002 (-0.31) -0.016 0.011 
Cholesterol           0.023** (2.78) 0.007 0.039 
_cons          -1.398*** (-4.55) -2.001            -0.80 
Observations                                    3691   
R
2
                                                       0.656   
adj. R
2
                                                0.655   
     t statistics in parentheses 
           * p < 0.05, ** p < 0.01, *** p < 0.001 
 
In order to simplify this interpretation, OLS was performed again using only significant 
independent variables and dependent variable VPT. The analysis has been performed and 






Table 6.4 : Ordinary least squares performed on significant BoxCox transformed variables 
 Coefficients t-statistics 95% confidence limits 
Box-Cox transformed 
risk factors 
 Upper bound Lower bound 
Age 0.020*** (73.39) 0.019 0.020 
Height 0.007*** (15.54) 0.006 0.008 
Weight 0.002*** (9.24) 0.002 0.003 
HbA1c 0.033*** (7.03) 0.024 0.042 
Acr 0.002*** (6.01) 0.001 0.002 
Cholesterol 0.018*** (3.71) 0.009 0.028 
Duration of diabetes          0.002* (2.52) 0.001 0.004 
_cons         -1.524*** (-12.02)            -1.772            -1.275 
Observations 3788    
R
2
 0.646    
adj. R
2
 0.645    
      t statistics in parentheses 
         * p < 0.05, ** p < 0.01, *** p < 0.001 
 
Table 6.5 : Significant predictors 
 F - statistics p-values R
2
 Change in R
2
 
Age 5148.12 <0.001 0.576  
Height 447.99 <0.001 0.621 0.045 
Weight 133.04 <0.001 0.634 0.013 
HbA1c 68.74 <0.001 0.641 0.007 
 ACR 45.62 <0.001 0.645 0.004 
Cholesterol 11.53 <0.001 0.646 0.001 
Duration of diabetes 6.34   0.012 0.646 0.001 
 
As shown in Table 6.5, as expected all the variables are statistically significant as the p-value is 
less than 0.05 and can be considered as the risk factors for the development of diabetic 
neuropathy as per the analysis results. It shows age is the most significant predictor while 
duration of diabetes is the least significant predictor. 
The advantage of applying this classical statistical method on the collected data is to get the 
hint of significant predictors in the collected data for getting classical information and can be 
useful to compare with the neural network predication success later on. 
 The original patient data set was pre-processed and information was extracted using required 
transformation of the variables where VPT was measured continuously. Now, this can be used 
to get the point prediction of VPT or VPT can be predicted with the confidence interval. If the 
confidence interval of predicted VPT is too large then it is less helpful to the user. In order to 
simplify the interpretation of the outcome variable (VPT) for both clinicians and subject itself, 
it was decided to interpret the VPT prediction in terms of cumulative risk levels. For solving 
this problem in terms of classification, the first step is to divide the data into specific 
categories based on VPT thresholds. By considering clinician’s insight in the field of diabetic 
neuropathy it was decided to categories the dataset into three classes according to VPT 
measurement in voltages (V) as low risk (0 to 20.99 V), medium risk (21 to 30.99 V) and high 
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risk (≥ 31 V) diabetic neuropathy. To approach this dataset for further analysis where VPT was 
continuously measured, it is important to identify data’s behaviour and its significant 
predictors for the categorical data set. To achieve this information, categorical data were 
analysed using ordinal logistic regression. 
6.4 Ordinal Logistic Regression using summarised patient data  
Ordinal logistic regression (OLR) is the statistical analysis method performed using SPSS 
statistical  software to find the relationship between ordinal responsive (dependent) variable 
and independent explanatory variables (O'Connell 2006). The type of ordinal logistic 
regression implemented was the cumulative odds ordinal logistic regression with proportional 
odds that have cumulative categories. The ordinal variable is the categorical variable with the 
ordering of the category levels. As discussed before, the data is divided into three ordinal 
categories based on the VPT measurements along with the number of instances is presented 
as shown in Table 6.6. To analysis these categories after dividing the data, OLR was 
implemented. As per the case summary table, it shows a number of instances available in each 
level of the responsive variable. The total number of instances available in the data set is 2450, 
however, in two of these levels, there are fewer cases. SPSS does listwise deletion of cases if 
missing values are available in any of the variables. 
Table 6.6 : Case summary of real patient data 
 Categories of the dependent 
variables 
The range of VPT score in 
Volts (V) 
No. of instances 
(2450) 
Low risk 0 to 20.99 1696 
Medium risk 21 to 30.99 459 
High risk  31 onwards 295 
 
In the model fitting information as shown in Table 6.7, the degree of freedom (df) is 7 i.e. 7 
independent significant variables (age, height, weight, HbA1c, ACR, cholesterol and duration of 
diabetes) were used as determined from the previous analysis to OLR. Chi-Square is the 
difference between the two –2 log-likelihood values. The last row of the table presents the 
information that either all or some of the variables are statistically significant. In other words, 
added variables are statistically significantly improving the model compared to the intercept 
only (no added variables). As p < 0.001 means model predicts the dependent variable better 
than the intercept-only model.  




-2 Log  
Likelihood Chi-Square df  Sig. 
Intercept Only  4034.042     
Final  3223.445 810.597 7  < 0.001 
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As in Table 6.8, p < 0.05 (from the Sig. column) indicate model does not fit well with the data. 
Good models have large observed significance levels.  
The model estimates from ordinal logistic regression are maximum likelihood estimated 
through an iterative process. As they are not calculated to minimise the variance, to evaluate 
the goodness of fit of logistic models, several pseudo R squared is calculated as displayed in 
Table 6.9. These pseudo R squares are like R square in terms of scale (but cannot be 
interpreted as OLS R square) i.e. ranging from 0 to 1, higher the value better the model fit.  
                                  Table 6.8 : Goodness-of-Fit                                                                                   
 Chi-Square df Sig. 
 Pearson 5399.082 4891 < 0.001 
Deviance 3223.445 4891 1.000 
Table 6.9 : Pseudo R-Square 
Pseudo R-square 
Cox and Snell .282 
Nagelkerke .349 
McFadden .201 
There are coefficient, their standard errors, the Wad test and associated p- values (Sig.) and 
95% confidence interval of the coefficient as available in the estimated parameter Table 6.10. 
The dataset has three level of a variable called <cat> (coded 1, 2, and 3) that are outcome 
variables. It can be used to determine the number of statistical significant independent 
variables on the dependent variable (VPT). Out of seven predictors age, weight and height 
were significant predictors while HbA1c, ACR, Cholesterol and duration of diabetes were not. 
As per the results, one unit increase in age (from 0 to 1), there can be 0.1 increase in the 
logarithmic odds of being a higher level of cat, with all the other variables in the model being 
constant. For weight variable, one unit increase in weight (from 0 to 1), there can be 0.02 
increase in the logarithmic odds of being a higher level of cat, keeping other variables 
constant. For the height variable, one unit increase in height (from 0 to 1), there can be 0.05 
increase in the logarithmic odds of being a higher level of cat, with other variables as constant 
as shown in Table 6.10.  
This can be expressed in form of equation 13 as below: 
            𝑦∗ =  𝑥𝑇𝛽 + 𝜖                                                                              (13) 
Where 𝑦∗ is the unobserved dependent variable, xT is  the vector of the independent variable, 
β is the estimated coefficient and ϵ is the error term. 
And   𝑦 =  {
0           𝑖𝑓 𝑦∗ ≤  𝜇1,
1 𝑖𝑓  𝜇1 < 𝑦
∗ ≤ 𝜇2,
2 𝑖𝑓𝜇2 < 𝑦
∗ ≤ 𝜇3  
 
Where 𝑥𝑖 are the independent variables,  μi are the set thresholds of the categories and using 






Table 6.10 : Parameter estimates 
 
Estimate Std. Error Wald df Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
Threshold [cat = 1.00] 19.678 1.238 252.833 1 < 0.001 17.252 22.103 
[cat = 2.00] 21.202 1.251 287.450 1 < 0.001 18.751 23.653 
Location HbA1c .013 .043 .099 1 .753 -.070 .097 
ACR .004 .002 2.678 1 .102 -.001 .008 
Age .111 .005 412.044 1 < 0.001 .100 .122 
Weight .021 .003 54.160 1 < 0.001 .015 .027 
Height .056 .006 90.113 1 < 0.001 .044 .068 
Cholesterol .069 .042 2.668 1 .102 -.014 .152 
Duration of 
diabetes 
.000 .008 .003 1 .958 -.016 .015 
 
By comparing all the values of the responsive variable with the values of the predicted 
outcome, it is possible to calculate the classification success for each class. Using SPSS, the 
cross-tabulation (confusion matrix) was obtained as shown in Table 6.11 where data is 
presented for each of the classes in terms of true positive, true negative, false positive and 
false negative. It measures the percentage overall classification success estimated as 71.5%, in 
which low-risk category achieves classification success of 75.8%. This could be probably 
inflated by a large number of instances in category 1 i.e. 1629 is more probable by chance 
compared to the other classes. 
Table 6.11 : Predicted Response Category Cross-tabulation 
 
Predicted Response Category 











Low risk Count 1629 41 26 1696 
% within cat 96.0% 2.4% 1.5% 100.0% 
% within Predicted 
Response Category 
75.8% 30.4% 15.8% 69.2% 
Medium risk  Count 344 50 65 459 
% within cat 74.9% 10.9% 14.2% 100.0% 
% within Predicted 
Response Category 
16.0% 37.0% 39.4% 18.7% 
High risk Count 177 44 74 295 
% within cat 60.0% 14.9% 25.1% 100.0% 
% within Predicted 
Response Category 
8.2% 32.6% 44.8% 12.0% 
Total Count 2150 135 165 2450 
% within cat 87.8% 5.5% 6.7% 100.0% 
% within Predicted 
Response Category 
100.0% 100.0% 100.0% 100.0% 
Using this model, it gives an overview regarding significant predictors when the continuous 
data is categorised into three classes based on VPT measurement. These results were obtained 
from the conventional statistical methods; however, for developing a risk assessment tool, it 
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can be possible to use a classifier that can handle these data more precisely and accurately. 
Various research studies based on a clinical characteristic of the subjects were studied to get 
the idea for developing the tool. 
6.5 Methods for developing a risk assessment tool 
In one of the research study, assessment of DPN was performed using the Michigan 
Neuropathy Screening Instrument (MNSI) questionnaire examination. It was focused on the 
relationship between risk factors and the prevalence of diabetic neuropathy in youth with type 
1 diabetes and type 2 diabetes. Out of 1734 youth, the prevalence of DPN was 7% in youth 
with type 1 diabetes and 22% in youth with type 2 diabetes. Older age, longer diabetes 
duration, smoking, increased diastolic blood pressure, obesity, increased LDL cholesterol and 
triglycerides, and lower HDL cholesterol are the selected risk factor for type 1 diabetes and 
older age, male sex, longer diabetes duration, smoking, and lower HDL-c were the risk factors 
for type 2 diabetes. It was found that the effect of the glycaemic control was getting poor over 
time with DN in youth with type 1 diabetes than another type (Jaiswal et al. 2017). 
Another study was performed using 110 diabetic patients in which Michigan Neuropathic 
Diabetic Scoring (MNDS) was used to differentiate the cases among the normal and abnormal. 
In this study Nerve conduction study was used to assess diabetic neuropathy. It was found that 
age, duration of disease, gender, quality of diabetes control have a significant relationship with 
diabetic neuropathy and no correlation was found with risk factors like hyperlipidemia, high 
BP, cigarette smoking (Booya et al. 2005). 
A study was performed to identify the risk factors associated with the prevalence of diabetic 
neuropathy by comparing the prevalence of diabetic neuropathy with known diabetes mellitus 
and with newly detected diabetes mellitus. In this study monofilament test, pinprick and 
vibration perception threshold was used to categories diabetic neuropathy into normal, mild, 
moderate and severe neuropathy. A total of 586 patients was identified with developed DN. 
Regression analysis was used to identify the risk factors associated with DN. It was found that 
age, dyslipidemia, alcoholic status, macro and microvascular complication significant risk 
factors for diabetic neuropathy (Bansal et al. 2014). 
In most of the research studies, assessment of diabetic neuropathy was performed either by 
measuring vibration perception threshold or using various questionnaires to identify the risk 
factors of diabetic neuropathy. In most of the cases, data analysis was performed using 
conventional statistical methods to identify the significant risk factors of DN. To the best of 
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knowledge, there are no such tools available which make use of these risk factors for 
determining diabetic neuropathy of an individual which seems possible by analysing a large 
number of clinical data of DN. As discussed before, the focus is to develop the risk assessment 
tool to help the clinicians for analysing complex relationship between the risk factors and 
predicting the most likelihood level of DN. After getting the results from the classical statistical 
analysis and looking at the complexity and nonlinearity in the data, idea of using standard 
artificial neural network classifier was taken into consideration. The introduction of ANN 
showing capability of learning the data, structure, architecture, various methods, training the 
model and comparison with another classifier’s result are discussed in the following sections. 
6.5.1 Artificial neural networks  
Artificial neural networks (ANN) technique is extensively used for prediction, forecast or 
classification.  Capabilities of finding the pattern and recognising the relationship between the 
input variable is much faster than the other existing conventional methods for which ANN was 
widely used in  medical (Yao and Liu 1999), ecology, cost estimation (Londhe and Deo 2004), 
forecasting (Ho et al. 2001), computer science and in physical sciences. ANN uses the 
intelligent mechanism similar to the human brain to solve the complex problems. There are 
different types of neural networks available based on the type of processes to be performed. 
Some of the neural networks are relatively simple and some are complex. The artificial neural 
network is used in performing various tasks like prediction, forecasting, pattern classification 
and clustering (He and Xu 2010). In the current study, pattern classification was used in ANN. 
However, by using the neural network classifier, it is important to get an idea of how well the 
neural network is working based on true predicted class for which loss function or cost 
function is used i.e. it maps the value of the variable with the real number to represent the 
cost associated with the event. To understand the working of the classifier and the way it 
learns the pattern of the data to perform classification, need to get into the basic theory 
behind the neural network. So the concept of neural network, neural network classifier, 








Biological Neuron and Artificial neuron: 
Neural networks emulate the procedure used by the human brain to process the data that 
consists of learning the relationship between the data gathered and the data obtained. Here 
similarities in terms of structure and processing the signals are shown by comparing the 
Biological neuron and artificial neuron. 
 
Figure 6.1 : The biological Neuron 
For processing information in the human brain, it consists of a large number of neural cells. 
Each Biological neuron consists of three main components such as dendrites, axon and soma 
as shown in Figure 6.1 (Fausett 1994). The electric impulses as the input signal transmitted 
through the synaptic gap. The information is received by the dendrites which gather in the 
soma and deliver to the neuron’s axon to the dendrites at its end. The information pass again 






      
Figure 6.2 : The artificial Neuron 
Similarly, an artificial neuron is a simple processing unit consist of three components shown in 
Figure 6.2 where a fixed number of inputs having activation from other neuron is connected 
with the neuron by weighted link 𝑤𝑖 , neurons will sum up all the inputs and apply the 





𝑆𝑜𝑓𝑡𝑚𝑎𝑥 𝑓𝑢𝑛𝑐𝑡𝑖𝑜𝑛 𝑖𝑠 𝑎𝑝𝑝𝑙𝑖𝑒𝑑 𝑡𝑜 𝑜𝑢𝑡𝑝𝑢𝑡 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑖𝑒𝑠 𝑜𝑓 𝑡ℎ𝑟𝑒𝑒 𝑜𝑢𝑡𝑝𝑢𝑡 𝑐𝑙𝑎𝑠𝑠𝑒𝑠. 𝑇ℎ𝑒 𝑖𝑛𝑝𝑢𝑡 𝑋 𝑖𝑠 𝑚𝑢𝑙𝑡𝑖𝑝𝑙𝑖𝑒𝑑 𝑏𝑦 𝑤𝑒𝑖𝑔ℎ𝑡 𝑊 𝑎𝑛𝑑 𝑎𝑑𝑑𝑒𝑑 𝑡𝑜 𝑏𝑖𝑎𝑠 𝑡𝑜 𝑔𝑒𝑛𝑒𝑟𝑎𝑡𝑒 𝑎𝑐𝑡𝑖𝑣𝑎𝑡𝑖𝑜𝑛𝑠. 
𝑦_𝑖
= 𝑠𝑜𝑓𝑡𝑚𝑎𝑥 (∑_𝑗▒〖𝑊_(𝑖, 𝑗) 𝑥_𝑗
+ 𝑏_𝑖 〗) 












Axon from a neuron 
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6.5.2 Classification using neural network 
Depending on the number of class, neural network classification can be used. To start with first 
neural network binary classification is explained which is followed by multiclass classification. 
Neural network Binary classification: 
 
Figure 6.3 : A single layer perceptron 
In the binary classification, there is an artificial neuron in which an input neurons layer is feed-
forwarded to an output neurons layer as displayed in Figure 6.3. The inputs are directly 
connected to the output layer via a single layer of weights. Here the links are from each input 
to the output in one direction. 
The initial weights are assigned randomly in single layer perceptron. Single layer perceptron is 
activated when the threshold reaches its maximum value. The threshold value is either 1 or 0. 
It is given as below: 
Ʃ𝑤𝑖𝑥𝑖 > 𝜃   => Output is 1 
Ʃ𝑤𝑖𝑥𝑖 ≤ 𝜃    => Output is 0 
The input is provided to the input layer to obtain the predicted output; if the predicted output 
is not equal to the desired or expected output then the weights will be adjusted to reduce the 
error. The process of adjusting the weights to obtain the expected results is known as training 
the network. If the predicted output matches the expected output there will not be any 
changes in the weights. 
Single layer perceptron / binary classification networks can perform pattern classifications task 
to classify correctly into one or two classes. It is used to classify the objects according to their 
position in n-dimensional hyperspace (using n inputs) where the problem can be defined as a 
linear separable classification problem. It can be implemented on those patterns which are 
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only linearly separable patterns irrespective of non-linearity used. In the current scenario, 
there are three categories so more advanced neural network classifier should be used as 
described in the following section.  
Neural network structure model (binary to multiclass classification): 
Neural networks don’t depend on pre-prepared program or mathematical equations to 
estimate the results. This complex nonlinear task can be achieved by neural network structure.  
 
Figure 6.4 : Neural network structure for classification 
This is the structure of the neural network classifier using feedforward learning algorithm as 
illustrated in Figure 6.4. It is a three layer feed-forward neural network which consists of the 
input layer, hidden layers and output layers. These layers having thirteen nodes in the input 
layer, N number of nodes in the hidden layer and three nodes in the output layer.  Selecting a 
number of neurons in hidden units is a problem specific i.e. Number of hidden neurons may be 
appropriate for one model but may not work well for another dataset. The model might miss 
some of the minute details if selected neurons are less. If the neuron size is less or 
underestimated then it may lead to poor approximation and if excessive neurons are used 
then it may lead to a problem of overfitting. In the same way, hidden layers which consist of 
hidden units also need to be set. Increasing number of hidden layers also demands to specify 
the hidden units for each hidden layers.  A number of hidden layers should be selected based 
Bias- b 






on the complexity of the data set. Selecting the number of hidden layers and neurons are an 
iterative process which needs to be properly assessed in terms of accuracy. 
In the feed-forward architecture, the signal propagates from input to output and updating the 
whole cycle by obtaining the error value from calculated values and real values. This process is 
achieved when input values from the input layer propogates to the hidden layer node by 
multiplying the weight connecting the node. The entire training data set passes through a 
neural network is known as a number of epochs. The values of weights get updated in every 
epoch and associated error should get minimised with each epoch. If less number of epochs is 
set then there could be a problem of underfitting. Number of times the value of weight 
changes the graph can change from under fitting to optimal. A large number of epochs may 
result in overfitting of the curve. These weights and biases get updated in the direction 
depending on the types of training algorithms implemented in the network. To train the 
network various training algorithms are available, out of which resilient backpropagation 
algorithms and scaled conjugate gradient algorithm are fast and used for pattern classification 
of ANN (Mathworks 2018) (Sharma and Venugopalan 2014). Scaled conjugate algorithm 
(Trainscg) is fast because it does not require line search during each learning iteration step. 
Trainscg requires more iterations to converge than other algorithms, however number of 
computations decreases as it avoid each line of search (Hager and Zhang 2006). Resilience 
backpropagation (Trainrp) runs on the basis of eliminating the effects of the partial derivatives 
(Anastasiadis et al. 2005). Depending on the sign of the derivatives the direction of updating 
the weights will be decided; however there will not be any effect of magnitude of derivatives. 
After this, the hidden layer value is computed through the transfer function i.e. sigmoid 
function commonly used as the activation function provided in the following equation to get 
the output value.  
                  𝐹(𝑋) =  
1
1+𝑒𝑥
                   (14) 
It produces “S” shaped graph when plotted. There are two types of sigmoid functions log 
sigmoid function and tan-sigmoid function. The range of log sigmoid function is from 0 to 1 
while the range of the tan-sigmoid function is -1 to 1. Preferably the tan-sigmoid function 
should be used due to its output range. The main advantage of this activation function is 
negative inputs will be strongly associated with negative output and zero inputs will be 
mapped near zero in the tan graph. Log and tan-sigmoid functions are commonly used in 
feedforward neural network. The neural network gets trained depending on selecting the 
value of the learning rate. Learning rate can be defined by adjusting the weights with respect 
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to loss gradient. Lower the value of the learning rate, it takes more time to learn. The 
advantage of using a low value of learning rate is, it will not miss any of the local minima but 
will take a longer time to converge. 
At the output node, the softmax activation function is used yields the probability values of the 
classification provided by the nodes. The softmax usually takes the un-normalised vector and 
normalises in terms of probability distribution over predicted output classes. Here X is the 
input, where inputs are values of all the 13 attributes =  (𝑥1, 𝑥2, 𝑥3, … , 𝑥13) . Y is the output: 
Output of the classifier is 1 of the 3 classes’ probabilities (1 to 3). 𝑌 = (𝑦1, 𝑦2, 𝑦3). Each 𝑦𝑖  
represents the input values belongs to class i. 
Softmax function is applied to output probabilities of multiple output class and can be given as 
the input X is multiplied by weights W and added to bias to generate activations. 
         𝑦𝑖 = 𝑠𝑜𝑓𝑡𝑚𝑎𝑥 (∑ 𝑊𝑖 .𝑗𝑥𝑗 + 𝑏𝑖𝑗 )      (15)                  






In, 3 – class classification problem with 3 output nodes, softmax normalise the 3-dimensional 
vector into the range of [1, 0] ϵ R. Here yi, is the predicted probability. The input and output of 
the softmax function are both vectors defined in the equation. In order to evaluate how well 
the classifier is working, the loss function is used. Loss function of the model plays an 
important role in measuring the inconsistency between the predicted output and actual 
output. The loss function is known as the performance goal. Here cross entropy loss function is 
used to get the classification success given by the equation as below: 
              𝑐𝑟𝑜𝑠𝑠𝑒𝑛𝑡𝑟𝑜𝑝𝑦(𝑙𝑎𝑏𝑒𝑙, 𝑦) =  − ∑ 𝑙𝑎𝑏𝑒𝑙𝑖log (𝑦𝑖)𝑖      (16) 
This model will be used to train the neural network as per the numbers of provided attributes. 
6.5.3 Experimental methodology 
Experiments were carried out on a window operating system with an i5 processor with 8 GB 
RAM. All the neural network implementations were achieved using pattern classification 
feature of neural network toolbox in MATLAB platform.  
1. Pre-process the medical data to achieve the class balance before using a neural 
network for classification. 
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2. Follow the file format like (labels, attr1, attr2, attr3,… attrN) where labels should be 
encoded as [1,0,0], [0,1,0] and [0,0,1]. (where attr means attributes  ----> risk factors 
of the DN) 
3. Divide dataset into three sets as training (70%), testing 15% (unseen data) and 
validation sets (15%). 
4. Adjust the important hyperparameters such as hidden neurons ϵ (10, 15, 25, 50), 
hidden layers ϵ (1), learning rate ϵ (0.1), iterations ϵ (1000) and measure the epochs. 
5. Train the neural network using resilient backpropagation (Trainrp) and scaled 
conjugate gradient (Trainscg) algorithm.  
6. Train neural network with 13 attributes using training, test and validation set. Select 
the model that gives optimal result by changing the values of required 
hyperparameters. 
7. Confusion matrix is computed to assess the neural network performance. 
8. Based on the classification success of training, testing and validation set, calculate 
overall accuracy for comparison. 
9. Repeat steps 2 to 8 to train the neural network using 7 best predictors. 
10. Compare the accuracies of the dataset with a different number of attributes. 
Pre-processing of the medical dataset 
Before selecting any of the classification models it is important to understand the property of 
the medical data. For training any of the medical data, the issues and challenges that are 
related to those data need to be carefully handled.  As the medical data is collected directly 
from the medical database, possibly common issues can be identified as follow: 
1. A total number of variables: It is essential to have relevant information in the data for 
any medical diagnosis. To perform any machine learning technique the complexities 
associated with these data is not linear. As the number of variables increases the 
complexities also increases. Another limitation of collected data is that it may have a 
specific number of attributes that may vary according to the patient’s requirements. 
For research purpose, if the required number of attributes are more, this may not be 
fulfilled when the data is collected from the medical database. 
 
2. Missing data: Medical database system does not have all the required data that are 
useful for research. In the clinical practice, it happens that patients do no fill all the 
details asked in the report because  they feel it is not essential or in some cases, they 
are not in a position to record few of the attributes (Almeida et al. 2010). Because of 
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this reason, there are patients in the database who have missing data in some of the 
attributes. In the collected data total number of observations was around 5158. In this 
huge number of observations, there were missing values in few of the attributes. For 
neural network training, it requires full sets of input data. In this situation for getting 
full set of input data, those observations were discarded with the missing value in any 
of the attributes, due to that a set of 2450 observations were available having input 
values in all the attributes. 
 
3.  Noisy data: Data available in the medical database have noise which involves implicit 
errors introduced by the measurement tools or by the experts while gathering the 
data. Due to this there is a possibility of extreme values in some of the attributes, i.e. 
either very low value or very high values because of which the mean value of the 
attributes gets affected. 
 
4. Class Imbalance in medical data:  In most of the medical datasets, datasets are not 
balanced in terms of class labels. When the dataset is extremely imbalanced, 
classification method does not work well on the minority class. In the current medical 
dataset VPT scores of these observations were used to define class labels. The range of 
the VPT score is from 0 to 50 Volts. All the collected observations were associated with 
this VPT score. In this datasets, data were divided into three class labels such as Low 
risk, medium risk and high risk with the threshold value of 0 - 20 Volts, 21 - 30 Volts 
and 31 Volts onwards respectively. When the data is divided into these classes it was 
interesting to see the observations available in each class as shown in Table 6.12: 
Table 6.12 : Class imbalance 
Class labels Number of instances – 
(Total number of 
instances is  2450) 
Percentage distribution % 
Low risk – class 1 1696 69.2 
Medium risk – class 2 459 18.73 
High risk – class 3 295 12.0 
 
 This shows that the dataset is highly imbalanced as the number of instances available in class 
2 and 3 is very less.  The percentage of instances available in class 1 is 69.2% called the 
majority class. The number of instances available in class 2 and class 3 are 18.73% and 12.0% 
respectively of the whole dataset called minority classes. If the classification algorithm is 
applied then more correctly classified will belongs to majority class only. Data sampling 
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techniques can be used to solve the problems with distribution of the dataset. This can be 
achieved by under-sampling the majority class or oversampling the minority class. The data 
available in class 1 is 1696 and if undersampling of the majority class is implemented then 
overall data will be reduced and so oversampling of minority class technique had been chosen 
for class balance. In this technique, it will not add any new information to the dataset but will 
reuse the existing data sample (Song et al. 2010). In order to balance both class 2 and class 3, it 
should have 1696 instances. This data sampling technique is applied using MATLAB software 
where the original data file is loaded in the workspace and instances were added in class 2 and 
3 by replicating their sample data to balance the class. 
Due to class sampling technique, all the classes were having the same number of instances as 
shown in below Table 6.13: 
Table 6.13 : Class balance after data sampling 
Class labels Number of instances – 
(Total number of 
instances is  5088) 
Percentage distribution % 
Low risk – class 1 1696 33.3 
Medium risk – class 2 1696 33.3 
High risk – class 3 1696 33.3 
This shows that now all the three classes are having an equal number of instances. Before 
using these data for performing the experiments as the input data range are different from 
each other in order to reduce the calculation time and obtain better results, all the input data 
of each variable (attribute) were normalized prior to neural network training (Sola and Sevilla 
1997). 
6.5.4 Results of neural network classifier using 13 attributes 
An experiment was performed using 13 attributes and some of the basic hyper-parameters 
were kept fixed as shown below: 
1. Max_epoch = 1000 
2. Time = infinite 
3. Minimum gradient  = 1 
4. Maximum_validation_fail = 20  

















1 Trainscg 10 1 191 0.1 61.6 
2 Trainscg 15 1 248 0.1 63.7 
3 Trainscg 25 1 188 0.1 64.2 
4 Trainscg 50 1 226 0.1 66.9 
5 Trainrp 10 1 164 0.1 60 
6 Trainrp 15 1 261 0.1 62.2 
7 Trainrp 25 1 345 0.1 65.1 
8 Trainrp 50 1 129 0.1 67.9 
 
The confusion matrix of the overall data set (consists of testing, validation, training sets) is 
shown in Table 6.15. The confusion matrix is the summary of prediction results on 
classification problems and presents the accuracy of the classifier. It will give correct 
classification as ‘True positive’ or ‘true negative’ as mentioned in green coloured boxes 
(diagonal of the square) and incorrect classification is listed by ‘false positive’ and ‘false 
negative’ as mentioned in red coloured boxes.  
The row indicates how much each target class are classified into each output classes. 
1. 1696 samples from class 1, 1139 samples were correctly classified as class 1,  
2. 1696 samples from class 2, 1016 samples were correctly classified as class 2 and  
3. 1696 samples form class 3, 1264 samples were correctly classified as class 3. 
Each row of the matrix correlate to the predicted class and each column of the matrix 
correlate to an actual class. The accuracy has been calculated based on Equation 17 below: 
                                       𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 =  
∑ 𝑇𝑟𝑢𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 +∑ 𝑇𝑟𝑢𝑒 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒
∑ 𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑖𝑛𝑠𝑡𝑎𝑛𝑐𝑒𝑠
   (17) 
 









          
6.5.5 Results of neural network classifier using 7 best attributes 
Neural network was trained using 7 attributes as shown in Table 6.16.  
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1 Trainscg 10 1 134 0.1 58 
2 Trainscg 15 1 47 0.1 60 
3 Trainscg 25 1 172 0.1 60.3 
4 Trainscg 50 1 335 0.1 67.4 
5 Trainrp 10 1 90 0.1 57.7 
6 Trainrp 15 1 426 0.1 62.7 
7 Trainrp 25 1 144 0.1 61.1 
8 Trainrp 50 1 53 0.1 58.3 
 
 
Table 6.17 : Confusion matrix with a dataset of 7 attributes (hidden unit 50 with scaled Conjugate backpropagation) 
 
As per the confusion matrix overall classification success obtained was 67.4% shown in Table 
6.17.  
The main purpose of applying NN classifier on both the datasets was to identify the difference 
in results using all the attributes and using only 7 attributes. Table 6.14 shows the comparison 
resilient backpropagation algorithms (Trainrp) and scaled Conjugate back propagation 
(Trainscg) algorithms using 13 attributes. Results show epochs varied from 188 to maximum 
345 epochs this means that the training has stopped when it has stopped improving and 
reached the performance goal of 0. The maximum validation check has been set to 20, means 
that the training will stop when the validation subset error rate increases continuously for 
more than 20. Another important parameter is the learning rate, learning rate (LR) is the 
parameter which controls the adjustment of the weight with respect to the loss gradient. If the 
value of the learning rate is too low then it takes a long time to converge and if the value of 
learning rate too high that it might miss any local minima. Typically learning rate can be 
configured by an iterative process. The value has been tested for 0.1, 0.01 and 0.001. In Figure 
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6.5 (a), it shows that based on the choice of learning rate can affect the convergence of the 
algorithm.  
       
(a) Learning rate curves  
(b) Curve with LR equal to 0.1  
Figure 6.5: (a) showing the different effect of various learning rates (Fei-Fei Jan 2015) (b) Effect of leaning rate at 0.1 
Figure 6.5 (b) shows the loss function over time, that by selecting the value of 0.1 it looks more 
satisfactory for the selected dataset. Because of this reason the learning rate has been kept 
fixed at 0.1. It shows that the error is decreasing over time as per the requirement and then 
becoming constant. 
 
Similarly, using above mentioned algorithms neural network was trained with 7 attributes 
shown in Table 6.16. A dataset with 13 attributes was trained using resilient backpropagation 
algorithm with 50 hidden units and 1 hidden layer it provides optimal accuracy of 67.9%. In a 
dataset with 7 attributes, the scaled conjugate gradient algorithm with 50 hidden units and 1 
hidden layer provides the maximum percentage of correctly classified data to 67.2%.  
 By comparing the results between these datasets, the range of accuracy varies from 60% to 
67.9% in the dataset with 13 attributes while dataset with significant predictors in Table 6.14, 
the accuracy of the model varies from 57.7 to 67.4% in Table 6.16. It appears that there is no 
much distinction in accuracy, thus dataset with significant predictors can be used for further 
analysis. 
These are the results obtained by comparing various models of neural network classifier; 
however, it is essential to compare the results using a conventional classifier to assess the 
neural network classifier performance capability in handling these data. For comparison 
purpose discriminant functional analysis was implemented. 
6.6 Discriminant Function Analysis using summarised patient data 
DFA is performed on the patient data in order to compare the results with the neural network 
model output using the same class balanced patient data. DFA builds the predictive model of 
group membership. It is composed of discriminant functions depending on the linear 
combination of the variables to obtain the best discrimination between the groups. Its main 
purpose is to separate the groups at maximum level. It is used to obtain the relationship 
LR = 0.1 
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between all the independent variables groups and categorical labels. With this relationship, it 
is possible to predict the classification depending on how well these independent variables 
separate the categories in the classification. DFA is implemented using SPSS software with all 
the seven independent variables and three categories. 
6.6.1 Results from DFA analysis 
                                                                         
 
Figure 6.6 : Discriminant group of VPT categories (1-3) cat1 = Low, cat2 = medium and cat3 = high  
The three group mean is fully explained in the two-dimensional space. The graphical 
representation of group’s mean and the scatter of individual observations along with the 
centroid of each group in the discriminant coordinate system are shown in Figure 6.6. 
Function1 and Function 2 are calculated using standardized coefficients and the standardized 
variables as given below: 
𝑭𝒖𝒏𝒄𝒕𝒊𝒐𝒏𝟏 = 0.17*zHbA1c + 0.087*zACR + 0.966*zAge + 0.315*zWeight + 0.358*zHeight + 
0.063*zCholesterol – 0.064*duration of diabetes 
𝑭𝒖𝒏𝒄𝒕𝒊𝒐𝒏𝟐 =  0.171*zHbA1c - 0.417*zACR + 0.332*zAge - 0.748*zWeight - 0.009*zHeight + 
0.429zCholesterol – 0.064*duration of diabetes 
Where zHbA1c, zACR, zAge, zWieght, zHeight, zCholesterol and zduration of diabetes are the 
standardised variables multiplied by the magnitude of the coefficient. The magnitude of the 
coefficient can be used to indicate the impact on the discriminant score, so, for example, 
standardized coefficient of age in the first function is greater than the other coefficient which 
means age will have the greatest impact than other variables in the first discriminant score.   
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 The separations between the groups are not clear. The closer the group centroids, it is likely 
to have more errors of classification. The samples available in each group are overlapping with 
each other in the discriminant space due to which it is difficult to achieve a good classification.  






 Low Medium High  
Count Low 1048 420 228 1696 
Medium 276 829 591 1696 
High 171 640 885 1696 
% Low 61.8 24.8 13.4 100.0 
Medium 16.3 48.9 34.8 100.0 
High 10.1 37.7 52.2 100.0 
 
The error count can be calculated (or misclassified) for each observation as 38.2% (i.e. 24.8% + 
13.4%) for low risk, similarly 51.1% for medium risk and 47.8% for high-risk categories as per 
Table 6.18. The overall correctly classified cases are calculated as 54.3%. The classification of 
individuals into their original population varied from 48.9% to 61.8%. Among the three 
categories, the portion of correctly classified low-risk samples into their original population 
was the highest as 61.8% while a portion of correctly classified medium risk samples into their 
original population was the lowest as 48.9%. 
Comparison between neural network classifier and conventional classifier has been performed 
to analyse the results. The percentage of correctly classified classes obtained using 
conventional classifier i.e. DFA is 54.3% while 67.4% accuracy was achieved using neural 
network classifier given in Table 6.16. This shows that neural network classifier is performing 
better than the conventional classifier. 
 By using DFA, we get an idea about the data distribution of each class in the discriminant 
space which were highly overlapped. In order to obtain higher accuracy, either data need to be 
collected precisely or need to process the data in a way to reduce the noise. Instead of 
choosing the prolonged process of collecting patient data again, the second option of 






6.7 Method of generating simulated patient data 
For generating simulated patient data with similar property, real patient data’s mean and 
covariance of each predictor were used with reduced standard error to increase the precision 
of data. The  summarised real patient data (summarised patient data as discussed in section 
6.3 is addressed as real patient data) consist of a number of observations, mean and standard 
error of all the seven significant predictors which were calculated as shown in Table 6.19. This 
simulated data were generated with real patient’s mean and covariance’s but with the 
reduced standard error. By this method, larger dataset can be obtained for improving 
predictor’s precision. The simulated data was generated using R software where genCor Code 
simstudy package was used (Goldfeld 2018). It requires the mean, standard error, correlation 
matrix or correlation coefficient of real patient data to use. 
Table 6.19 : Mean and standard deviation of the real patient data 






17.82      
 
11.13        
 
1.5            
 
50 
HbA1c 5143 8.73      1.29 4.77     14.4 
Urine albumin to creatinine ratio (ACR) 3886 7.15 18.35 0 293.83 
Age 5158 57.73      18.45 7 98 
Weight 5156 83.42     19.67 32.77 192.2 
Height 5111 168.67      10.06 81 207 
Cholesterol 4852 4      1.19       1.43 18.7 
Duration of diabetes 5158 10.63 6.75             1 28 
Using this function, it will generate multivariate normal data. If data is generated by using the 
same standard error of the real patient data then the spread of the data may remain the same 
for each predictor, therefore standard error was reduced for independent variables. Two data 
sets were generated wherein the first dataset; 50% of standard error and named as simulated 
patient data 1. For comparison purpose, another dataset was generated by 40% of standard 
error and named simulated patient data 2. Around 1 million data was generated for each set 
by this method. The summary of the real patient simulated data were compared with the real 
patient’s summary in terms of range of each predictor. It was found that the tails in some of 
the predictors were far too long which means the values of the variable are outside the 
required limit. For example, as the range of the VPT from 0 to 50 Volts and in the generated 
data if the value is more than 50 Volts then the relationship of those values are unknown with 
the rest of the predictors and needs to be ignored. Similarly, for all of those variables whose 
data were out of the real patient data range were deleted from the simulated file to generate 
a more realistic simulated patient data set. After truncating data rows from the file, 757323 
and 830365 numbers of observations in each attribute were available in which 50% and 40% of 
standard error as shown in Table 6.20 and Table 6.21 respectively. 
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Table 6.20 : Summary of the simulated data 1 










1.01      
 
44.2 
HbA1c 757323 8.75     0.64  5.54  11.85 
Urine albumin to creatinine ratio (ACR) 757323 10.62 6.90 0 52.74 
Age 757323 58.06      9.23 19.16 97.86 
Weight 757323 83.70     9.79 37.17 128.13 
Height 757323 168.65      5.03 142.15 193.18 
Cholesterol 757323 4.01     .71       1.43 7.23 
Duration of diabetes 757323 10.66 3.37             1 22.12 
 
Table 6.21 : Summary of the simulated patient data 2 










1.5      
 
37.89 
HbA1c 830365 8.74 0.52 6.34 11.22 
Urine albumin to creatinine ratio (ACR) 830365 9.33 5.80 0 42.47 
Age 830365 57.95 7.40 24.04 93.69 
Weight 830365 83.58 7.84 48.36 118.67 
Height 830365 168.66 4.02 149.10 188.29 
Cholesterol 830365 4.01 0.57 1.45 6.88 
Duration of diabetes 830365 10.63 2.72 1.00 23.70 
 
The comparison was made between summarised real patient data and simulated patient 
datasets (Table 6.19, 6.20 and 6.21), it was found that they compare pretty close in mean and 
the range of each variable, in correlation and covariance, however, variance and standard 
error is reduced to 50% in (Table 6.20) and 40% in (Table 6.21) of the patient data as expected. 
This dataset were used for neural network modelling to calculate the percentage correctly 
classified class or accuracy. 
6.7.1 Experimental methodology 
1. Divide the simulated data into three categories based on VPT thresholds. (Low risk- 0 
to 20.99, medium risk - 21 to 30.99 and high risk - ≥ 31) 
2. Pre-process the simulated data or use a random sampling technique to achieve class 
balance for both the dataset. 
3. Divide both dataset into three sets as training (70%), testing 15% (unseen data) and 
validation sets (15%). 
4. Set important hyperparameters such as hidden neurons ϵ (10, 15, 25, and 50), hidden 
layers ϵ (1), learning rate ϵ (0.1), iterations ϵ (1000) and measure the epochs. 
5. Train the neural network using resilient backpropagation (Trainrp function) and scaled 
conjugate gradient (Trainscg function) algorithm.  
6. Train the neural network using simulated patient data 1. Select the model that gives 
optimal result by changing the values of required hyperparameters. 
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7. Train the neural network using simulated patient data 2. Select the model that gives 
optimal result by changing the values of required hyperparameters. 
8. Compute Confusion matrices to assess the neural network performance. 
9. Based on the classification success of training, testing and validation set, calculate 
overall accuracy for each trial for comparison. 
10. Compare the accuracy of both the dataset to select the best. 
Pre-processing the simulated patient dataset: 
The dataset was divided into three classes based on the VPT scores same as the real patient 
data.  After dividing the data into three classes, the number of instances available in each class 
for both the datasets was calculated. 
Table 6.22 : Instances per class of simulated patient data 1 
Class labels Number of instances – 
(Total number of 
instances -   757323) 
Percentage distribution % 
Low risk – class 1 529294 69.8 
Medium risk – class 2 220531 29.1 
High risk – class 3 7498 0.9 
 
As per the calculations it was found that class 1 is inflated with lot instances covering around 
69.8% of the total data while class 3 is having least number of instances around 0.95% of the 
total data as shown in Table 6.22. This shows that data is highly imbalanced to be trained for 
any classifier.  
 
Table 6.23 : Instances per class simulated patient data 2 
Class labels Number of instances – 
(Total number of 
instances -   830365) 
Percentage distribution % 
Low risk – class 1 623137 75 
Medium risk – class 2 205842 24.78 
High risk – class 3 1386 0.16 
 
Similarly, simulated patient data 2, 830365 data was generated in which the same issue of 
class imbalance was recognised as shown in Table 6.23. In order to use this dataset for any of 
the classifiers it is important to undergo a class balance technique as implemented for the real 
patient data. 
The benefit of using the simulated data is that large number of data can be generated as per 
the requirement. There are two options to adjust the class distribution of a dataset,  one is 
either oversampling of the minority class as performed on real patient data or undersampling 
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of the majority class (Hernandez et al. 2013). As per the data available in class 3, it is possible 
to perform undersampling of majority class on both the datasets of simulated patient data. 
As per the instances available in class 3, class 1 and class 2 were undersampled with the 
number of instance 7498.  Undersampling was successfully applied and the updated number of 
instances available in each class is displayed in Table 6.24: 
Table 6.24 : Class balanced for simulated patient data with 50% of standard error  
Class labels Number of instances – 
(Total number of 
instances -   22494) 
Percentage distribution % 
Low risk – class 1 7498 33.3 
Medium risk – class 2 7498 33.3 
High risk – class 3 7498 33.3 
Similarly undersampling of the majority classes was performed in simulated patient data 2 as 
well. Here 1386 instances were obtained by undersampling the majority classes by using 
MATLAB function as presented in Table 6.25. 
Table 6.25 : Class balanced for simulated patient data with 40% of standard error 
Class labels Number of instances – 
(Total number of 
instances -   4158) 
Percentage distribution % 
Low risk – class 1 1386 33.3 
Medium risk – class 2 1386 33.3 
High risk – class 3 1386 33.3 
In order to get all the attributes in the comparable range, all the data available in each 
attribute was normalised. After pre-processing the data, it can be trained by neural network 
classifier to get the classification success. 
6.7.2 Results  
 As the data been generated from the real patient data all the hyperparameters and specific 
training algorithms were used again for training this dataset. Some of the hyperparameters 
were kept fixed for both the data sets as mentioned below: 
1. Max_epoch = 1000 
2. Time = infinite 
3. Minimum gradient  = 1 
4. Maximum_validation_fail = 20  

















1 Trainscg 10 1 95 0.1 65.4 
2 Trainscg 15 1 62 0.1 65.4 
3 Trainscg 25 1 111 0.1 65.4 
4 Trainscg 50 1 113 0.1 65.1 
5 Trainrp 10 1 52 0.1 65.3 
6 Trainrp 15 1 92 0.1 65.5 
7 Trainrp 25 1 55 0.1 65.3 
8 Trainrp 50 1 37 0.1 65.8 
 
As per the results obtained, it shows that by using all these training functions the achieved 
range of the percentage of correctly classified classes is from 65.1% to 65.8% (this is the 
overall accuracy which includes trained, test and validation set confusion matrix). This means 
that by changing hidden neurons there is no further increase in accuracy. It will be interesting 
to know the results by using the simulated patient data 2 i.e. dataset with 40% of standard 
error. 
The results obtained using this simulated patient dataset 2 is as shown in Table 6.27. 












1 Trainscg 10 1 59 0.1 68.3 
2 Trainscg 15 1 47 0.1 68 
3 Trainscg 25 1 59 0.1 68.6 
4 Trainscg 50 1 48 0.1 67.1 
5 Trainrp 10 1 54 0.1 68.6 
6 Trainrp 15 1 34 0.1 68.3 
7 Trainrp 25 1 43 0.1 68.6 
8 Trainrp 50 1 75 0.1 70.1 
 
As per the results obtained using dataset with a reduced standard error the range of overall 
percentage of correctly classified classes range varied from 68% to 70.1%. The resilient 
backpropagation with 50 hidden neurons with 75 epochs has provided the best result.  
Analysis of the results using simulated patient data 
First of all, by generating the simulated patient data from the real patient data by using means, 
covariance’s of each variable it was possible to reduce the skewness of the data and that of 
the real patient data. By comparing the accuracy obtained using both the dataset, it can be 
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concluded that by reducing the standard error of each predictor the accuracy is definitely 
increasing. Based on the obtained results it can be concluded that simulated patient data 2 i.e. 
40% of standard error can be used for further studies. However, for comparison purpose, the 
classifier outcome can be compared with the discriminant function analysis results as well. 
One limitation of reducing the standard error is, it could start affecting the range of the VPT. If 
the range of VPT is reduced more than the very less data or instances will be available in class 
3 which may lead to extreme imbalance of the class distribution.  
6.8 Discriminant Function Analysis using simulated patient data   
For comparison purpose the conventional classifier called discriminant functional analysis 
(DFA) was also implemented using simulated patient data 2 with 7 attributes.  
6.8.1 Results from simulated patient data 
 
Figure 6.7 : Discriminant group of VPT categories (1-3) cat1 = Low, cat2 = medium and cat3 = high using simulated 
data 
The three group mean are fully explained in the two dimensional space as shown in Figure 6.7. 
The function scores can be given as below: 
𝑭𝒖𝒏𝒄𝒕𝒊𝒐𝒏𝟏 = 0.041*zHbA1c + 0.127*zACR + 0.965*zAge + 0.208*zWeight + 0.399*zHeight + 
0.042*zCholesterol – 0.007*duration of diabetes 
𝑭𝒖𝒏𝒄𝒕𝒊𝒐𝒏𝟐 =  0.466*zHbA1c - 0.503*zACR + 0.059*zAge + 0.057*zWeight - 0.535*zHeight + 
0.298zCholesterol – 0.261*duration of diabetes 
Where zHbA1c, zACR, zAge, zWieght, zHeight, zCholesterol and zduration of diabetes are the 
standardised variables multiplied by the magnitude of the coefficient. The graphical 
representation of group’s mean and the distribution of individual observations along with the 
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centroid of each group are shown in the discriminant coordinate system. The separations 
between the groups are much clearer than the real patient data. This clarity in the distribution 
shows that the simulated patient data is much more precise and accurate than the real patient 
data and definitely has the capability to gain more accuracy, since the portion of the data 
available in the classes are not much overlapped in the discriminant space when the dataset is 
divided into three categories.  
Table 6.28 : Confusion matrix of simulated patient data 2 
 
Cat 
Predicted Group Membership 
Total Low risk  Medium risk High risk 
Count Low risk 1014 345 27 1386 
Medium risk 340 753 293 1386 
High risk 18 272 1096 1386 
% Low risk 73.2 24.9 1.9 100.0 
Medium risk 24.5 54.3 21.1 100.0 
High risk 1.3 19.6 79.1 100.0 
The error count (or misclassification) for each observation was estimated as 26.8% for low risk, 
45.6% for medium risk and 20.9% for high-risk categories. The overall correctly classified cases 
are calculated as 68.9% [calculated as (73.2 + 54.3 + 79.1) / 3)]. 
The classification of individuals into their original population varied from 54.3% to 79.1%. 
Among the three categories, the portion of correctly classified low-risk samples into their 
original population was the highest as 79.1% while a portion of correctly classified medium risk 
samples into their original population was the lowest as 54.3%. 
Using neural network classifier accuracy of 70.1% was achieved. However, using DFA classifier 
gains accuracy of 68.7%. This shows that neural network classifier is more capable of handling 
the data than the conventional classifier (DFA). At this stage, it can be assumed that the neural 
network trained on the simulated data with 40% of standard error is performing at the best 
level and can be used for further analysis.  
Limitations of using neural network classifier and DFA 
The best-trained model is saved in the workspace of MATLAB and results were analysed. When 
new inputs are provided results were obtained in terms of three probabilities of risk levels. So 
in order to test the neural network model as trained using all the seven best predictors, the 
input should be provided as the vector of 7 inputs in the same sequence i.e. HbA1c, acr, Age, 
Weight, Height, Cholesterol and duration of diabetes as followed during training procedure to 




Input variable  Output probabilities 
HbA1c  -  8.9 Low  risk  - 96% 
Acr  -  13 
Age -  41 Medium risk  -  4% 
Weight – 82 
Height – 174 
Cholesterol – 3.6 High risk  - 0% 
Duration of diabetes -13 
 
Here the inputs were provided with all the best predictors as shown in the Example 1. The 
value of most significant predictor i.e. age is given as 41 years along with rest of the predictors 
and model predicted the outcome in terms of probability. The prediction shows that subject at 
low risk of developing diabetic neuropathy.  
Example 2: 
Input variable  Output probabilities 
HbA1c  -  8.9 Low  risk  - 13% 
Acr  -  13 
Age -  65 Medium risk  - 54% 
Weight – 82 
Height – 174 
Cholesterol – 3.6 High risk  - 32.2% 
Duration of diabetes -13 
Looking at Example 2, here keeping all the other predictors as constant, age was increase to 65 
and as seen the predicted probabilities changed as Low risk - ’13%’, medium risk - ’54%’ and 
high risk – ’32.2%’ which means subject is at medium risk of developing diabetic neuropathy. 
This reflects that based on the trained pattern, neural network is updating all the probabilities.  
Example 3: 
Input variable  Output probabilities 
HbA1c  -  9 Low  risk  - 30% 
Acr  -  13 
Age -  65 Medium risk  -  26% 
Weight – 88 
Height – 171 
Cholesterol – 5 High risk  - 44% 
Duration of diabetes -9 
 
Example 3 shows that based on the above mentioned inputs or predictors, the output 
probabilities were predicted by the model. This example shows that low risk is greater than 
medium risk and medium risk is less than high risk. In the practical scenario, we do not want to 
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get such kind of predictions where order is not maintained.  This unordered prediction is due 
to the limitation of the data and also the type of typical softmax based neural network model 
which was used but does not explicitly maintaning the order.  
This problem also persists while using discriminant function analysis, because DFA is normally 
applied when dependent variables are divided into two or more categories and these 
categories need to be mutually exclusive. So when DFA was applied using real patient data and 
simulated patient data, a test was performed to identify this type of unordered 
misclassification. It was found that using real patient data, the number of times class 1 
predicted class 3 was 53 times and a number of times class 3 predicted class 1 was 8 times and 
using simulated data set no such cases were found.  In the present dataset we have only 3 
class labels; however, if there are more than 3 classes then this type of error may increase a lot 
and may create confusion. The problem was seen more in real patient data may be because a 
portion of data in each class highly overlaps with each other and also not having large dataset, 
while in the simulated dataset it is much less due to less class overlaps as shown in the 
discriminant graph (Figure 6.6 and 6.7).  
Similarly, when neural network classifier was trained on real patient data, there was around 15 
to 20% of misclassification. And when NN was trained on simulated data only 1 or 2 cases were 
found. 
In fact, it shows that unordered misclassification is higher using real patient data than using 
simulated patient data. Perhaps the problem of misclassification may not occur once we have 
large enough dataset, however, in current scenario it is not possible to get more data, and 
therefore simulated patient data can be used for further analysis. Hence, ordinal logistic 
regression was implemented on simulated patient data 2 which will explicitly maintain the 
order of classification as shown in the next section. 
6.9 Ordinal logistic regression using simulated patient data  
 Ordinal logistic regression is applied on simulated dataset to obtain the information about the 
significant predictors along with classification success using simulated dataset as given in Table 
6.29. 
Table 6.29 : Case summary 
Categories of the dependent variables Range of VPT score in Volts (V) No. of instances (4158) 
Low risk 0 to 20.99 1386 
Medium risk 21 to 30.99 1386 
High risk  31 onwards 1386 
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In the model fitting information as shown in Table 6.30, as per the degree of freedom seven 
independent variables were used in the data set for performing the analysis. The last row (Sig.) 
of the table presents the information that either all or some of the variables are statistically 
significant and the mean variables are statistically significantly improving the model compered 
to intercept only model (no added variables). As p < 0.001 means model predicts the 
dependent variable better than the intercept only model.   
Table 6.30 : Model Fitting Information 
Model -2 Log Likelihood Chi-Square Df Sig. 
Intercept Only 9136.060    
Final 5602.161 3533.899 7 .000 
 
In the goodness of fit table, large chi-square values indicate poor fit of the model. A 
statistically significant value (p < 0.5) indicates that model does not fit well. The first row that 
is Pearson means, Pearson chi-square statistic as well as Deviance chi- square have  p > 0.05 
(from the Sig. column) i.e. not statistically significant indicates that model fits well with the 
data.  Pseudo R- squared presented in Table 6.32. The indicated pseudo R squared is higher 
than the Pseudo R squared of the real patient data seems that the model better predicts the 
outcome in this case.  
Table 6.31 : Goodness-of-Fit 
 Chi-Square df Sig. 
Pearson 7015.429 8303 1.000 
Deviance 5602.161 8303 1.000 
Table 6.32 : Pseudo R-square 
 
Pseudo R-Square 
Cox and Snell .573 
Nagelkerke .644 
McFadden .387 
There are coefficient, their standard errors, the Wad test and associated p- values (Sig.) and 
95% confidence interval of the coefficient as available in parameter estimated in Table 6.33. 
The dataset has three level of variable called <cat> (coded 1, 2, and 3) which will be used as an 
outcome variable. It can be used to determine number of statistical significant independent 
variables on the dependent variable (VPT). Out of all the seven predictors / attributes HbA1c, 
ACR, age, weight, height are significant predictors while Cholesterol and duration of diabetes 
are not significant. So for HbA1c variable, one unit increase in age (from 0 to 1), there can be 
0.140 increase in the logarithmic odds of being higher level of cat, with all the other variables 
in the model are constant. For ACR variable, one unit increase in age (from 0 to 1), there can 
be 0.37 increase in the logarithmic odds of being higher level of cat, with all the other variables 
in the model are constant. For age variable, one unit increase in age (from 0 to 1), there can be 
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0.25 increase in the logarithmic odds of being higher level of cat, with all the other variables in 
the model are constant. Similarly for rest of the variables can be interpreted from the table.   
 
Table 6.33 : Parameter Estimates 
 Estimate Std. 
Error 







[cat = 1.00] 50.221 1.976 646.017 1 < 0.001 46.348 54.094 
[cat = 2.00] 53.066 2.002 702.941 1 < 0.001 49.143 56.989 
Location HbA1c .140 .070 4.058 1 .044 .004 .277 
ACR .037 .006 37.443 1 < 0.001 .025 .048 
Age .250 .006 1616.672 1 < 0.001 .238 .262 
Weight .047 .005 80.779 1 < 0.001 .037 .057 
Height .174 .010 287.566 1 < 0.001 .154 .195 
Cholesterol .109 .066 2.772 1 .096 -.019 .238 
Duration of  
diabetes 
-.001 .013 .008 1 .928 -.027 .024 
 
By comparing all the values of the responsive variable with the values of the predicted 
outcome, it is possible to calculate the classification success for each class. Table 6.34 shows 
the cross tabulation (confusion matrix) of the model where data is presented for each of the 
classes in terms of true positive, true negative, false positive and false negative. It measures 
the percentage overall classification success estimated as  68.4%, where low risk category 
achieves classification success of 72%, medium risk category as 56.3%  and high risk category 
as 77.1% . 
Table 6.34 : cat * Predicted Response Category Cross tabulation 
 Predicted Response Category Total 











Low risk Count 998 367 21 1386 
% within cat 72.0% 26.5% 1.5% 100.0% 
% within Predicted 
Response Category 
74.3% 25.3% 1.5% 33.3% 
Medium risk Count 330 781 275 1386 
% within cat 23.8% 56.3% 19.8% 100.0% 
% within Predicted 
Response Category 
24.6% 53.8% 20.2% 33.3% 
High risk Count 15 303 1068 1386 
% within cat 1.1% 21.9% 77.1% 100.0% 
% within Predicted 
Response Category 
1.1% 20.9% 78.3% 33.3% 
Total Count 1343 1451 1364 4158 
% within cat 32.3% 34.9% 32.8% 100.0% 
% within Predicted 
Response Category 




By using ordinal logistic regression it is possible to obtain the overall classification success of 
68.4% with five significant predictors out of seven independent variables. Using this analysis a 
hint regarding significant predictors, and on the other hand it treat the data into the set of 
ordered category i.e. (Low risk < medium risk < high risk) (Chu and Ghahramani 2005) . So the 
issue of considering these classes as nominal did not arise in the above used classifier. This 
means that ordinal regression analysis applied on the data set is better to use, however if he 
data is trained using neural network then it might work better than the conventional method. 
So if it is possible to use a neural network based model which can take care of ordinal 
categories and predict the outcome in terms of probability then it can be used for developing a 
risk assessment tool. The advantages of using artificial neural network based model are 
learning in both real time and in batch mode, training on very large data and providing  good 
performance,  better in handling non- linear data, rapid prediction and model can be 
optimised using trained and tested data (unseen data set) with various hyper parameters like 
hidden neurons, hidden layers, no. of iterations to obtain better results (Cheng et al. 2008). In 
order to use such a model for taking advantages of neural network, neural network based 
proportional odds model was implemented. 
6.10 Neural Network based Proportional Odds Model  
There are many classifiers available to classify or predict the numerical values from the 
labelled patterns while less consideration was paid on ordinal classification problems in which 
labels of the dependent variable or targets have a natural ordering. In the current scenario, as 
stated before, labels are ordered as (Low risk, medium risk and high risk). While working with 
the problems misclassification which has more error if the patient of low risk was classified as 
high risk than misclassified as medium risk. This encouraged us to use an ordinal classification 
model to carefully handle an ordinal labels. Ordinal regression models are commonly used in 
many research areas such as medical research (Jang et al. 2011), brain computer interface, age 
estimation and more (Gutierrez et al. 2016). To adopt a probabilistic framework, Neural 
Network based Proportional Odds Model (NNPOM) is considered which is proposed by 
Mathieson (Mathieson 1996; Gutiérrez et al. 2014). The model approaches ordinal 
classification by estimating the latent variable belonging to ordinal categories and the model 
will learn based on the set of thresholds discretising variable. NNPOM is also called as 
threshold model that has been seen to perform well when classes are defined from a 




Figure 6.8 : Structure of the probabilistic neural network model (NNPOM) 
The structure of the NNPOM model is shown in Figure 6.8.  It consists of input layer; hidden 
layer and output layer same as the previously used neural network classifier. It has one input 
layer with 7 input nodes i.e. 7 best predictors given by variable X (X1 to X7). The input signal 
propagates through input layer by multiplying with weights W.  It has one hidden layer where 
number of hidden neurons M can be arbitrarily defined and can be given as B (B1 to BM). The 
input of the hidden layer propagates by multiplying with weights 𝜷 = (𝜷1 … 𝜷M) and transmit to 
the output layer. It has one output layer consisting of one neuron with as many thresholds as 
the number of classes minus one. The thresholds of each class 𝐶𝑞 are denoted by 𝑒𝑞 where 𝑞 is 
the number of thresholds. The main difference in the structure of NNPOM is standard softmax 
activation function in the output nodes used in traditional neural network classifier is replaced 
with a sigmoidal function as it will consider ordered partitions encoding instead of traditional 
encoding. Sigmoidal unit is define as 𝐵𝑗(𝑥𝑡 , 𝑤𝑗) =  𝜎 (𝑊𝑗
𝑇 . (1, 𝑥𝑡)),  𝑤𝑗 = {𝑤𝑗0, 𝑤𝑗1, … ., 𝑤𝑗𝑟} , 
𝑤0 is the bias and r is the number of inputs.  The whole parameter vector of NNPOM can be 
given as 𝐾 = {β, 𝐖, 𝒂𝟏, 𝒂𝟐, … , 𝒂𝐐−𝟏}. The cross entropy loss function is optimised by iRprop
+ 
algorithm (improved resilient back propagation algorithm) to estimate the parameters of the 
model (Igel and Hüsken 2003). This model is adjusted and updates the weights by minimising 
cross entropy loss in every iteration iter. NNPOM is a linear combination of nonlinear basis 
functions i.e. hidden neurons (Pérez-Ortiz et al. 2018) given as: 
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      𝑓(𝑋𝑡 , 𝜃) =  ∑ 𝛽𝑗
𝑀
𝑗=1 𝐵𝑗 (𝑋𝑡 , 𝑤𝑗)                         (18) 
Where 𝜃 is the weight given as 𝜃 = (𝜷, W) and 𝑓(𝑋𝑡 , 𝜃) is the projection of the model for 
pattern 𝑋𝑡. 
In NNPOM, probabilities can be estimated in the following equations (Pérez-Ortiz et al. 2018):  
  𝑃(𝑦𝑡+𝑠 = 𝐶1|𝑋𝑡) =  𝜎(𝑓(𝑋𝑡 , 𝜃) − 𝑒1,  
𝑃(𝑦𝑡+𝑠 = 𝐶𝑞|𝑋𝑡) =  𝜎(𝑓(𝑋𝑡 , 𝜃) −  𝑒𝑞) −  𝜎( 𝑓(𝑋𝑡, 𝜃) - 𝑒𝑞−1),    (19) 
𝑞 ∈ (2, … 𝑁 − 1), 
𝑃(𝑦𝑡+𝑠 = 𝐶𝑁|𝑋𝑡) =  1 −  𝜎(𝑓(𝑋𝑡 , 𝜃) −  𝑒𝑁−1) . 
Where 𝑠 is the input nodes,  𝑒𝑞 is the threshold of class  𝐶𝑞 and 𝑒𝑞 can be defined as follow: 
𝑒𝑞 =  𝑒1 + ∑ 𝑎𝑗
2𝑞
𝑗=2         (20) 
𝑎𝑗 is the padding variable  and is kept square to make the threshold positive. 
NNPOM model can be adjusted by three hyper parameters as hidden neurons M, number of 
Iterations iter and value of lambda λ, where λ is the regularisation parameter that is used in 
the error function to avoid over fitting. 
6.10.1 Experiment methodology 
1. Use the categorical simulated dataset 2 with 7 best predictors (attributes). 
2. Divide the data into two sets i.e. training set (75%) and testing set (25%) save as 
text files. 
3. The format of the file should be (attribute1 attribute2 ….attribute7 label) where 
labels should be coded as [1, 2, 3]. 
4. Set the hyper parameter of such as hidden neurons M, number of iteration iter 
and regularisation parameter λ until the model achieve the optimal results. 
5. Compute confusion matrices of both training and testing sets to get the overall 
classification success. 
6. Compare the results with classical ordinal regression. 




The training of neural network based proportion odds model was performed on MATLAB 
framework.  The performance of the model may vary depending on number of attributes; the 
percentage partition of training and testing sets and number of instances in the data file. The 
summary of the dataset is shown in Table 6.35 as below: 
Table 6.35 : Summary of the dataset 
Categories of the dependent variables Range of VPT score in Volts (V) No. of instances (4158) 
Training Testing 
Low risk 0 to 20.99 3188 970 
Medium risk 21 to 30.99 3188 970 
High risk  31 onwards 3188 970 
 
The data files were loaded in to the MATLAB workspace and NNPOM model was trained with 
prior setting of all the hyper parameters. The range was explored using different number of 
hidden neurons M ϵ {10, 40, 60, 80, 85, 120, 130}, iter ϵ {1000, 1500} and λ ϵ {0.01, 0.001}. The 
results obtained by using these range is given in Table 6.36. Accuracy of the model is 
calculated based on the percentage correctly classified class. The sum of training accuracy and 
test accuracy gives the total percentage of correctly classified class. 
Table 6.36 : Performance evaluation 












10 1000 0.01 68 68.7 68.25 
40 1000 0.01 68.6 69.5 68.8 
60 1000 0.01 69.1 69.1 69.14 
60 1000 0.001 68.5 69.5 68.75 
80 1000 0.01 68.9 68.9 68.9 
60 1500 0.01 68.9 69.1 68.9 
60 1500 0.001 63.6 63.7 63.6 
85 1500 0.001 69.3 69.6 69.4 
120 1500 0.01 70.02 69.79 70.1 
130 1500 0.01 69.3 69.7 69.7 
 
As per the results obtained in Table 6.36, various ranges of hidden neurons, iteration and value 
of lambda were used to select the optimal results. By increasing the number of hidden 
neurons the accuracy was increasing with lambda value equal to 0.01 and when lambda value 
was changed to 0.001 the accuracy was decreasing. By increasing the hidden units, training 
time increases. By changing these hyper parameters, results changes from 68.25% to 70.1%. 
By selecting M = 120, iter = 1500 and lambda value = 0.01 the highest percentage correctly 
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classified class was obtained as 70.1%. The overall confusion matrix (training and testing) of 
the whole data is displayed in Table 6.37 where the diagonal of the matrix is the truly 
predicted class used to calculate the accuracy (LR: Low risk, MR: Medium risk and HR: High 
risk). 
Table 6.37 : Confusion matrix (M = 120, iter = 1500 and λ = 0.01) 
 LR MR HR 
Classification 
overall 
Low risk(LR) 1017 344 25 1386 
Medium risk(MR) 234 831 262 1386 
High risk (HR) 16 303 1067 1386 
Truth overall 1267 1478 1354 4158 
 
This version of trained model with highest accuracy was selected to develop risk assessment 
tool for diabetic neuropathy. 
6.10.3 Development of risk assessment tool of VibraScan 
To make it user friendly and easy to use, an application was developed on MATLAB framework 
using the trained neural network model as shown in Figure 6.9. 
 
 
Figure 6.9 : Graphic user interface (GUI) of VibraScan risk assessment tool 
 
There are several user friendly steps to follow for operating this application: 
1. Open the Graphic User Interface on MATLAB platform. 
Load the trained NN model parameters 
User’s input 





2. The application will be displayed as shown in the Figure 6.9. 
3. There is a button called <Neural network model> needs to be used  to load all the 
necessary parameters like weights, output labels of the trained model as discussed 
before to predict the new outputs. 
4. In the input panel, there are seven inputs needs to be provided by the subject as per 
the clinical results. 
5. Use the button called <Predict> to obtain all the three predicted VPT level probabilities 
for low risk (0 - 20.99 V), medium risk (21 - 30.99 V) and high risk (≥ 31 V). 
6. Out of the three probabilities, highest probability can be used to measure the risk level 
of the subject. 
The following examples shown below were used to show case the usability of the tool and its 
advantages. 
1. Subject has provided following inputs in the input panel as displayed in the Figure 
6.10. 
 
Figure 6.10 : VibraScan risk assessment tool prediction based on input variable (Example 1) 
Based on the input values provided to the tool, VPT probabilities were predicted from the 
learnt model with 2% chance of low risk, 23% chance if medium risk and 75% chance of 
high risk. The result shows that the person is likely to have high risk of diabetic neuropathy 
according to their clinical characteristic. 
Second example was test by keeping all the parameter as constant and just decreasing age 




Figure 6.11 : VibraScan risk assessment tool prediction based on input variable (Example 2) 
By keeping all the other inputs as constant other than age, it shows that when age is 
decreasing the risk level of diabetic neuropathy is reduces from high to medium risk 
showing approximate VPT level between 21 to 30.99 Volts. Thus, based on the 
combination and relationship between clinical inputs of the subject, tool can predict the 
VPT level to determine the risk level of diabetic neuropathy.  
Discussion: 
The risk assessment tool based on vibration perception thresholds is developed for the 
first time for easy and early diagnosis of diabetic neuropathy. The advantage of using this 
tool is to get the results in terms of probability and can be used as an alarm for 
progressiveness of this devastating disease. The study was started with the longitudinal 
data with the continuous measurement of VPT for which Box Cox transformation on all the 
independent variables with natural logarithmic transformation of dependent variable 
(VPT) was implemented to improve the skewness of the data. Then, ordinary least square 
method was used on this transformed variable to determine the significant predictors. Out 
of 13 variables, 7 variables were identified as the significant predictors. For easy 
interpretation of the risk level of DN, VPT was divided into three categories based on the 
VPT thresholds. For determining the significant predictors on this categorical VPT based 
dataset, Ordinal logistic regression (OLR) was implemented. OLR has achieved the accuracy 
of 71.5%. However, this high accuracy could be because category 1 was inflated with large 
number of data. Results of OLR have shown that age, weight and height as the significant 
predictors providing scope for further analysis. The determination of significant predictors 
using OLR is based on linear association; however, advanced model such as artificial neural 
network (ANN) can also learn non-linear association along with linear association from the 
132 
 
data. Due to this ability of ANN, we have considered all 13 variables for the training. At 
first multiclass neural network was implemented on the 2450 instance of summarised 
patient data. Due to data division, it has been identified that there is a class imbalance, for 
which oversampling of minority class was performed. The ANN was trained on 13 
attributes and accuracy of 67.9% was achieved. The ANN trained on 7 best predictors an 
accuracy of 67.4% was achieved. This comparison is giving an indication of using only 
significant predictors rather than all the attributes. Another classifier called discriminant 
functional analysis was used and achieved an accuracy of 54.3%. It has shown the 
distribution of summarised patient data on discriminant space where data in each class 
were highly overlapped.  
In order to improve the precision of summarised patient data, data with similar property 
was simulated using summarised patient’s covariance and mean value but with reduces 
standard error. Simulated data with 50% of standard error (simulated patient data 1) and 
40% of standard error (simulated patient data 2) was generated out of which simulated 
patient data 2 was considered for further analysis because of its higher precision. Due to 
class imbalance in the dataset, under sampling of majority classes was implemented. 
Neural network was trained on simulated data 2 and achieved accuracy of 70.1% and DFA 
classifier has achieved an accuracy of 68.7%.  From this new dataset, DFA has shown the 
distribution of the simulated data in the discriminant space where data in each class were 
less overlapped showing more precise dataset. This improvement in accuracy is due to less 
class overlap, however some class overlaps still exist and size of data may not be sufficient 
to train the models. Therefore, neural network and DFA analysis have shown to struggle 
for maintaining the order during classification in few cases. 
 As ordinal logistic regression is capable of handling this order, so OLR was implemented 
again using simulated dataset 2 where accuracy of 68.4% was achieved and has identified 
five significant predictors. However, as we have stated earlier this cannot deal with 
nonlinearity of the data, so the efforts were made to implement model using neural 
network which can maintain the orders explicitly. This order based neural network is called 
Proportional odds model. Finally, NNPOM is trained on simulated dataset 2 where 
accuracy of 70.1% was achieved with seven predictors. This method is working as per the 
requirements and risk assessment tool of VibraScan has been developed.  
Thus, the overall analysis of the data allowed us in getting the insight for selecting the right 
model as well as the importance of quality of the data. This limitation of quality of data is 
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handled by using simulated patient data the quality of data was increased by improving 
the precision of the variables. Hence, the achieved accuracy can be improved by collecting 
more patient data from the clinics specifically for the analysis purpose and can be trained 
using a suitable neural network model for early diagnosis of the disease. A futuristic 
framework of risk assessment tool is proposed in the concluding chapter using the 
VibraScan risk assessment tool with the advantage of collecting precise patient data and at 




















Chapter 7 Conclusions  
 
This chapter provides the conclusions derived from the designing and experimental analysis 
conducted in developing the risk assessment tool for diabetic neuropathy. These conclusions 
are discussed based on fulfilling the set objectives of this thesis. It also discusses the 
limitations and future scope of the risk assessment tool where VibraScan and artificial neural 
network based application can be used together to enhance the capability of diagnosing 
diabetic neuropathy. 
7.1 Achieving the set objectives of the thesis 
 In order to detect diabetic neuropathy develop a smart, operator independent and user-
friendly device, which is capable of generating a vibration stimulus with a required 
frequency and varying amplitude. 
These conclusions are based on the literature survey conducted in Chapter 1, 2 and the 
developmental phase of device discussed in Chapter 3.  In the literature survey, study 
related to types of diabetes (type 1 and type 2) and its related complications were 
discussed. Diabetic neuropathy is one of the serious complications of diabetes. It has been 
found that the rate of neuropathy in type 1 diabetes is higher than type 2 diabetes. Various 
types of diabetic neuropathy, its prevalence and importance of early detection of DN were 
studied. The detailed discussion of the currently available methods and devices for 
diagnosing diabetic neuropathy are conducted in Chapter 2. Devices based on vibration 
perception were generally considered as the gold standard for diabetic neuropathy, a 128-
hertz tuning fork was the first tool used to assess the neuropathy based on vibration 
perception. Later more advanced device Biothesiometer was developed which was then 
replaced by Neurothesiometer. This works in the same way but with a self-contained power 
source. The method of conducting the test, generating vibration, vibration property such as 
a range of vibration amplitude and frequency of Neurothesiometer were carefully studied. 
By looking at the limitations, such as operator dependency, range of the vibration 
amplitude causing the ceiling effect, time is taken to conduct the test and manual 
interpretation of results in Neurothesiometer led to the idea of developing a smart device. 
Typically a Biothesiometer or Neurothesiometer vibrates at a fixed frequency and varying 
the vibration amplitude which is operator dependent was a major limitation. VibarScan can 
be used to measure VPT independently. It is developed as a platform based device where 
subject has to lay their feet on the device and provided a manual switch to capture VPT 
level.  The device will automatically calculate the VPT level and display the results in the 
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form of severity of DN. The vibration actuator C2- HDLF tactor was used in VibraScan which 
is capable of generating the vibration with the required range of frequency and amplitude. 
Pulse width modulation technique was used for generating vibration of required fixed 
frequency and varying voltage, discussed in Chapter 3. The vibration applied using the 
vibration actuator is digitally controlled and is fully programmable. Thus, the objective of 
generating fixed frequency with varying voltage in VibraScan device is successfully achieved 
where neuropathy assessment is possible without the need of an operator.  
 
 To be able to robustly detect diabetic neuropathy, develop a vibration generating device 
which can effectively increase the vibration intensity, in order to detect the vibration 
perception threshold of the subject. 
 These conclusions are based on the modelling and simulation conducted in Chapter 4 and 
5. The feeling of sensing the vibration is also based on the type of vibration motor and 
design of the test rig (discussed in Chapter 3). Using the Plate-form based device, the 
subject can comfortably place from their feet on the plate. Various vibration characteristics 
such as the nature of vibration, vibration site and safety measures during the test were 
analysed for developing the device.  By selecting the platform based device it was 
necessary that vibration should be applied perpendicularly to the skin. Various vibration 
motors such as Eccentric Rotating Mass Vibration Motors (ERM), linear actuators and C2 - 
high displacement and low frequency (C2- HDLF) tactor were analysed to make selection 
criterion, C2- HDLF was selected as it was capable of generating the required nature of 
vibration. Using PWM signals, this vibration motor can be controlled easily for increasing 
the vibration amplitude covering the same range of Neurothesiometer vibration amplitude. 
Initially, a device was made for testing purpose for one foot where platform inclination is 
allowed to change from 44 to 26 degree. By successfully testing the first version of the 
device, it was redesigned for both feet with all necessary advancement. In the latest 
version of the device, based on the flexibility of the user, the inclination was kept fixed at 
approximately 36 degrees. The software was also upgraded to measure the VPT from both 
feet and results are automatically interpreted in terms of severity level of neuropathy. In 
the latest version, vibration isolation technique using spring was implemented to avoid the 
background vibration. To obtain the comparative range of the vibration amplitude with that 
of the Neurothesiometer, an experimental study was performed to measure the 
displacement of the vibration amplitude for each device. Curve fitting technique was used 
to develop the equation for finding the relationship between VibraScan and 
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Neurothesiometer. The comparative study discussed in Chapter 5, was conducted between 
VibraScan and Neurothesiometer using twenty healthy subjects after getting approval from 
the ethical committee of Bournemouth University. The VPT was alternately measured for 
each foot using both devices. To get the linear interdependency of both the measurements, 
correlation coefficient was calculated as r = 0.816, p < 0.001 for left foot and r = 0.893, p < 
0.001 for right foot.  Although there is a strong correlation between both techniques it is 
possible to say that both the techniques are agreeing with each other. To support this 
Bland and Altman analysis was used which showed that there is a close agreement 
between both the measurement techniques. Hence, the vibration stimulation applied to 
the subject/patient using VibraScan is made effective by careful designing of the device, by 
selecting the appropriate vibration motor (which is capable of generating higher vibration 
amplitude than Neurothesiometer vibration probe i.e. greater than 250 micrometer) and 
depending on the experimental results using human subject, VibraScan can be used an 
smart screening tool for diabetic neuropathy.  
 
 To develop a more reliable device by maintaining a constant pressure while applying 
vibration stimuli to the patient. 
These conclusions are based on the evaluation of the pressure measurement carried out in 
Chapter 3. By studying all the devices available for measurement of vibration perception 
threshold, it was found that none of these devices like Biothesiometer / Neurothesiometer 
are considering pressure measurement during the test. In these devices, vibration stimulus 
are applied to the subject by holding the vibration probe. So while conducting the test 
there could be a possibility of applying vibration with higher pressure which can result in 
activating the human skin receptors abnormally. To overcome this limitation, with the 
special design of VibraScan, it is possible to conduct the test at constant pressure by simply 
placing the foot on the device. However, there could still be a chance of pressure change if 
it is not monitored during the test. Therefore force sensitive resistors (FSRs) were used to 
capture any change of pressure during the test. Based on the experimental analysis, the 
placement of FSRs was decided i.e. on the top of the C2 - HDLF tactor where the great toe 
of the subject is placed. These FSRs were used to monitor the pressure and also verify the 
correct placement of the foot.  A user-friendly graphic user interface (GUI) was developed 
on the Matlab framework to wirelessly control the device which captures and show the 
real-time pressure change during the test. The real-time pressure graph is useful for 




 To develop the risk assessment tool that is capable of utilising the clinical characteristics 
of a patient to predict the risk level of Diabetic neuropathy. 
These conclusions are based on the analysis conducted in Chapter 6. By developing 
VibraScan, diabetic neuropathy can be assessed by measuring vibration perception 
threshold; however, there is no consideration for clinical risk assessment of diabetic 
neuropathy. To help with the idea of assessing the disease through risk factors, summarised 
patient data were used. The data were analysed by classical statistical method using Box-
Cox transform to get information related to significant predictors from the summarised 
patient data. Ordinal logistic regression was applied using Box-Cox transforms variable with 
output variable as logarithmic VPT to identify the significant predictors such as age, height, 
weight, urine albumin to creatinine ratio (ACR), HbA1c, cholesterol, and duration of 
diabetes. The analysis results from the classical statistics have given the direction of 
predicting VPT using these significant predictors. Predicting VPT in terms of the continuous 
variable was considered less helpful. As a result, VPT is divided into low risk (0 to 20.99 V), 
medium risk (21 to 30.99 V) and high risk (≥ 31 V). To increase the precision of the 
summarised patient data, simulated patient data was generated with the similar property 
of summarised patient data but with reduced standard error. Ordinal logistic regression 
was applied to get the best predictor set based on this categorical outcome. The 
information obtained from this analysis has helped in creating the baseline for this 
classification problem and focus was set to find the best classifier. Finally, a neural network 
based proportional odds model (NNPOM) was implemented using simulated patient data 
that could obtain the highest accuracy of 70.1%, slightly higher than the classical classifiers. 
A version of this model is used to develop the risk assessment tool of VibraScan.  
Thus, VibraScan device diagnosis based on vibration perception and risk assessment tool of 
VibraScan using risk factors of the disease helps in providing a comprehensive assessment tool 
for diabetic neuropathy. 
 
7.2 Limitations and Future scope 
The VibraScan has been developed and was tested on healthy subjects. Although comparative 
study between Neurothesiometer and VibraScan has shown a strong agreement, but, the 




For the risk assessment of the VibraScan, the challenge was to deal with the summarised 
patient data in which VPT was measured continuously and was divided into categorised VPT. 
Due to this division, data sample available in each class was not equal; this was handled by 
sampling technique to obtain the class balance. Due to noise in the summarised data, the 
simulated patient data were used for developing the risk assessment tool to show the 
potential of the tool when clean patient dataset will be used in the future. The challenge was 
to get the large patient data which can be used to train the neural network for better 
prediction of VPT. 
 
The futuristic Model 
As VibraScan device is developed to measure the VPT of the subject and risk assessment tool is 
used to predict the VPT. Taking an opportunity of using both these features of the device, a 





















Figure 7.1: The futuristic model 
 
This model involves both VibraScan device and risk assessment tool of VibraScan as shown in 
Figure 7.1. For collecting a large patient data, the first subject needs to be tested using 
VibraScan, the measured VPT value should be collected in the central database.  
Secondly, subject should also use risk assessment tool so when they enter the values of risk 
factors i.e. age, height, weight, urine albumin to creatinine ratio (ACR), HbA1c, cholesterol, and 
duration of diabetes, it can be captured and transfered to the central database which is 
currently filled with simulated patient data. The format of collecting the data in the central 
database should maintain in the form of [attr1, attr2, attr3…. attrN, VPT] where attr is the 
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attributes/risk factors of diabetic neuropathy. The simulated patient data which is available in 
the central database should be replaced as per the VPT to maintain the categories with the 












Attr1 Attr2  Attr3 Attr4 Attr5 Attr6 Attr7 
 
Here sVPT is the simulated VPT present in the database. Likewise, all the simulated patient 
data will be replaced by real patient data gradually. The monthly scheduler should fetch the 
data from the central data-base and neural network should be trained using the newly 
updated dataset. Once the optimal classification accuracy is achieved the weights should be 
transferred to the risk assessment tool. This process can be continued until large patient data 












assessment  Tool 
 
Figure 7.2: Overall benefits of the futuristic model 
Using this latest model we can obtain mainly three benefits like a collection of the patient 
data, VPT measurement using VibraScan device and enriching the dataset of the risk 
assessment tool. 
1. Collection of patient data: At the moment the tool was modeled using simulated data, 
however with this proposal, it will eventually replace all the existing simulated patient 
data with new patient data. A large amount of patient data can be collected with this 
method covering the whole range of VPT.  There is a possibility of considering more 
attributes for research purpose during the collection of data. It is also possible to 
collect the data using internet where many VibraScan devices and risk assessment tool 
can be connected to the cloud for data collection.  
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2. VPT measurement using VibraScan device: This method gives an opportunity of using 
VibraScan for measuring VPT instead of Neurothesiometer. By using VibraScan device, 
it can be tested on patients as well.  
3. Upgrading risk assessment tool: The risk assessment tool will be upgraded on a timely 
basis. Neural networks should show their potential of performing better when more 
data is fed into it. In this way, the risk assessment tool can be updated to improve its 
prediction over time. 
When neural network model is trained with a large amount of the patient data which involves 
the VPT measurement using VibraScan, the updated version of the risk assessment tool should 
work as the standalone tool for predicting VPT without using the VibraScan device. Later on, 
the final version of the risk assessment tool software can be used as a mobile application 
where patients/subjects can easily measure their risk levels of diabetic neuropathy. 
 
Hence, the state-of-the-art diabetic neuropathy assessment tool VibraScan has been 
developed in the current project. This is an advanced tool with its intuitive mode of operation 
and independently assessing the disease based on the clinical history of the patient. There is 
further scope where knowledge of VibraScan can be converted into a smart application in 
which patients can just access the user-friendly risk assessment tool to get an instant 
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Appendix B: Participant Information sheet 
 
The title of the research project  
 Medical Device development for comprehensive clinical assessment of Peripheral Neuropathy 
Invitation 
You are being invited to take part in this research project conducted by Jugal Manoj Dave, a 
postgraduate researcher, in the Department of Computing and Informatics, Faculty of Science 
& Technology, Bournemouth University, UK. Before you decide, it is important for you to 
understand why the research is being done and what it will involve. Please take time to read 
the following information carefully and discuss it with others if you wish. Ask us if there is 
anything that is not clear or if you would like more information. Take time to decide whether 
you wish to take part. 
Who is organizing/funding the research? 
This research is being funded by Bournemouth University and Poole Hospital NHS Foundation 
Trust. 
What is the purpose of the project? 
The Purpose of this project is to detect diabetic neuropathy at the early stage. Diabetic 
neuropathy is the disease in which there is a reduction in the touch sensation causing the 
numbness in the feet and hands. 
As per World Health Organization (WHO), approximately 150 million people have diabetes 
mellitus worldwide, and that number may well double by the year 2025. Diabetic Neuropathy 
is common complications of diabetes. Studies suggest that up to 50% of people with diabetes 
are affected to some degree. To get into the effectiveness we have developed a device to 
detect neuropathy and conduct an experiment which will provide us the data from the normal 
people i.e. people having no history of neuropathy, and helps in diagnosing diabetic 
neuropathy at the early stage. 
You may have several questions in your mind such as: 
When this research is focused on diabetic patients. Why are we looking for normal subjects?  
How will this going to contribute to the research? What will be the potential benefits when 
considering normal subjects? 
As the focus is on early detection of neuropathy one has to establish the potential risk of 
neuropathy occurrence on normal people. It is important to explain that the subjects to be 
examined are to be provided with mechanical vibration to the foot so as to get whether the 
subject examined is normal or a progressive neuropathy patient. Due to diabetic neuropathy, 
patients may not feel the mechanical vibration in their extremities. It is important that level of 




Based on data analysis of the subject examined the threshold level of sensing the mechanical 
vibration of the normal subject can be determined. 
Why have I been chosen? 
This is an open call that aims to reach those who fulfills the criteria below can contribute to 
the research by providing their valuable feedback.  
Criteria: 
1.         above 18 years old. 
2.         Should be non-diabetic. 
3.   Should not have any injury or ulcers on the sole of the foot. 
4.   Should not have any problem in foot movement. 
Do I have to take part? 
It is up to you to decide whether to take part. If you do decide to take part, you will be given 
this information sheet to keep (and be asked to sign a participant agreement form).  You can 
withdraw at any time, up to the point where the data are processed and become anonymous, 
so your identity cannot be determined, without it affecting any benefits that you are entitled 
to in any way. You do not have to give a reason. Deciding to take part or not will not affect 
your treatment/care /education or studies at BU. 
What would taking part involve? 
Before the experiment: 
 You will be asked to remove the shoes and socks. 
 Once you are relaxed and ready test will start which will take approximately 5 minutes. 
During the experiment: 
 You will be given information about the study. 
 You will be attached with three surface electrodes in such a way that it will capture the 
muscle activity as shown in the Fig.1. 
 These electrodes are totally non- invasive and just stick to the surface of the skin as 
shown in Fig.1 
 







 Then you will be asked to sit on the chair and to place your right foot on the 
inclined plate as shown in Fig 2 which consists of a vibrator and Force resistive 
sensor to monitor the pressure distributed at the planter surface of the foot.   
 The device will provide mechanical vibration starting with a low intensity and 
increasing where the subject will be asked to respond ‘Yes’ or ‘No’ when the 
vibration sensation is felt. (Vibration intensity will be similar to that of mobile 
phone vibration). 
 The Answer ‘Yes’ will be recorded against the vibration intensity level to 
determine the neuropathy level. 
 The vibration intensity will only be increased gradually till the vibration is felt. 
After the experiment: 
 Surface electrodes will be removed and you will be free to pop up your socks and 
shoes. 
What are the advantages and possible disadvantages or risks of taking part? 
Whilst there are no immediate benefits for those people participating in the project. There 
could be long term benefit to diabetic patients once the efficiency of device is proven. There is 
very low risk in the experiment as the experiment is limited to low intensity mechanical 
vibration. Vibration provided by the system will be on the skin surface. It is not going to 
rupture the skin and is totally safe. There is no chance of electric shock or mechanical piercing. 
The vibration will be applied at the speed of 100 cycles per second with the maximum of 1 mm 
displacement. The whole setup is wireless to make it safe to operate. You can withdraw at any 
time if feeling uncomfortable. 
Will my taking part in this study be kept confidential? 
All the information that we collect about you during the research will be kept in accordance 
with the Data Protection Act 1998. You will not be able to be identified in any reports or 
publications. All data relating to this study will be kept for 5 years on a BU password protected 
secure network. 
What type of information will be sought from me and why is the collection of this 
information relevant for achieving the research project’s objectives? 
The data collected are not going to be of a sensitive nature. 
The test will help us getting the data of Vibration perception threshold (VPT) for the normal 
subjects and can lead to early detection of Diabetic Neuropathy in patients. Your participation 
is very important in analyzing the hypothesis for early detection of diabetic Neuropathy. 
 
 
Figure 1: Electrodes attachment 
to capture muscle activity. 
Figure 2: Inclined plane with vibrator for 
the placement of the foot. 
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Who has reviewed the study? 
This study has been reviewed and approved in line with Bournemouth University’s Research 
Ethics Code of Practice. 
Will I be recorded, and how will the recorded media be used? 
Not applicable. 
Contact for further information 
If you have any queries about this research, please contact Prof. Venky Dubey by email on 
VDubey@bournmeouth.ac.uk or by phone on 01202 965986 or by post to: 
Prof. Venky Dubey 
Faculty of Science and Technology  
Bournemouth University 
BH12 5BB  
Complaints 
If you have any complaints about this project please contact Professor Keith Phalp, Executive 
Dean of the Faculty of Science and Technology at Bournemouth University at the following 
address: 
Professor Keith Phalp 
Poole House P426  
Talbot Campus, Fern Barrow, Poole, BH12 5BB 
E-mail: researchgovernance@bournemouth.ac.uk 
Tel: 01202 965571 
Thank you for taking the time to read this information sheet, and please do not hesitate to 











Appendix C: Participant Agreement Form 
 
Full title of project: Medical Device development for comprehensive clinical assessment of 
Peripheral Neuropathy 
Name, position and contact details of researcher: Jugal Manoj Dave, Postgraduate researcher, 
Department of Computing and Informatics, Faculty of Science & Technology, Bournemouth 
University. Email: jdave@bournmeouth.ac.uk                                                                                                                                      
                  
I have read and understood the participant information sheet for the above 
research project. 
 
I confirm that I have had the opportunity to ask questions.  
I understand that my participation is voluntary.  
I understand that I am free to withdraw up to the point where the data are 
processed and become anonymous, so my identity cannot be determined.  
 
During the tasks of the study, I am free to withdraw without giving a reason and 
without there being any negative consequences. 
 
Should I not wish to answer any particular question(s), complete a test I am free 
to decline. 
 
I give permission for members of the research team to have access to my 
anonymised responses. I understand that my name will not be linked with the 
research materials, and I will not be identified or identifiable in the outputs that 
result from the research. 
 
I agree to take part in the above research project.  
 
____________________________      _______________      
__________________________________ 
Name or Initials of the Participant                        Date                              Signature 
____________________________      _______________      
__________________________________ 
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3. C2 High displacement low frequency 
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